Alteration	Alteration type	Assay type	Association	Biomarker	Comments	Curation date	Curator	Drug	Drug family	Drug full name	Drug status	Evidence level	Gene	Metastatic Tumor Type	Primary Tumor acronym	Primary Tumor type full name	Source	TCGI included	Targeting	cDNA	gDNA	individual_mutation	info	region	strand	transcript	Primary Tumor type
AKT1:Q79K,E17K	MUT		Resistant	AKT1 (Q79K,E17K)		03/16	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	AKT1		CM	Cutaneous melanoma	PMID:24265152	1.0		c.235C>A	chr14:g.105243048G>T	AKT1:Q79K	CSQN=Missense;reference_codon=CAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105243046_105243048delCTGinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000554581	Cutaneous melanoma
AKT1:Q79K,E17K	MUT		Resistant	AKT1 (Q79K,E17K)		03/16	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	AKT1		CM	Cutaneous melanoma	PMID:24265152	1.0		c.49G>A	chr14:g.105246551C>T	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Cutaneous melanoma
ABL1:T315I	MUT		Responsive	ABL1 (T315I)		03/16	DTamborero	Axitinib	VEGFR inhibitor	Axitinib (VEGFR inhibitor)		Pre-clinical	ABL1		CANCER	Any cancer type	PMID:25686603	1.0		c.944C>T	chr9:g.133748283C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Any cancer type
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.943A>G	chr9:g.133748282A>G	ABL1:T315A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>C	chr9:g.133748288T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>G	chr9:g.133748288T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>A	chr9:g.133748288T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.950T>G	chr9:g.133748289T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.757T>C	chr9:g.133738357T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.763G>A	chr9:g.133738363G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.764A>T	chr9:g.133738364A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>G	chr9:g.133748414T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1076T>G	chr9:g.133748415T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)			RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>A	chr9:g.133748414T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ARAF:.	MUT		Resistant	ARAF oncogenic mutation			RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor]	BRAF inhibitor + EGFR mAb inhibitors		Case report	ARAF		COREAD	Colorectal adenocarcinoma	ENA 2014 (abstr 428)	1.0									Colorectal adenocarcinoma
ABL1:V299L	MUT		Responsive	ABL1 (V299L)		03/16	DTamborero	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	ABL1		CANCER	Any cancer type	PMID:26924578	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
ABL1:V299L	MUT		Responsive	ABL1 (V299L)		03/16	DTamborero	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ABL1		CANCER	Any cancer type	PMID:26924578	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>G	chr9:g.133748414T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1076T>G	chr9:g.133748415T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>A	chr9:g.133748414T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.757T>C	chr9:g.133738357T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.763G>A	chr9:g.133738363G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.764A>T	chr9:g.133738364A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ARAF:.	MUT		Resistant	ARAF oncogenic mutation			RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	ARAF		COREAD	Colorectal adenocarcinoma	ENA 2014 (abstr 428)	1.0									Colorectal adenocarcinoma
ABL1:V299L	MUT		Responsive	ABL1 (V299L)		03/16	DTamborero	Foretinib 	MET inhibitor	Foretinib  (MET inhibitor)		Pre-clinical	ABL1		CANCER	Any cancer type	PMID:26924578	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
B2M:.	MUT		Resistant	B2M oncogenic mutation		07/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	B2M		CM	Cutaneous melanoma	PMID:27433843	1.0									Cutaneous melanoma
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)			RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.943A>G	chr9:g.133748282A>G	ABL1:T315A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)			RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>C	chr9:g.133748288T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)			RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>G	chr9:g.133748288T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)			RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>A	chr9:g.133748288T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)			RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.950T>G	chr9:g.133748289T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)			RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	REMAP: from T315. to T315I, 12/15 label update states the complete aminoacid change	12/15	CRubio-Perez;DTamborero;RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	Chronic myeloid leukemia;Acute lymphoblastic leukemia	FDA	1.0		c.944C>T	chr9:g.133748283C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia;Acute lymphoblastic leukemia
ABL1:T315I	MUT		Responsive	ABL1 (T315I)			RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	NCCN guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.944C>T	chr9:g.133748283C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L	MUT		Responsive	ABL1 (V299L)		03/16	DTamborero	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Pre-clinical	ABL1		CANCER	Any cancer type	PMID:26924578	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
AKT1:E17K	MUT		Responsive	AKT1 (E17K)		11/15	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors	Clinical Trials	Pre-clinical	AKT1		CANCER	Any cancer type	PMID:21464312;PMID:17611497;PMID:23134728;ENA 2015 (abstr B109)	1.0		c.49G>A	chr14:g.105246551C>T	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Any cancer type
AKT1:E17K	MUT		Responsive	AKT1 (E17K)		07/17	RDientsmann	[]	[allosteric AKT inhibitor]	allosteric AKT inhibitors		Early trials	AKT1		CANCER	Any cancer type	ENA 2015 (abstract B109);PMID:28489509	1.0		c.49G>A	chr14:g.105246551C>T	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Any cancer type
BRAF:V600E,G469A	MUT		Resistant	BRAF (V600E,G469A)	UPDATE: delete G469A mutation in v16 GDKD?	04/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Case report	BRAF		LUAD	Lung adenocarcinoma	PMID:22773810	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E,G469A	MUT		Resistant	BRAF (V600E,G469A)	UPDATE: delete G469A mutation in v16 GDKD?	04/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Case report	BRAF		LUAD	Lung adenocarcinoma	PMID:22773810	1.0		c.1406G>C	chr7:g.140481402C>G	BRAF:G469A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsGG,chr7:g.140481401_140481402delTCinsCG,chr7:g.140481401_140481402delTCinsAG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Lung adenocarcinoma
AKT1:E17K	MUT		Responsive	AKT1 (E17K)		07/17	RDientsmann	[]	[non-allosteric AKT inhibitor]	non-allosteric AKT inhibitors	Clinical Trials	Early trials	AKT1		CANCER	Any cancer type	ENA 2015 (abstract B109);PMID:28489509	1.0		c.49G>A	chr14:g.105246551C>T	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Any cancer type
AKT1:E17K	MUT		Responsive	AKT1 (E17K)		07/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	AKT1		HNSC	Head and neck squamous cell carcinoma	PMID:26763254	1.0		c.49G>A	chr14:g.105246551C>T	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Head and neck squamous cell carcinoma
AKT1:H238Y	MUT		Responsive	AKT1 (H238Y)			RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	AKT1		FH	Fibrous histiocytoma	ASCO 2015 (abstr 11010)	1.0		c.712C>T	chr14:g.105239908G>A	AKT1:H238Y	CSQN=Missense;reference_codon=CAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr14:g.105239906_105239908delGTGinsATA;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000554581	Fibrous histiocytoma
AKT1:E17K	MUT		Responsive	AKT1 (E17K)		07/16	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Early trials	AKT1		ED	Endometrial carcinoma	PMID:27016228	1.0		c.49G>A	chr14:g.105246551C>T	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Endometrial carcinoma
ALK:F1174L	MUT		Responsive	ALK (F1174L)		01/16	RDientsmann	[]	[novel ALK inhibitor]	novel ALK inhibitors		Pre-clinical	ALK		LUAD	Lung adenocarcinoma	PMID:24327273	1.0		c.3520T>C	chr2:g.29443697A>G	ALK:F1174L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:E1408V	MUT		Responsive	ALK (E1408V)		07/17	RDientsmann	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 9065)	1.0		c.4223A>T	chr2:g.29416730T>A	ALK:E1408V	CSQN=Missense;reference_codon=GAA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr2:g.29416729_29416730delTTinsGA,chr2:g.29416729_29416730delTTinsCA,chr2:g.29416729_29416730delTTinsAA;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_29]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M	MUT		Responsive	ALK (L1196M)		07/17	RDientsmann	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 9065)	1.0		c.3586C>A	chr2:g.29443631G>T	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK::consequence::inframe_insertion:.1151T.	MUT		Responsive	ALK inframe insertion (1151T)		01/16	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	Lung adenocarcinoma	PMID:24670165	1.0									Lung adenocarcinoma
CTNNB1:.	MUT		Resistant	CTNNB1 oncogenic mutation			RDientsmann	[]	[Tankyrase inhibitor]	Tankyrase inhibitors		Pre-clinical	CTNNB1		COREAD	Colorectal adenocarcinoma	PMID:23539443	1.0									Colorectal adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)		01/16	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	Lung adenocarcinoma	PMID:24670165;PMID:24327273	1.0		c.3586C>A	chr2:g.29443631G>T	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)		01/16	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	Lung adenocarcinoma	PMID:24670165;PMID:24327273	1.0		c.3617C>A	chr2:g.29443600G>T	ALK:S1206Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29443599_29443600delGGinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)		01/16	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	Lung adenocarcinoma	PMID:24670165;PMID:24327273	1.0		c.3806G>C	chr2:g.29432682C>G	ALK:G1269A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29432681_29432682delTCinsGG,chr2:g.29432681_29432682delTCinsCG,chr2:g.29432681_29432682delTCinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_25]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)		01/16	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	Lung adenocarcinoma	PMID:24670165;PMID:24327273	1.0		c.3512T>C	chr2:g.29445213A>G	ALK:I1171T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
EGFR::consequence::inframe_deletion:30-336	MUT		Not Responsive	EGFR inframe deletion (30-336)			RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	EGFR		G	Glioma	PMID:19204207	1.0									Glioma
EGFR::consequence::inframe_insertion:762-823	MUT		Resistant	EGFR exon 20 insertions		12/16	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Late trials	EGFR		L	Lung carcinoma	PMID:21764376;PMID:26773740;PMID:26051236	1.0									Lung carcinoma
EGFR:D761Y	MUT		Resistant	EGFR (D761Y)			DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Case report	EGFR		NSCLC	Non-small cell lung cancer	PMID:19680293	1.0		c.2281G>T	chr7:g.55242511G>T	EGFR:D761Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr7:g.55242511_55242513delGATinsTAC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung cancer
EGFR:T790M	MUT		Resistant	EGFR (T790M)		01/16	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Late trials	EGFR		NSCLC	Non-small cell lung cancer	PMID:19680293	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR::consequence::inframe_deletion:30-336	MUT		Not Responsive	EGFR inframe deletion (30-336)			RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Early trials	EGFR		G	Glioma	PMID:19204207	1.0									Glioma
ALK:F856S,A348D	MUT		Responsive	ALK (F856S,A348D)		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		AML	Acute myeloid leukemia	PMID:26032424	1.0		c.2567T>C	chr2:g.29455235A>G	ALK:F856S	CSQN=Missense;reference_codon=TTC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr2:g.29455235_29455236delAAinsCT,chr2:g.29455234_29455235delGAinsAG,chr2:g.29455234_29455235delGAinsCG,chr2:g.29455234_29455235delGAinsTG,chr2:g.29455234_29455236delGAAinsACT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000389048	Acute myeloid leukemia
ALK:F856S,A348D	MUT		Responsive	ALK (F856S,A348D)		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		AML	Acute myeloid leukemia	PMID:26032424	1.0		c.1043C>A	chr2:g.29754892G>T	ALK:A348D	CSQN=Missense;reference_codon=GCC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr2:g.29754891_29754892delGGinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000389048	Acute myeloid leukemia
ALK:L1198F	MUT		Responsive	ALK (L1198F)		04/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:26698910	1.0		c.3592C>T	chr2:g.29443625G>A	ALK:L1198F	CSQN=Missense;reference_codon=CTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr2:g.29443623_29443625delGAGinsAAA;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	Glioma	PMID:22072639	1.0		c.3824G>A	chr2:g.29432664C>T	ALK:R1275Q	CSQN=Missense;reference_codon=CGA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.29432663_29432664delTCinsCT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_25]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	Glioma	PMID:22072639	1.0		c.3383G>C	chr2:g.29445450C>G	ALK:G1128A	CSQN=Missense;reference_codon=GGG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29445449_29445450delCCinsTG,chr2:g.29445449_29445450delCCinsGG,chr2:g.29445449_29445450delCCinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_21]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	Glioma	PMID:22072639	1.0		c.3512T>A	chr2:g.29445213A>T	ALK:I1171N	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	Glioma	PMID:22072639	1.0		c.3575G>C	chr2:g.29443642C>G	ALK:R1192P	CSQN=Missense;reference_codon=CGG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr2:g.29443641_29443642delCCinsAG,chr2:g.29443641_29443642delCCinsTG,chr2:g.29443641_29443642delCCinsGG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	Glioma	PMID:22072639	1.0		c.3734T>G	chr2:g.29436859A>C	ALK:F1245C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr2:g.29436858_29436859delGAinsAC;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_24]	-	ENST00000389048	Glioma
ALK:C1156Y	MUT		Responsive	ALK (C1156Y)		07/17	RDientsmann	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Pre-clinical	ALK		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.3467G>A	chr2:g.29445258C>T	ALK:C1156Y	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
APC:.	MUT		Responsive	APC oncogenic mutation			RDientsmann	[]	[Tankyrase inhibitor]	Tankyrase inhibitors		Pre-clinical	APC		COREAD	Colorectal adenocarcinoma	PMID:22440753;PMID:23539443	1.0									Colorectal adenocarcinoma
EGFR:T790M	MUT		Resistant	EGFR (T790M)		01/16	DTamborero	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Late trials	EGFR		NSCLC	Non-small cell lung cancer	PMID:22452896	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR::consequence::inframe_deletion:30-336	MUT		Not Responsive	EGFR inframe deletion (30-336)			RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		G	Glioma	PMID:19204207	1.0									Glioma
FBXW7:.	MUT		Resistant	FBXW7 oncogenic mutation			RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	FBXW7		CANCER	Any cancer type	PMID:21368834	1.0									Any cancer type
ARAF:S214C	MUT		Responsive	ARAF (S214C)		09/15	JAlbanell;ARovira;RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)	FDA approved	Case report	ARAF		LUAD	Lung adenocarcinoma	PMID:24569458	1.0	Direct:primary target	c.641C>G	chrX:g.47426121C>G	ARAF:S214C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chrX:g.47426121_47426122delCCinsGT;aliases=ENSP00000366244;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000377045	Lung adenocarcinoma
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation		07/17	RDientsmann	[]	[ATR inhibitors]	ATR inhibitors		Pre-clinical	ARID1A		CANCER	Any cancer type	PMID:27958275	1.0									Any cancer type
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation		01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	ARID1A		OV	Ovarian carcinoma	PMID:25686104	1.0									Ovarian carcinoma
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation		11/15	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ARID1A		CANCER	Any cancer type	PMID:26069190	1.0									Any cancer type
FGFR3:V555M	MUT		Resistant	FGFR3 (V555M)			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	Myeloma	PMID:22869148	1.0		c.1663G>A	chr4:g.1807494G>A	FGFR3:V555M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000440486	Myeloma
ATM:.	MUT		Responsive	ATM oncogenic mutation		11/15	RDientsmann	[]	[ATR inhibitor]	ATR inhibitors		Case report	ATM		COREAD	Colorectal adenocarcinoma	ENA 2015 (abstr A48)	1.0									Colorectal adenocarcinoma
ATM:.	MUT		Responsive	ATM oncogenic mutation		11/15	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	ATM		LY	Lymphoma	PMID:23761041	1.0									Lymphoma
ATM:.	MUT		Responsive	ATM oncogenic mutation			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	ATM		ST	Gastric carcinoma	ENA 2014 (abstr 8LBA)	1.0									Gastric carcinoma
ATM:.	MUT		Responsive	ATM oncogenic mutation		09/15	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	ATM	BLCA	BLCA	Bladder carcinoma	PMID:26238431	1.0	Indirect								Bladder carcinoma
ATM:.	MUT		Responsive	ATM oncogenic mutation		01/16	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	ATM		ST;PRAD	Gastric carcinoma;Prostate adenocarcinoma	ENA 2014 (abstr 8LBA);PMID:26510020	1.0									Gastric carcinoma;Prostate adenocarcinoma
ATM:.	MUT		Responsive	ATM oncogenic mutation			RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	ATM		G	Glioma	PMID:23960094	1.0									Glioma
ATR:.	MUT	Cell line	Responsive	ATR oncogenic mutation			CRubio-Perez;ECampo;RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Pre-clinical	ATR		OV;CANCER	Ovarian carcinoma;Any cancer type	PMID:23548269	1.0	Indirect								Ovarian carcinoma;Any cancer type
ATR:.	MUT		Responsive	ATR oncogenic mutation			RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	ATR		G	Glioma	PMID:23960094	1.0									Glioma
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation		11/15	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	BAP1		MESO	Mesothelioma	PMID:26437366	1.0									Mesothelioma
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation			RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	BAP1		CM	Cutaneous melanoma	PMID:22038994	1.0									Cutaneous melanoma
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BAP1		R;CANCER	Renal carcinoma;Any cancer type	PMID:22683710	1.0									Renal carcinoma;Any cancer type
BCOR:.	MUT		Responsive	BCOR oncogenic mutation		07/16	RDientsmann	Enzastaurin	PKCb inhibitor	Enzastaurin (PKCb inhibitor)		Pre-clinical	BCOR		ST	Gastric carcinoma	PMID:27397505	1.0									Gastric carcinoma
JAK1:.	MUT		Resistant	JAK1 oncogenic mutation		07/17	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK1		COREAD	Colorectal adenocarcinoma	PMID:27903500	1.0									Colorectal adenocarcinoma
JAK1:.	MUT		Resistant	JAK1 oncogenic mutation		07/16	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK1		CM	Cutaneous melanoma	PMID:27433843	1.0									Cutaneous melanoma
JAK2:.	MUT		Resistant	JAK2 oncogenic mutation		07/16	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK2		CM	Cutaneous melanoma	PMID:27433843	1.0									Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	[]	[BRAF inhibitor;CDK2/4 inhibitor]	BRAF inhibitor + CDK2/4 inhibitors		Pre-clinical	BRAF		CM	Cutaneous melanoma	PMID:22997239	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600.	MUT		Responsive	BRAF (V600)		07/17	RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor]	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors		Early trials	BRAF		COREAD	Colorectal adenocarcinoma	PMID:28363909	1.0									Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	[]	[BRAF inhibitor;HSP90 inhibitor]	BRAF inhibitor + HSP90 inhibitors		Pre-clinical	BRAF		CM	Cutaneous melanoma	PMID:22351686	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Early trials	BRAF		TH	Thyroid carcinoma	ASCO 2013 (abstr 9029)	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Thyroid carcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	[]	[BRAF inhibitor;PI3K pathway inhibitor]	BRAF inhibitor + PI3K pathway inhibitors		Pre-clinical	BRAF		CM	Cutaneous melanoma	PMID:22389471;PMID:21156289	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:L597R	MUT		Responsive	BRAF (L597R)		01/16	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	BRAF		CM	Cutaneous melanoma	PMID:23715574	1.0		c.1790T>G	chr7:g.140453145A>C	BRAF:L597R	CSQN=Missense;reference_codon=CTA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453145_140453146delAGinsCT,chr7:g.140453144_140453145delTAinsGC,chr7:g.140453144_140453145delTAinsCC,chr7:g.140453144_140453145delTAinsAC,chr7:g.140453144_140453146delTAGinsCCT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	BRAF		G	Glioma	PMID:22038996;PMID:22586120	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Glioma
BRAF:V600E	MUT		Responsive	BRAF (V600E)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	BRAF		OV	Ovarian carcinoma	PMID:22608338	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Ovarian carcinoma
KRAS:.	MUT		Not Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Early trials	KRAS		PA	Pancreatic carcinoma	ASCO 2015 (abstr 4119)	1.0									Pancreatic carcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	BRAF		CM	Cutaneous melanoma	PMID:23614898;PMID:22997239	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:G469A	MUT		Responsive	BRAF (G469A)		07/17	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Case report	BRAF		HNSC	Head and neck squamous cell carcinoma	ASCO 2017 (abstr 2508)	1.0		c.1406G>C	chr7:g.140481402C>G	BRAF:G469A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsGG,chr7:g.140481401_140481402delTCinsCG,chr7:g.140481401_140481402delTCinsAG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Head and neck squamous cell carcinoma
BRAF:L485W	MUT		Responsive	BRAF (L485W)		07/17	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Case report	BRAF		BT	Biliary tract cancer	ASCO 2017 (abstr 2508)	1.0		c.1454T>G	chr7:g.140477854A>C	BRAF:L485W	CSQN=Missense;reference_codon=TTG;candidate_codons=TGG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000288602	Biliary tract cancer
BRAF:V600E	MUT		Responsive	BRAF (V600E)		07/17	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Early trials	BRAF		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 2508)	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Early trials	BRAF		TH	Thyroid carcinoma	PMID:22241789	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Thyroid carcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	BRAF		OV	Ovarian carcinoma	PMID:19018267	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Ovarian carcinoma
BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.	MUT		Responsive	BRAF inframe deletion (L485),inframe deletion (P490)		04/16	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Pre-clinical	BRAF		CANCER	Any cancer type	PMID:26732095	1.0									Any cancer type
BRAF:V600E	MUT		Responsive	BRAF (V600E)		07/17	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Early trials	BRAF		CM	Cutaneous melanoma	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)			RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	Cutaneous melanoma	PMID:23248257;PMID:22805292;PMID:23248257	1.0		c.1802A>G	chr7:g.140453133T>C	BRAF:K601R	CSQN=Missense;reference_codon=AAA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453132_140453133delTTinsCC,chr7:g.140453133_140453134delTTinsCG,chr7:g.140453132_140453134delTTTinsGCG,chr7:g.140453132_140453134delTTTinsCCG,chr7:g.140453132_140453134delTTTinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)			RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	Cutaneous melanoma	PMID:23248257;PMID:22805292;PMID:23248257	1.0		c.1790T>G	chr7:g.140453145A>C	BRAF:L597R	CSQN=Missense;reference_codon=CTA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453145_140453146delAGinsCT,chr7:g.140453144_140453145delTAinsGC,chr7:g.140453144_140453145delTAinsCC,chr7:g.140453144_140453145delTAinsAC,chr7:g.140453144_140453146delTAGinsCCT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)			RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	Cutaneous melanoma	PMID:23248257;PMID:22805292;PMID:23248257	1.0		c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
KRAS:G13D	MUT		Not Responsive	KRAS (G13D)		06/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	KRAS		COREAD	Colorectal adenocarcinoma	PMID:27114605	1.0		c.38G>A	chr12:g.25398281C>T	KRAS:G13D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr12:g.25398280_25398281delGCinsAT;aliases=ENSP00000256078;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000256078	Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		04/16	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Early trials	BRAF		LUAD;TH	Lung adenocarcinoma;Thyroid carcinoma	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma;Thyroid carcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		06/16	CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		NCCN guidelines	BRAF		NSCLC	Non-small cell lung cancer	NCCN	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer
BRAF:V600E	MUT		Responsive	BRAF (V600E)			CRubio-Perez;DTamborero;RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)			RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Case report	BRAF		GIST	Gastrointestinal stromal	PMID:23470635;PMID:22608338	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Gastrointestinal stromal
BRAF:V600R	MUT		Responsive	BRAF (V600R)			RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Early trials	BRAF		CM	Cutaneous melanoma	PMID:23237741	1.0		c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		Early trials	BRAF		COREAD	Colorectal adenocarcinoma	PMID:26392102;ASCO 2015 (abstr 8006)	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		07/16	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		Case report	BRAF		NEU	Neuroendocrine tumor	PMID:27048246	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Neuroendocrine tumor
BRAF:V600E	MUT		Responsive	BRAF (V600E)		12/16	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		FDA guidelines	BRAF		LUAD	Lung adenocarcinoma	PMID:27283860	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)			RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)			RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:G466V	MUT		Responsive	BRAF (G466V)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	BRAF		LUAD	Lung adenocarcinoma	PMID:22649091	1.0		c.1397G>T	chr7:g.140481411C>A	BRAF:G466V	CSQN=Missense;reference_codon=GGA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.140481410_140481411delTCinsGA,chr7:g.140481410_140481411delTCinsCA,chr7:g.140481410_140481411delTCinsAA;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Lung adenocarcinoma
BRAF:Y472C	MUT		Responsive	BRAF (Y472C)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	BRAF		LUAD	Lung adenocarcinoma	PMID:22649091	1.0		c.1415A>G	chr7:g.140481393T>C	BRAF:Y472C	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.140481392_140481393delGTinsAC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600.	MUT		Responsive	BRAF (V600)		07/17	RDientsmann	Irinotecan;Vemurafenib;Cetuximab	TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor	Irinotecan + Vemurafenib + Cetuximab (TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)		Early trials	BRAF		COREAD	Colorectal adenocarcinoma	PMID:27729313	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Not Responsive	KRAS oncogenic mutation		04/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	KRAS		L	Lung carcinoma	PMID:26802155	1.0									Lung carcinoma
BRAF:V600.	MUT		Responsive	BRAF (V600)		01/16	RDientsmann	Panitumumab;Dabrafenib;BYL719	EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor	Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Approved; Approved;Clinical Trials	Early trials	BRAF		COREAD	Colorectal adenocarcinoma	ENA 2014 (abstr 11LBA)	1.0	Indirect								Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		01/16	RDientsmann	Panitumumab;Dabrafenib;Trametinib	EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor	Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Approved; Approved;Clinical Trials	Early trials	BRAF		COREAD	Colorectal adenocarcinoma	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	1.0	Indirect	c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
BRAF:V600E	MUT	Cell line	Responsive	BRAF (V600E)		09/15	MMartínez	PLX4720	BRAF inhibitor	PLX4720 (BRAF inhibitor)		Pre-clinical	BRAF		MA	Malignant astrocytoma	PMID:22038996	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Malignant astrocytoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		09/15	MMartínez	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)	Clinical Trials	Early trials	BRAF		PG	Pediatric glioma	NCT01089101	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Pediatric glioma
BRAF:D594G,G469E	MUT		Responsive	BRAF (D594G,G469E)			RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM	Cutaneous melanoma	PMID:18794803	1.0		c.1781A>G	chr7:g.140453154T>C	BRAF:D594G	CSQN=Missense;reference_codon=GAT;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453153_140453154delATinsCC,chr7:g.140453153_140453154delATinsTC,chr7:g.140453153_140453154delATinsGC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:D594G,G469E	MUT		Responsive	BRAF (D594G,G469E)			RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM	Cutaneous melanoma	PMID:18794803	1.0		c.1406G>A	chr7:g.140481402C>T	BRAF:G469E	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsCT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)			CRubio-Perez;DTamborero;RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)			CRubio-Perez;DTamborero;RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
NRAS:.12.,.13.,.59.,.61.,.117.,.146.	MUT		Resistant	NRAS (12,13,59,61,117,146)			RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	NCCN guidelines	NRAS		COREAD	Colorectal adenocarcinoma	PMID:24024839;PMID:20619739;PMID:23325582	1.0									Colorectal adenocarcinoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)		16/06	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	Cutaneous melanoma	NCCN	1.0		c.1799_1800delTGinsAC	chr7:g.140453135_140453136delCAinsGT	BRAF:V600D	CSQN=Missense;reference_codon=GTG;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)		16/06	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	Cutaneous melanoma	NCCN	1.0		c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)		16/06	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	Cutaneous melanoma	NCCN	1.0		c.1798G>A	chr7:g.140453137C>T	BRAF:V600M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)		16/06	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	Cutaneous melanoma	NCCN	1.0		c.1799T>G	chr7:g.140453136A>C	BRAF:V600G	CSQN=Missense;reference_codon=GTG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAC,chr7:g.140453135_140453136delCAinsTC,chr7:g.140453135_140453136delCAinsGC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)		16/06	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	Cutaneous melanoma	NCCN	1.0		c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		04/16	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Case report	BRAF		LUAD;HCL;MYMA	Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma	PMID:22743296;PMID:22621641;PMID:23612012	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma
BRAF:V600E	MUT		Responsive	BRAF (V600E)		09/15	MMartínez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		MA	Malignant astrocytoma	PMID:22586120	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Malignant astrocytoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)			CRubio-Perez;DTamborero;RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)			RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		THCA	Thyroid carcinoma	PMID:22608338;PMID:20818844;PMID:23489023	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Thyroid carcinoma
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	PMID:26287849	1.0	Indirect	c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	PMID:26287849	1.0	Indirect	c.1799_1800delTGinsAC	chr7:g.140453135_140453136delCAinsGT	BRAF:V600D	CSQN=Missense;reference_codon=GTG;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	PMID:26287849	1.0	Indirect	c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	PMID:26287849	1.0	Indirect	c.1798G>A	chr7:g.140453137C>T	BRAF:V600M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	PMID:26287849	1.0	Indirect	c.1799T>G	chr7:g.140453136A>C	BRAF:V600G	CSQN=Missense;reference_codon=GTG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAC,chr7:g.140453135_140453136delCAinsTC,chr7:g.140453135_140453136delCAinsGC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	PMID:26287849	1.0	Indirect	c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung cancer;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)		11/15	RDientsmann	Vemurafenib;Cobimetinib	BRAF inhibitor;MEK inhibitor	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)		11/15	RDientsmann	Vemurafenib;Cobimetinib	BRAF inhibitor;MEK inhibitor	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	Cutaneous melanoma	FDA	1.0		c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		04/16	RDientsmann	[]	[PARP inhibitor;Chemotherapy]	PARP inhibitor + Chemotherapys		Early trials	BRCA1		OV	Ovarian carcinoma	PMID:22307137;ASCO 2012 (abstr 1009)	1.0									Ovarian carcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	BRCA1		PA	Pancreatic carcinoma	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685	1.0									Pancreatic carcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation			RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Case report	BRCA1		CANCER	Any cancer type	PMID:25964244	1.0									Any cancer type
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation			RDientsmann;JAlbanell	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)		Early trials	BRCA1		BRCA	Breast adenocarcinoma	PMID:20609467;PMID:25366685	1.0									Breast adenocarcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		01/16	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	BRCA1		PRAD	Prostate adenocarcinoma	PMID:26510020	1.0									Prostate adenocarcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		04/16	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	FDA guidelines	BRCA1		OV	Ovarian carcinoma	FDA	1.0									Ovarian carcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		01/16	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Early trials	BRCA1		BRCA	Breast adenocarcinoma	PMID:25847936	1.0									Breast adenocarcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		04/16	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Late trials	BRCA1		OV	Ovarian carcinoma	PMID:22406760;PMID:22711857	1.0									Ovarian carcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		04/16	RDientsmann	Rucaparib	PARP inhibitor	Rucaparib (PARP inhibitor)		FDA guidelines	BRCA1		OV	Ovarian carcinoma	FDA	1.0									Ovarian carcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation		07/16	RDientsmann	Veliparib;Cisplatin	PARP inhibitor;Chemotherapy	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)		Early trials	BRCA1		BRCA	Breast adenocarcinoma	PMID:26801247	1.0									Breast adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		04/16	RDientsmann	[]	[PARP inhibitor;Chemotherapy]	PARP inhibitor + Chemotherapys		Early trials	BRCA2		OV	Ovarian carcinoma	PMID:22307137;ASCO 2012 (abstr 1009)	1.0									Ovarian carcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		04/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	BRCA2		CM	Cutaneous melanoma	PMID:26997480	1.0									Cutaneous melanoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		09/15	JAlbanell;ARovira;RDientsmann	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)	Approved	Early trials	BRCA2		BRCA	Breast adenocarcinoma	PMID:20609467	1.0	Indirect								Breast adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		01/16	RDientsmann;ARodriguez-Vida	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Early trials	BRCA2		PRAD	Prostate adenocarcinoma	PMID:26510020;NCT01682772;AACR 2015 (abstr CT322)	1.0	Indirect								Prostate adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation			RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	FDA guidelines	BRCA2		OV	Ovarian carcinoma	FDA	1.0									Ovarian carcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		01/16	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Early trials	BRCA2		BRCA	Breast adenocarcinoma	PMID:25847936	1.0									Breast adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		04/16	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Late trials	BRCA2		OV	Ovarian carcinoma	PMID:22406760;PMID:22711857	1.0									Ovarian carcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation			RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	BRCA2		PA	Pancreatic carcinoma	PMID:25719666	1.0									Pancreatic carcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		04/16	RDientsmann	Rucaparib	PARP inhibitor	Rucaparib (PARP inhibitor)		FDA guidelines	BRCA2		OV	Ovarian carcinoma	FDA	1.0									Ovarian carcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation		07/16	RDientsmann	Veliparib;Cisplatin	PARP inhibitor;Chemotherapy	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)		Early trials	BRCA2		BRCA	Breast adenocarcinoma	PMID:26801247	1.0									Breast adenocarcinoma
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	CBL		MDPS	Myelodisplasic proliferative syndrome	PMID:23696637	1.0		c.1111T>C	chr11:g.119148891T>C	CBL:Y371H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr11:g.119148891_119148893delTACinsCAT;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	CBL		MDPS	Myelodisplasic proliferative syndrome	PMID:23696637	1.0		c.1150T>C	chr11:g.119148930T>C	CBL:C384R	CSQN=Missense;reference_codon=TGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.119148930_119148932delTGTinsAGG,chr11:g.119148930_119148932delTGTinsAGA,chr11:g.119148930_119148932delTGTinsCGA,chr11:g.119148930_119148932delTGTinsCGC,chr11:g.119148930_119148932delTGTinsCGG;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CBL		MDPS	Myelodisplasic proliferative syndrome	PMID:23696637	1.0		c.1111T>C	chr11:g.119148891T>C	CBL:Y371H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr11:g.119148891_119148893delTACinsCAT;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CBL		MDPS	Myelodisplasic proliferative syndrome	PMID:23696637	1.0		c.1150T>C	chr11:g.119148930T>C	CBL:C384R	CSQN=Missense;reference_codon=TGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.119148930_119148932delTGTinsAGG,chr11:g.119148930_119148932delTGTinsAGA,chr11:g.119148930_119148932delTGTinsCGA,chr11:g.119148930_119148932delTGTinsCGC,chr11:g.119148930_119148932delTGTinsCGG;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
KRAS:.12.,.13.	MUT		Resistant	KRAS (12,13)			CRubio-Perez	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	FDA guidelines	KRAS		COREAD	Colorectal adenocarcinoma	FDA guidelines	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation			DTamborero	[]	[EGFR inhibitor]	EGFR inhibitors		Pre-clinical	KRAS		NSCLC	Non-small cell lung cancer	PMID:19238210	1.0									Non-small cell lung cancer
KRAS:.	MUT		Resistant	KRAS oncogenic mutation			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Pre-clinical	KRAS		ST	Gastric carcinoma	PMID:22614881;PMID:22290393	1.0									Gastric carcinoma
CDH1:.	MUT		Responsive	CDH1 oncogenic mutation		07/16	RDientsmann	Bicalutamide	AR inhibitor	Bicalutamide (AR inhibitor)		Pre-clinical	CDH1		BRCA	Breast adenocarcinoma	PMID:27397505	1.0									Breast adenocarcinoma
CDK12:.	MUT		Responsive	CDK12 oncogenic mutation		12/16	RDientsmann	[]	[PARP inhibitors]	PARP inhibitors		Pre-clinical	CDK12		OV	Ovarian carcinoma	PMID:24240700;PMID:24554720	1.0									Ovarian carcinoma
CDK4:.	MUT		Responsive	CDK4 oncogenic mutation			CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK4		LIP;LY;CANCER	Liposarcoma;Lymphoma;Any cancer type	NCT02187783;NCT01237236;ASCO 2011 (abstr 8061)	1.0	Direct								Liposarcoma;Lymphoma;Any cancer type
CDK6:.	MUT		Responsive	CDK6 oncogenic mutation			CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK6		LIP;LY;CANCER	Liposarcoma;Lymphoma;Any cancer type	NCT02187783;NCT01237236	1.0	Direct								Liposarcoma;Lymphoma;Any cancer type
CDKN1A:.	MUT		Responsive	CDKN1A oncogenic mutation			RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1A		CANCER	Any cancer type	PMID:22471707;PMID:22997239	1.0									Any cancer type
CDKN1B:.	MUT		Responsive	CDKN1B oncogenic mutation			RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1B		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CDKN2A		CM	Cutaneous melanoma	ASCO 2013 (abstr 2500)	1.0									Cutaneous melanoma
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2A		G;CANCER	Glioma;Any cancer type	PMID:22471707;PMID:22586120;PMID:22711607	1.0									Glioma;Any cancer type
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation			CRubio-Perez;DTamborero	Ilorasertib	AURKA-VEGF inhibitor	Ilorasertib (AURKA-VEGF inhibitor)	Clinical Trials	Early trials	CDKN2A		CANCER	Any cancer type	NCT02478320	1.0	Indirect								Any cancer type
CDKN2B:.	MUT		Responsive	CDKN2B oncogenic mutation			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2B		G;CANCER	Glioma;Any cancer type	PMID:22471707;PMID:22711607	1.0									Glioma;Any cancer type
CDKN2C:.	MUT		Responsive	CDKN2C oncogenic mutation			RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CDKN2C		G;CANCER	Glioma;Any cancer type	PMID:22471707;PMID:22997239;PMID:22711607	1.0									Glioma;Any cancer type
CHEK2:.	MUT		Responsive	CHEK2 oncogenic mutation		01/16	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	CHEK2		PRAD	Prostate adenocarcinoma	PMID:26510020;AACR 2015 (abstr CT322)	1.0									Prostate adenocarcinoma
MAP2K1:P124.	MUT		Resistant	MAP2K1 (P124)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	MAP2K1		CM	Cutaneous melanoma	PMID:25370473	1.0									Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L;C121S	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L;C121S)		03/16	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144;PMID:21383288	1.0									Cutaneous melanoma
MAP2K1:.	MUT		Resistant	MAP2K1 oncogenic mutation			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Case report	MAP2K1		COREAD	Colorectal adenocarcinoma	PMID:26030179	1.0									Colorectal adenocarcinoma
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	Reference added by carlota		RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	Any cancer type	PMID:19915144	1.0									Any cancer type
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144;PMID:23444215;PMID:21383288	1.0		c.371C>T	chr15:g.66729163C>T	MAP2K1:P124L	CSQN=Missense;reference_codon=CCG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr15:g.66729163_66729164delCGinsTT,chr15:g.66729163_66729164delCGinsTA,chr15:g.66729163_66729164delCGinsTC,chr15:g.66729162_66729163delCCinsTT,chr15:g.66729162_66729164delCCGinsTTA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144;PMID:23444215;PMID:21383288	1.0		c.171G>C	chr15:g.66727455G>C	MAP2K1:K57N	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr15:g.66727455G>T;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144;PMID:23444215;PMID:21383288	1.0		c.361T>A	chr15:g.66729153T>A	MAP2K1:C121S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr15:g.66729154G>C;candidate_mnv_variants=chr15:g.66729153_66729155delTGCinsAGT,chr15:g.66729154_66729155delGCinsCT,chr15:g.66729154_66729155delGCinsCG,chr15:g.66729154_66729155delGCinsCA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)		03/16	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144	1.0		c.167A>C	chr15:g.66727451A>C	MAP2K1:Q56P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)		03/16	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144	1.0		c.370C>T	chr15:g.66729162C>T	MAP2K1:P124S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr15:g.66729162_66729164delCCGinsTCT,chr15:g.66729162_66729164delCCGinsTCC,chr15:g.66729162_66729164delCCGinsTCA,chr15:g.66729162_66729164delCCGinsAGC,chr15:g.66729162_66729164delCCGinsAGT;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)		03/16	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:19915144	1.0		c.371C>T	chr15:g.66729163C>T	MAP2K1:P124L	CSQN=Missense;reference_codon=CCG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr15:g.66729163_66729164delCGinsTT,chr15:g.66729163_66729164delCGinsTA,chr15:g.66729163_66729164delCGinsTC,chr15:g.66729162_66729163delCCinsTT,chr15:g.66729162_66729164delCCGinsTTA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
CSF1R:Y571D	MUT		Responsive	CSF1R (Y571D)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	CSF1R		MDPS	Myelodisplasic proliferative syndrome	PMID:18971950	1.0		c.1711T>G	chr5:g.149441328A>C	CSF1R:Y571D	CSQN=Missense;reference_codon=TAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr5:g.149441326_149441328delGTAinsATC;aliases=ENSP00000286301;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000286301	Myelodisplasic proliferative syndrome
CSF3R::consequence::frameshift_variant:D771.,::frameshift_variant:S783.	MUT		Responsive	CSF3R frameshift variant (D771),frameshift variant (S783)		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	Atypical chronic myeloid leukemia	PMID:23656643	1.0									Atypical chronic myeloid leukemia
MAP2K2:Q60P	MUT		Resistant	MAP2K2 (Q60P)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K2		CM	Cutaneous melanoma	PMID:24265154	1.0		c.179A>C	chr19:g.4117541T>G	MAP2K2:Q60P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.4117540_4117541delCTinsAG,chr19:g.4117540_4117541delCTinsTG,chr19:g.4117540_4117541delCTinsGG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)			RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	Endometrial carcinoma	PMID:25624430	1.0		c.106C>T	chr3:g.41266109C>T	CTNNB1:H36Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.41266109_41266111delCATinsTAC;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrial carcinoma
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)			RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	Endometrial carcinoma	PMID:25624430	1.0		c.110C>G	chr3:g.41266113C>G	CTNNB1:S37C	CSQN=Missense;reference_codon=TCT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr3:g.41266113_41266114delCTinsGC;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrial carcinoma
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)			RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	Endometrial carcinoma	PMID:25624430	1.0		c.110C>A	chr3:g.41266113C>A	CTNNB1:S37Y	CSQN=Missense;reference_codon=TCT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.41266113_41266114delCTinsAC;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrial carcinoma
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)			RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	Endometrial carcinoma	PMID:25624430	1.0		c.95A>T	chr3:g.41266098A>T	CTNNB1:D32V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr3:g.41266098_41266099delACinsTA,chr3:g.41266098_41266099delACinsTG,chr3:g.41266098_41266099delACinsTT;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrial carcinoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.103G>A	chr19:g.4117617C>T	MAP2K2:V35M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.136C>T	chr19:g.4117584G>A	MAP2K2:L46F	CSQN=Missense;reference_codon=CTT;candidate_codons=TTT,TTC;candidate_mnv_variants=chr19:g.4117582_4117584delAAGinsGAA;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.376A>G	chr19:g.4110581T>C	MAP2K2:N126D	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.4110579_4110581delGTTinsATC;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.373T>A	chr19:g.4110584A>T	MAP2K2:C125S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr19:g.4110583C>G;candidate_mnv_variants=chr19:g.4110582_4110584delGCAinsACT,chr19:g.4110582_4110583delGCinsAG,chr19:g.4110582_4110583delGCinsCG,chr19:g.4110582_4110583delGCinsTG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.1912A>T	chr1:g.162745497A>T	DDR2:I638F	CSQN=Missense;reference_codon=ATC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.162745497_162745499delATCinsTTT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.716T>G	chr1:g.162729630T>G	DDR2:L239R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr1:g.162729629_162729630delCTinsAG,chr1:g.162729630_162729631delTGinsGA,chr1:g.162729630_162729631delTGinsGC,chr1:g.162729630_162729631delTGinsGT,chr1:g.162729629_162729631delCTGinsAGA;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.757G>T	chr1:g.162729671G>T	DDR2:G253C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.162729671_162729673delGGCinsTGT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.2321G>T	chr1:g.162748407G>T	DDR2:G774V	CSQN=Missense;reference_codon=GGG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.162748407_162748408delGGinsTA,chr1:g.162748407_162748408delGGinsTC,chr1:g.162748407_162748408delGGinsTT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.187C>G	chr1:g.162724415C>G	DDR2:L63V	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.162724415_162724417delCTGinsGTA,chr1:g.162724415_162724417delCTGinsGTC,chr1:g.162724415_162724417delCTGinsGTT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.1513G>A	chr1:g.162741822G>A	DDR2:G505S	CSQN=Missense;reference_codon=GGT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.162741822_162741824delGGTinsAGC,chr1:g.162741822_162741823delGGinsTC,chr1:g.162741822_162741824delGGTinsTCG,chr1:g.162741822_162741824delGGTinsTCC,chr1:g.162741822_162741824delGGTinsTCA;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:S768R	MUT		Responsive	DDR2 (S768R)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.2304T>G	chr1:g.162748390T>G	DDR2:S768R	CSQN=Missense;reference_codon=AGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.162748390T>A,chr1:g.162748388A>C;candidate_mnv_variants=chr1:g.162748388_162748390delAGTinsCGA,chr1:g.162748388_162748390delAGTinsCGC,chr1:g.162748388_162748390delAGTinsCGG;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000367922	Squamous cell lung carcinoma
DDR2:S768R	MUT		Responsive	DDR2 (S768R)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	DDR2		LUSC	Squamous cell lung carcinoma	PMID:22328973	1.0		c.2304T>G	chr1:g.162748390T>G	DDR2:S768R	CSQN=Missense;reference_codon=AGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.162748390T>A,chr1:g.162748388A>C;candidate_mnv_variants=chr1:g.162748388_162748390delAGTinsCGA,chr1:g.162748388_162748390delAGTinsCGC,chr1:g.162748388_162748390delAGTinsCGG;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000367922	Squamous cell lung carcinoma
DNMT3A:.	MUT		Responsive	DNMT3A oncogenic mutation			RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	DNMT3A		AML	Acute myeloid leukemia	PMID:22417203	1.0									Acute myeloid leukemia
DPYD::consequence::splice_donor_variant:.	MUT		Increased Toxicity	DPYD splice donor variant		01/16	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0									Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)		01/16	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0		c.1679T>G	chr1:g.97981343A>C	DPYD:I560S	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000370192	Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)		01/16	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0		c.2846A>T	chr1:g.97547947T>A	DPYD:D949V	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000370192	Any cancer type
DPYD::consequence::splice_donor_variant:.	MUT		Increased Toxicity	DPYD splice donor variant		01/16	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0									Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)		01/16	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0		c.1679T>G	chr1:g.97981343A>C	DPYD:I560S	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000370192	Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)		01/16	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0		c.2846A>T	chr1:g.97547947T>A	DPYD:D949V	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000370192	Any cancer type
DPYD::consequence::splice_donor_variant:.	MUT		Increased Toxicity	DPYD splice donor variant		01/16	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	Any cancer type	PMID:23988873	1.0									Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)		01/16	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	Any cancer type	PMID:23988873	1.0		c.1679T>G	chr1:g.97981343A>C	DPYD:I560S	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000370192	Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)		01/16	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	Any cancer type	PMID:23988873	1.0		c.2846A>T	chr1:g.97547947T>A	DPYD:D949V	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000370192	Any cancer type
MAP2K2:Q60P	MUT		Resistant	MAP2K2 (Q60P)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K2		CM	Cutaneous melanoma	PMID:24265154	1.0		c.179A>C	chr19:g.4117541T>G	MAP2K2:Q60P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.4117540_4117541delCTinsAG,chr19:g.4117540_4117541delCTinsTG,chr19:g.4117540_4117541delCTinsGG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.103G>A	chr19:g.4117617C>T	MAP2K2:V35M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.136C>T	chr19:g.4117584G>A	MAP2K2:L46F	CSQN=Missense;reference_codon=CTT;candidate_codons=TTT,TTC;candidate_mnv_variants=chr19:g.4117582_4117584delAAGinsGAA;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.376A>G	chr19:g.4110581T>C	MAP2K2:N126D	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.4110579_4110581delGTTinsATC;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	Cutaneous melanoma	PMID:24265153	1.0		c.373T>A	chr19:g.4110584A>T	MAP2K2:C125S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr19:g.4110583C>G;candidate_mnv_variants=chr19:g.4110582_4110584delGCAinsACT,chr19:g.4110582_4110583delGCinsAG,chr19:g.4110582_4110583delGCinsCG,chr19:g.4110582_4110583delGCinsTG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MET:D1246V	MUT		Resistant	MET (D1246V)		07/17	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		LUAD	Lung adenocarcinoma	PMID:27694386	1.0		c.3737A>T	chr7:g.116423408A>T	MET:D1246V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.116423408_116423409delACinsTA,chr7:g.116423408_116423409delACinsTG,chr7:g.116423408_116423409delACinsTT;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000318493	Lung adenocarcinoma
NF1:.	MUT		Resistant	NF1 oncogenic mutation		07/16	RDientsmann	[]	[Retinoic Acid]	Retinoic Acids		Pre-clinical	NF1		NB	Neuroblastoma	PMID:20655465	1.0									Neuroblastoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)		01/16	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		L	Lung carcinoma	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0									Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	Lung carcinoma	PMID:22753918	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0									Lung carcinoma
EGFR::consequence::inframe_insertion:762-823	MUT		Responsive	EGFR exon 20 insertions		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Case report	EGFR		L	Lung carcinoma	ASCO 2014 (abstr 8015)	1.0									Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 4380)	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0									Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)		01/16	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	Lung carcinoma	PMID:23102728	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:S492R	MUT		Responsive	EGFR (S492R)		01/16	RDientsmann	[]	[novel EGFR mAb inhibitor]	novel EGFR mAb inhibitors		Early trials	EGFR		COREAD	Colorectal adenocarcinoma	PMID:25962717	1.0		c.1476C>G	chr7:g.55228009C>G	EGFR:S492R	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)		01/16	CRubio-Perez;RDientsmann	[Rociletinib,HM61713]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc)		Late trials	EGFR		NSCLC	Non-small cell lung cancer	NCT02322281	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0									Non-small cell lung cancer
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions		01/16	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)		Late trials	EGFR		L	Lung carcinoma	PMID:22753918;PMID:25589191	1.0									Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0									Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	ESMO 2012 (abstr 1289)	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)		01/16	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	PMID:25074459	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)		06/16	RDientsmann	Afatinib;Nimotuzumab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	Lung carcinoma	PMID:26667485	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:P546S	MUT		Responsive	EGFR (P546S)		01/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		HNC	Head and neck cancer	PMID:23578570	1.0		c.1636C>T	chr7:g.55231430C>T	EGFR:P546S	CSQN=Missense;reference_codon=CCA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55231430_55231432delCCAinsTCT,chr7:g.55231430_55231432delCCAinsTCG,chr7:g.55231430_55231432delCCAinsTCC,chr7:g.55231430_55231432delCCAinsAGC,chr7:g.55231430_55231432delCCAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000275493	Head and neck cancer
EGFR:P753S	MUT		Responsive	EGFR (P753S)		01/16	RDientsmann	Cetuximab;Sirolimus	EGFR mAb inhibitor;MTOR inhibitor	Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor)		Case report	EGFR		HNC	Head and neck cancer	PMID:24934779	1.0		c.2257C>T	chr7:g.55242487C>T	EGFR:P753S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242487_55242489delCCGinsTCT,chr7:g.55242487_55242489delCCGinsTCC,chr7:g.55242487_55242489delCCGinsTCA,chr7:g.55242487_55242489delCCGinsAGC,chr7:g.55242487_55242489delCCGinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Head and neck cancer
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions	exon 19 deletions		RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0									Non-small cell lung cancer
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		L	Lung carcinoma	PMID:22190593	1.0									Lung carcinoma
EGFR::consequence::inframe_insertion:769-770	MUT		Responsive	EGFR inframe insertion (769-770)		12/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	Lung carcinoma	PMID:26773740;PMID:23328547	1.0									Lung carcinoma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	Glioma	PMID:17177598	1.0		c.866C>T	chr7:g.55221822C>T	EGFR:A289V	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.55221822_55221823delCCinsTA,chr7:g.55221822_55221823delCCinsTG,chr7:g.55221822_55221823delCCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000275493	Glioma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	Glioma	PMID:17177598	1.0		c.323G>A	chr7:g.55211080G>A	EGFR:R108K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.55211080_55211081delGAinsAG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000275493	Glioma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	Glioma	PMID:17177598	1.0		c.1793G>T	chr7:g.55233043G>T	EGFR:G598V	CSQN=Missense;reference_codon=GGA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.55233043_55233044delGAinsTC,chr7:g.55233043_55233044delGAinsTG,chr7:g.55233043_55233044delGAinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_15]	+	ENST00000275493	Glioma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	Glioma	PMID:17177598	1.0		c.787A>C	chr7:g.55221743A>C	EGFR:T263P	CSQN=Missense;reference_codon=ACC;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55221743_55221745delACCinsCCT,chr7:g.55221743_55221745delACCinsCCG,chr7:g.55221743_55221745delACCinsCCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000275493	Glioma
NRAS:Q61.	MUT		Resistant	NRAS (Q61)		01/16	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	NRAS		CM	Cutaneous melanoma	PMID:23569304;PMID:24265153	1.0									Cutaneous melanoma
EGFR:K757R,E746G	MUT		Responsive	EGFR (K757R,E746G)		12/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	Lung carcinoma	PMID:26773740	1.0		c.2270A>G	chr7:g.55242500A>G	EGFR:K757R	CSQN=Missense;reference_codon=AAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55242500_55242501delAGinsGA,chr7:g.55242499_55242500delAAinsCG,chr7:g.55242499_55242501delAAGinsCGA,chr7:g.55242499_55242501delAAGinsCGC,chr7:g.55242499_55242501delAAGinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung carcinoma
EGFR:K757R,E746G	MUT		Responsive	EGFR (K757R,E746G)		12/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	Lung carcinoma	PMID:26773740	1.0		c.2237A>G	chr7:g.55242467A>G	EGFR:E746G	CSQN=Missense;reference_codon=GAA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.55242467_55242468delAAinsGT,chr7:g.55242467_55242468delAAinsGG,chr7:g.55242467_55242468delAAinsGC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung carcinoma
EGFR:L858R	MUT		Responsive	EGFR (L858R)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861.,G719.,S768I	MUT		Responsive	EGFR (L858R,L861,G719,S768I)			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	NCCN	1.0									Non-small cell lung cancer
PIK3CA:E545*	MUT		Resistant	PIK3CA (E545*)		03/16	DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	PIK3CA		CM	Cutaneous melanoma	PMID:24265155	1.0		c.1633G>T	chr3:g.178936091G>T	PIK3CA:E545*	CSQN=Nonsense;reference_codon=GAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.178936091_178936093delGAGinsTAA,chr3:g.178936091_178936093delGAGinsTGA;aliases=ENSP00000263967;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000263967	Cutaneous melanoma
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0									Non-small cell lung cancer
PIK3CA:.	MUT		Not Responsive	PIK3CA oncogenic mutation		07/17	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Early trials	PIK3CA		L	Lung carcinoma	ASCO 2017 (abstr 9054)	1.0									Lung carcinoma
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>A	chr7:g.55259524T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>C	chr7:g.55241708G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>A	chr7:g.55241707G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2155G>T	chr7:g.55241707G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2156G>A	chr7:g.55241708G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2240T>C	chr7:g.55242470T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2303G>T	chr7:g.55249005G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>C	chr7:g.55259524T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2582T>G	chr7:g.55259524T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung cancer
PIK3CB:D1067Y	MUT		Resistant	PIK3CB (D1067Y)		04/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CB		BRCA	Breast adenocarcinoma	PMID:26759240	1.0		c.3199G>T	chr3:g.138374245C>A	PIK3CB:D1067Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000477593	Breast adenocarcinoma
EGFR:E690K	MUT		Responsive	EGFR (E690K)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)	Approved	Case report	EGFR		ED	Endometrial carcinoma	PMID:22885469	1.0		c.2068G>A	chr7:g.55241620G>A	EGFR:E690K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.55241620_55241622delGAGinsAAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Endometrial carcinoma
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions		01/16	CRubio-Perez	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	Early trials	EGFR		L	Lung carcinoma	NCT02465060	1.0									Lung carcinoma
EGFR::consequence::inframe_insertion:762-823	MUT		Responsive	EGFR exon 20 insertions	Insertion exon 20	12/16	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Pre-clinical	EGFR		L	Lung carcinoma	PMID:26515464	1.0									Lung carcinoma
PTEN:.	MUT		Resistant	PTEN oncogenic mutation			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	PTEN		COREAD	Colorectal adenocarcinoma	PMID:21163703;PMID:19398573	1.0									Colorectal adenocarcinoma
PTEN:.	MUT		Not Responsive	PTEN oncogenic mutation		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	PTEN		ED	Endometrial carcinoma	PMID:21788564;PMID:23238879	1.0									Endometrial carcinoma
EGFR:L858R	MUT		Responsive	EGFR (L858R)		01/16	CRubio-Perez	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	Early trials	EGFR		L	Lung carcinoma	NCT02465060	1.0		c.2573T>G	chr7:g.55259515T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung carcinoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)		01/16	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	FDA guidelines	EGFR		NSCLC	Non-small cell lung cancer	FDA	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung cancer
EGFR:S492R	MUT		Responsive	EGFR (S492R)		01/16	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	Colorectal adenocarcinoma	PMID:22270724	1.0		c.1476C>G	chr7:g.55228009C>G	EGFR:S492R	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR::consequence::inframe_deletion:6-273	MUT		Responsive	EGFR inframe deletion (6-273)	he EGFRvIII variant receptor is characterized by a deletion of exons 2–7 of the wild type (Wt) EGFR gene. This results in an in-frame truncation of amino acids (AA) 6 to 273 in the extracellular domain of the full length protein,	09/15	MMartínez	Rindopepimut	Vaccine	Rindopepimut (Vaccine)	Clinical Trials	Late trials	EGFR		GB	Glioblastoma	NCT01480479	1.0	Indirect								Glioblastoma
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	EPHA2		LUSC	Squamous cell lung carcinoma	PMID:20360610	1.0		c.1171G>A	chr1:g.16464489C>T	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Squamous cell lung carcinoma
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)			RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	EPHA2		LUSC	Squamous cell lung carcinoma	PMID:20360610	1.0		c.1171G>A	chr1:g.16464489C>T	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Squamous cell lung carcinoma
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		LUSC	Squamous cell lung carcinoma	PMID:20360610	1.0		c.1171G>A	chr1:g.16464489C>T	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Squamous cell lung carcinoma
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		LUSC	Squamous cell lung carcinoma	PMID:20360610	1.0		c.1171G>A	chr1:g.16464489C>T	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Squamous cell lung carcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20			RDientsmann	[Afatinib,Lapatinib,Neratinib]	[ERBB2 inhibitor]	ERBB2 inhibitors (Afatinib,Lapatinib,Neratinib,etc)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	PMID:26598547	1.0									Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20			RDientsmann	[Trastuzumab]	[ERBB2 mAb inhibitor]	ERBB2 mAb inhibitors (Trastuzumab,etc)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	PMID:26598547	1.0									Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:A775YVMA,::inframe_insertion:G776VC	MUT		Responsive	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)		07/17	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Early trials	ERBB2		L	Lung carcinoma	ASCO 2017 (abstr 8510)	1.0									Lung carcinoma
ERBB2:V659E,S310F	MUT		Responsive	ERBB2 (V659E,S310F)		07/17	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Early trials	ERBB2		L	Lung carcinoma	ASCO 2017 (abstr 8510)	1.0		c.1976_1977delTTinsAG	chr17:g.37879601_37879602delTTinsAG	ERBB2:V659E	CSQN=Missense;reference_codon=GTT;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37879601_37879602delTTinsAA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000269571	Lung carcinoma
ERBB2:V659E,S310F	MUT		Responsive	ERBB2 (V659E,S310F)		07/17	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Early trials	ERBB2		L	Lung carcinoma	ASCO 2017 (abstr 8510)	1.0		c.929C>T	chr17:g.37868208C>T	ERBB2:S310F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Lung carcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20		07/17	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	PMID:26598547;ASCO 2017 (abstr 9071)	1.0									Lung adenocarcinoma
ERBB2:T798I	MUT		Responsive	ERBB2 (T798I)		07/17	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:28274957	1.0		c.2393C>T	chr17:g.37881064C>T	ERBB2:T798I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881064_37881065delCAinsTC,chr17:g.37881064_37881065delCAinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation		06/16	EArriola	Dacomitinib	Pan ERBB inhibitor	Dacomitinib (Pan ERBB inhibitor)		Early trials	ERBB2		NSCLC	Non-small cell lung cancer	PMID:25899785	1.0									Non-small cell lung cancer
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2305G>T	chr17:g.37880261G>T	ERBB2:D769Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2305G>C	chr17:g.37880261G>C	ERBB2:D769H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2686C>T	chr17:g.37881616C>T	ERBB2:R896C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_22]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2329G>C	chr17:g.37881000G>C	ERBB2:V777L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr17:g.37881000G>T;candidate_mnv_variants=chr17:g.37881000_37881002delGTGinsCTT,chr17:g.37881000_37881002delGTGinsCTA,chr17:g.37881000_37881002delGTGinsCTC,chr17:g.37881000_37881002delGTGinsTTA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2524G>A	chr17:g.37881332G>A	ERBB2:V842I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881332_37881334delGTAinsATC,chr17:g.37881332_37881334delGTAinsATT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.926G>C	chr17:g.37868205G>C	ERBB2:G309A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsCC,chr17:g.37868205_37868206delGAinsCG,chr17:g.37868205_37868206delGAinsCT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:V659E	MUT		Responsive	ERBB2 (V659E)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA;LUAD	Breast adenocarcinoma;Lung adenocarcinoma	PMID:23950206	1.0		c.1976_1977delTTinsAG	chr17:g.37879601_37879602delTTinsAG	ERBB2:V659E	CSQN=Missense;reference_codon=GTT;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37879601_37879602delTTinsAA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000269571	Breast adenocarcinoma;Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20		07/17	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	PMID:26598547;ASCO 2017 (abstr 9071)	1.0									Lung adenocarcinoma
ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP	MUT		Responsive	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0									Breast adenocarcinoma
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	ESMO 2014 (abstr LBA39_PR)	1.0									Lung adenocarcinoma
ERBB2:K753E	MUT		Responsive	ERBB2 (K753E)		12/16	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:27697991	1.0		c.2257A>G	chr17:g.37880213A>G	ERBB2:K753E	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37880213_37880215delAAAinsGAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2264T>C	chr17:g.37880220T>C	ERBB2:L755S	CSQN=Missense;reference_codon=TTG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr17:g.37880220_37880221delTGinsCT,chr17:g.37880220_37880221delTGinsCC,chr17:g.37880220_37880221delTGinsCA,chr17:g.37880219_37880221delTTGinsAGC,chr17:g.37880219_37880221delTTGinsAGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.926G>C	chr17:g.37868205G>C	ERBB2:G309A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsCC,chr17:g.37868205_37868206delGAinsCG,chr17:g.37868205_37868206delGAinsCT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2305G>T	chr17:g.37880261G>T	ERBB2:D769Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2305G>C	chr17:g.37880261G>C	ERBB2:D769H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2686C>T	chr17:g.37881616C>T	ERBB2:R896C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_22]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2329G>C	chr17:g.37881000G>C	ERBB2:V777L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr17:g.37881000G>T;candidate_mnv_variants=chr17:g.37881000_37881002delGTGinsCTT,chr17:g.37881000_37881002delGTGinsCTA,chr17:g.37881000_37881002delGTGinsCTC,chr17:g.37881000_37881002delGTGinsTTA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)			RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:23220880	1.0		c.2524G>A	chr17:g.37881332G>A	ERBB2:V842I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881332_37881334delGTAinsATC,chr17:g.37881332_37881334delGTAinsATT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000269571	Breast adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20		07/17	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	PMID:26598547;ASCO 2017 (abstr 9071)	1.0									Lung adenocarcinoma
ERBB2:L869R	MUT		Responsive	ERBB2 (L869R)		07/17	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA	Breast adenocarcinoma	PMID:28274957	1.0		c.2606T>G	chr17:g.37881414T>G	ERBB2:L869R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37881413_37881414delCTinsAG,chr17:g.37881414_37881415delTGinsGA,chr17:g.37881414_37881415delTGinsGC,chr17:g.37881414_37881415delTGinsGT,chr17:g.37881413_37881415delCTGinsAGA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:S310.,L755.,V777.	MUT		Responsive	ERBB2 (S310,L755,V777)		07/17	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		CANCER	Any cancer type	AACR 2017 (abstr CT001)	1.0									Any cancer type
ERBB2::consequence::inframe_insertion:P780GSP,::inframe_insertion:.781GSP,::inframe_insertion:A775YVMA,::inframe_insertion:G776YVMA	MUT		Responsive	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)		07/17	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		CANCER	Any cancer type	AACR 2017 (abstr CT001)	1.0									Any cancer type
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation			RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	ESMO 2014 (abstr LBA39_PR)	1.0									Lung adenocarcinoma
STK11:.	MUT		Resistant	STK11 oncogenic mutation		04/16	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	STK11		L	Lung carcinoma	PMID:23129625;PMID:24045185	1.0									Lung carcinoma
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.2305G>T	chr17:g.37880261G>T	ERBB2:D769Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.2305G>C	chr17:g.37880261G>C	ERBB2:D769H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.2686C>T	chr17:g.37881616C>T	ERBB2:R896C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_22]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.926G>A	chr17:g.37868205G>A	ERBB2:G309E	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.929C>T	chr17:g.37868208C>T	ERBB2:S310F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.929C>A	chr17:g.37868208C>A	ERBB2:S310Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	Breast adenocarcinoma;Any cancer type	PMID:23220880;PMID:22908275	1.0		c.931T>C	chr17:g.37868210T>C	ERBB2:C311R	CSQN=Missense;reference_codon=TGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37868210_37868212delTGCinsAGG,chr17:g.37868210_37868212delTGCinsAGA,chr17:g.37868210_37868212delTGCinsCGA,chr17:g.37868210_37868212delTGCinsCGG,chr17:g.37868210_37868212delTGCinsCGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	Any cancer type	PMID:22908275	1.0		c.926G>A	chr17:g.37868205G>A	ERBB2:G309E	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	Any cancer type	PMID:22908275	1.0		c.929C>T	chr17:g.37868208C>T	ERBB2:S310F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	Any cancer type	PMID:22908275	1.0		c.929C>A	chr17:g.37868208C>A	ERBB2:S310Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	Any cancer type	PMID:22908275	1.0		c.931T>C	chr17:g.37868210T>C	ERBB2:C311R	CSQN=Missense;reference_codon=TGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37868210_37868212delTGCinsAGG,chr17:g.37868210_37868212delTGCinsAGA,chr17:g.37868210_37868212delTGCinsCGA,chr17:g.37868210_37868212delTGCinsCGG,chr17:g.37868210_37868212delTGCinsCGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	Any cancer type	PMID:22908275	1.0		c.962A>G	chr17:g.37868241A>G	ERBB2:E321G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr17:g.37868241_37868242delAGinsGT,chr17:g.37868241_37868242delAGinsGA,chr17:g.37868241_37868242delAGinsGC;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	Any cancer type	PMID:22908275	1.0		c.1000T>A	chr17:g.37868279T>A	ERBB2:C334S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr17:g.37868280G>C;candidate_mnv_variants=chr17:g.37868279_37868281delTGCinsAGT,chr17:g.37868280_37868281delGCinsCT,chr17:g.37868280_37868281delGCinsCG,chr17:g.37868280_37868281delGCinsCA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G776L	MUT		Responsive	ERBB2 (G776L)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Case report	ERBB2		LUAD	Lung adenocarcinoma	PMID:16775247	1.0		c.2326_2327delGGinsCT	chr17:g.37880997_37880998delGGinsCT	ERBB2:G776L	CSQN=Missense;reference_codon=GGT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr17:g.37880997_37880999delGGTinsCTG,chr17:g.37880997_37880999delGGTinsCTA,chr17:g.37880997_37880999delGGTinsCTC,chr17:g.37880997_37880999delGGTinsTTA,chr17:g.37880997_37880999delGGTinsTTG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20		07/17	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		LUAD	Lung adenocarcinoma	PMID:26598547;ASCO 2017 (abstr 9071)	1.0									Lung adenocarcinoma
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)			RDientsmann	[]	[ERBB3 mAb inhibitor]	ERBB3 mAb inhibitors		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.785C>A	chr12:g.56481857C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)			RDientsmann	[]	[ERBB3 mAb inhibitor]	ERBB3 mAb inhibitors		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.785C>A	chr12:g.56481857C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.2426A>G	chr12:g.56490980A>G	ERBB3:Q809R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000267101	Any cancer type
ERBB3:G284R,R103G	MUT		Responsive	ERBB3 (G284R,R103G)			RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	Bladder carcinoma	ASCO 2015 (abstr e15516)	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Bladder carcinoma
ERBB3:G284R,R103G	MUT		Responsive	ERBB3 (G284R,R103G)			RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	Bladder carcinoma	ASCO 2015 (abstr e15516)	1.0		c.307C>G	chr12:g.56478851C>G	ERBB3:R103G	CSQN=Missense;reference_codon=CGC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr12:g.56478851_56478853delCGCinsGGT,chr12:g.56478851_56478853delCGCinsGGG,chr12:g.56478851_56478853delCGCinsGGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000267101	Bladder carcinoma
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)		07/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	Bladder carcinoma	PMID:27044931	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Bladder carcinoma
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)		07/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	Bladder carcinoma	PMID:27044931	1.0		c.310G>A	chr12:g.56478854G>A	ERBB3:V104M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000267101	Bladder carcinoma
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)		07/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	Bladder carcinoma	PMID:27044931	1.0		c.307C>G	chr12:g.56478851C>G	ERBB3:R103G	CSQN=Missense;reference_codon=CGC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr12:g.56478851_56478853delCGCinsGGT,chr12:g.56478851_56478853delCGCinsGGG,chr12:g.56478851_56478853delCGCinsGGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000267101	Bladder carcinoma
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.785C>A	chr12:g.56481857C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.2426A>G	chr12:g.56490980A>G	ERBB3:Q809R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)			RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.785C>A	chr12:g.56481857C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)			RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.785C>A	chr12:g.56481857C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.850G>A	chr12:g.56481922G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	Any cancer type	PMID:23680147	1.0		c.2426A>G	chr12:g.56490980A>G	ERBB3:Q809R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000267101	Any cancer type
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	Cutaneous melanoma	PMID:19718025	1.0		c.949G>A	chr2:g.212578308C>T	ERBB4:E317K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212578306_212578308delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	Cutaneous melanoma	PMID:19718025	1.0		c.1354G>A	chr2:g.212566827C>T	ERBB4:E452K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212566825_212566827delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	Cutaneous melanoma	PMID:19718025	1.0		c.1630C>T	chr2:g.212537975G>A	ERBB4:R544W	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_14]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	Cutaneous melanoma	PMID:19718025	1.0		c.1177C>T	chr2:g.212570064G>A	ERBB4:R393W	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_10]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	Cutaneous melanoma	PMID:19718025	1.0		c.2614G>A	chr2:g.212295699C>T	ERBB4:E872K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212295697_212295699delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_21]	-	ENST00000342788	Cutaneous melanoma
ERCC1:.	MUT		Responsive	ERCC1 oncogenic mutation			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ERCC1		L	Lung carcinoma	PMID:23934192	1.0									Lung carcinoma
ERCC1:.	MUT		Responsive	ERCC1 oncogenic mutation		01/16	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC1		L	Lung carcinoma	PMID:23275151;PMID:23934192	1.0									Lung carcinoma
TP53:.	MUT		Resistant	TP53 oncogenic mutation		01/16	RDientsmann	[]	[MDM2 inhibitor]	MDM2 inhibitors		Early trials	TP53		LIP	Liposarcoma	PMID:23084521;ASCO 2015 (abstr 10564)	1.0									Liposarcoma
ERCC2:.	MUT		Responsive	ERCC2 oncogenic mutation			RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	ERCC2		BLCA	Bladder carcinoma	PMID:25096233	1.0									Bladder carcinoma
ERCC4:.	MUT		Responsive	ERCC4 oncogenic mutation			RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC4		OV	Ovarian carcinoma	PMID:25634215	1.0									Ovarian carcinoma
ERCC6:.	MUT		Responsive	ERCC6 oncogenic mutation			RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC6		OV	Ovarian carcinoma	PMID:25634215	1.0									Ovarian carcinoma
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)		01/16	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	Breast adenocarcinoma	AACR 2015 (abstr CT231)	1.0									Breast adenocarcinoma
NTRK1:G595R,G667C	MUT		Resistant	NTRK1 (G595R,G667C)		11/15	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	Colorectal adenocarcinoma	PMID:26546295	1.0		c.1783G>A	chr1:g.156846342G>A	NTRK1:G595R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.156846342G>C;candidate_mnv_variants=chr1:g.156846342_156846344delGGGinsAGA,chr1:g.156846342_156846344delGGGinsCGA,chr1:g.156846342_156846344delGGGinsCGC,chr1:g.156846342_156846344delGGGinsCGT;aliases=ENSP00000431418;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000524377	Colorectal adenocarcinoma
NTRK1:G595R,G667C	MUT		Resistant	NTRK1 (G595R,G667C)		11/15	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	Colorectal adenocarcinoma	PMID:26546295	1.0		c.1999G>T	chr1:g.156849107G>T	NTRK1:G667C	CSQN=Missense;reference_codon=GGT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.156849107_156849109delGGTinsTGC;aliases=ENSP00000431418;source=Ensembl	inside_[cds_in_exon_15]	+	ENST00000524377	Colorectal adenocarcinoma
ESR1:.	MUT		Responsive	ESR1 oncogenic mutation		06/16	RDientsmann	Fluvestrant	Hormonal therapy	Fluvestrant (Hormonal therapy)		Late trials	ESR1		BRCA	Breast adenocarcinoma	PMID:27269946	1.0									Breast adenocarcinoma
ERBB4:H809G	MUT		Resistant	ERBB4 (H809G)		11/15	RDientsmann	[Lapatinib]	[ERBB2 inhibitor]	ERBB2 inhibitors (Lapatinib,etc)		Case report	ERBB4		BRCA	Breast adenocarcinoma	PMID:26530965	1.0		c.2425_2426delCAinsGG	chr2:g.212426689_212426690delTGinsCC	ERBB4:H809G	CSQN=Missense;reference_codon=CAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr2:g.212426688_212426690delGTGinsACC,chr2:g.212426688_212426690delGTGinsCCC,chr2:g.212426688_212426690delGTGinsTCC;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_20]	-	ENST00000342788	Breast adenocarcinoma
ABL1:T315I	MUT		Resistant	ABL1 (T315I)	Has to be rechecked	12/15	CRubio-Perez	[Nilotinib,Dasatinib]	[BCR-ABL inhibitor 2nd gen]	BCR-ABL inhibitor 2nd gens (Nilotinib,Dasatinib,etc)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.944C>T	chr9:g.133748283C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
EZH2:Y641.,A677.	MUT	Cell line	Responsive	EZH2 (Y641,A677)			RDientsmann;ECampo	[EPZ-005687,EPZ-6438]	[EZH2 inhibitor]	EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)	Pre-clinical	Pre-clinical	EZH2		LY	Lymphoma	PMID:23023262;PMID:24563539	1.0	Direct								Lymphoma
FANCA:.	MUT		Responsive	FANCA oncogenic mutation		01/16	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	FANCA		PRAD	Prostate adenocarcinoma	PMID:26510020	1.0									Prostate adenocarcinoma
FANCC:.	MUT		Responsive	FANCC oncogenic mutation		09/15	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	FANCC	BLCA	BLCA	Bladder carcinoma	PMID:26238431	1.0	Indirect								Bladder carcinoma
FAT1:.	MUT		Responsive	FAT1 oncogenic mutation		07/16	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	FAT1		HNSC	Head and neck squamous cell carcinoma	PMID:27397505	1.0									Head and neck squamous cell carcinoma
FBXW7:.	MUT		Responsive	FBXW7 oncogenic mutation		01/16	RDientsmann	[]	[Steroid]	Steroids		Late trials	FBXW7		ALL	Acute lymphoblastic leukemia	PMID:20861909	1.0									Acute lymphoblastic leukemia
TP53:.	MUT		Resistant	TP53 oncogenic mutation		12/16	RDientsmann	Abemaciclib	CDK4/CDK6 inhibitor	Abemaciclib (CDK4/CDK6 inhibitor)		Early trials	TP53		BRCA	Breast adenocarcinoma	PMID:27217383	1.0									Breast adenocarcinoma
AR:L702H,T878A	MUT		Resistant	AR (L702H,T878A)	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	11/15	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	Prostate adenocarcinoma	PMID:26537258	1.0		c.2105T>A	chrX:g.66931463T>A	AR:L702H	CSQN=Missense;reference_codon=CTC;candidate_codons=CAT,CAC;candidate_mnv_variants=chrX:g.66931463_66931464delTCinsAT;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000374690	Prostate adenocarcinoma
AR:L702H,T878A	MUT		Resistant	AR (L702H,T878A)	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	11/15	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	Prostate adenocarcinoma	PMID:26537258	1.0		c.2632A>G	chrX:g.66943552A>G	AR:T878A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
FGFR2::consequence::inframe_insertion:A266.,::inframe_insertion:S267.	MUT		Responsive	FGFR2 inframe insertion (A266),inframe insertion (S267)		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		L	Lung carcinoma	PMID:26048680	1.0									Lung carcinoma
FGFR2:S252W,N550K	MUT		Responsive	FGFR2 (S252W,N550K)	REMAP: N549K to N500K to have all mutations in same transcript (ENST00000457416)		RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	Endometrial carcinoma	PMID:18552176;PMID:22238366;PMID:23002168	1.0		c.755C>G	chr10:g.123279677G>C	FGFR2:S252W	CSQN=Missense;reference_codon=TCG;candidate_codons=TGG;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000457416	Endometrial carcinoma
FGFR2:S252W,N550K	MUT		Responsive	FGFR2 (S252W,N550K)	REMAP: N549K to N500K to have all mutations in same transcript (ENST00000457416)		RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	Endometrial carcinoma	PMID:18552176;PMID:22238366;PMID:23002168	1.0		c.1650T>G	chr10:g.123258034A>C	FGFR2:N550K	CSQN=Missense;reference_codon=AAT;candidate_codons=AAG,AAA;candidate_snv_variants=chr10:g.123258034A>T;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000457416	Endometrial carcinoma
FGFR2:V565I	MUT		Responsive	FGFR2 (V565I)		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	Endometrial carcinoma	ENA 2014 (abstr 381)	1.0		c.1693G>A	chr10:g.123256219C>T	FGFR2:V565I	CSQN=Missense;reference_codon=GTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr10:g.123256217_123256219delAACinsGAT,chr10:g.123256217_123256219delAACinsTAT;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000457416	Endometrial carcinoma
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	Squamous cell lung carcinoma	PMID:23786770;PMID:25035393	1.0		c.870G>T	chr10:g.123279562C>A	FGFR2:W290C	CSQN=Missense;reference_codon=TGG;candidate_codons=TGT,TGC;candidate_snv_variants=chr10:g.123279562C>G;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000457416	Squamous cell lung carcinoma
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	Squamous cell lung carcinoma	PMID:23786770;PMID:25035393	1.0		c.959C>G	chr10:g.123278324G>C	FGFR2:S320C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr10:g.123278323_123278324delGGinsAC;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000457416	Squamous cell lung carcinoma
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	Squamous cell lung carcinoma	PMID:23786770;PMID:25035393	1.0		c.1980G>C	chr10:g.123247514C>G	FGFR2:K660N	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr10:g.123247514C>A;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_14]	-	ENST00000457416	Squamous cell lung carcinoma
ALK:I1171T	MUT		Resistant	ALK (I1171T)		01/16	RDientsmann	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:25228534	1.0		c.3512T>C	chr2:g.29445213A>G	ALK:I1171T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)		01/16	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	Endometrial carcinoma	PMID:23908597	1.0									Endometrial carcinoma
FGFR3:.	MUT		Responsive	FGFR3 oncogenic mutation		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR3		BLCA	Bladder carcinoma	PMID:27870574	1.0									Bladder carcinoma
FGFR3:K650.,Y373C	MUT		Responsive	FGFR3 (K650,Y373C)		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	Myeloma	PMID:16091734;PMID:20439987;PMID:22869148	1.0									Myeloma
FGFR3:S249C,G691R	MUT		Responsive	FGFR3 (S249C,G691R)		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		LUAD	Lung adenocarcinoma	PMID:27998968	1.0		c.746C>G	chr4:g.1803568C>G	FGFR3:S249C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr4:g.1803568_1803569delCCinsGT;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000440486	Lung adenocarcinoma
FGFR3:S249C,G691R	MUT		Responsive	FGFR3 (S249C,G691R)		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		LUAD	Lung adenocarcinoma	PMID:27998968	1.0		c.2071G>A	chr4:g.1808313G>A	FGFR3:G691R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr4:g.1808313G>C;candidate_mnv_variants=chr4:g.1808313_1808315delGGGinsAGA,chr4:g.1808313_1808315delGGGinsCGA,chr4:g.1808313_1808315delGGGinsCGC,chr4:g.1808313_1808315delGGGinsCGT;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000440486	Lung adenocarcinoma
AR:F877L	MUT		Resistant	AR (F877L)	REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge.	09/15	RDientsmann;ARodriguez-Vida	Arn-509	AR inhibitor	Arn-509 (AR inhibitor)		Case report	AR	PRAD	PRAD	Prostate adenocarcinoma	PMID:23779130	1.0		c.2629T>C	chrX:g.66943549T>C	AR:F877L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chrX:g.66943551C>A,chrX:g.66943551C>G;candidate_mnv_variants=chrX:g.66943549_66943551delTTCinsCTT,chrX:g.66943549_66943551delTTCinsCTG,chrX:g.66943549_66943551delTTCinsCTA;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
FGFR3:K650.	MUT		Responsive	FGFR3 (K650)			RDientsmann	Bortezomib	Proteasome inhibitor	Bortezomib (Proteasome inhibitor)		Pre-clinical	FGFR3		MYMA	Myeloma	PMID:19331127;PMID:21273588	1.0									Myeloma
FGFR4:N535.,V550.	MUT		Responsive	FGFR4 (N535,V550)	REMAP:changed N535 and V550 from K535 and E550. Reference added by carlota	04/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR4		RHBDS	Rhabdomyosarcoma	PMID:19809159;PMID:24124571	1.0									Rhabdomyosarcoma
FLCN:.	MUT		Responsive	FLCN oncogenic mutation		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	FLCN		R	Renal carcinoma	PMID:23995526	1.0									Renal carcinoma
FGFR3:Y373C	MUT		Resistant	FGFR3 (Y373C)			RDientsmann	Bortezomib	Proteasome inhibitor	Bortezomib (Proteasome inhibitor)		Pre-clinical	FGFR3		MYMA	Myeloma	PMID:19331127;PMID:21273588	1.0		c.1118A>G	chr4:g.1806099A>G	FGFR3:Y373C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr4:g.1806099_1806100delATinsGC;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000440486	Myeloma
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	ITD (codified as inframe) in Juxtamembrane domain	01/16	RDientsmann	[]	[FLT3 inhibitor]	FLT3 inhibitors		Early trials	FLT3		AML	Acute myeloid leukemia	PMID:16857985	1.0									Acute myeloid leukemia
FLT3:F691.	MUT		Responsive	FLT3 (F691)		01/16	RDientsmann	[]	[novel FLT3 inhibitor]	novel FLT3 inhibitors		Pre-clinical	FLT3		AML	Acute myeloid leukemia	PMID:25847190	1.0									Acute myeloid leukemia
FLT3:N676.	MUT		Responsive	FLT3 (N676)		01/16	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	FLT3		AML	Acute myeloid leukemia	PMID:24619500	1.0									Acute myeloid leukemia
FLT3:D835.	MUT		Responsive	FLT3 (D835)		01/16	RDientsmann	Lestaurtinib	Pan-TK inhibitor	Lestaurtinib (Pan-TK inhibitor)		Case report	FLT3		AML	Acute myeloid leukemia	PMID:16857985	1.0									Acute myeloid leukemia
FLT3:D835.	MUT		Responsive	FLT3 (D835)		01/16	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Case report	FLT3		AML	Acute myeloid leukemia	PMID:20733134	1.0									Acute myeloid leukemia
FLT3:N676.	MUT		Responsive	FLT3 (N676)		01/16	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	Acute myeloid leukemia	PMID:24619500	1.0									Acute myeloid leukemia
ABL1:T315I	MUT		Resistant	ABL1 (T315I)	Has to be rechecked	12/15	CRubio-Perez	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.944C>T	chr9:g.133748283C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	ITD (codified as inframe) in Juxtamembrane domain	01/16	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Early trials	FLT3		AML	Acute myeloid leukemia	ASH 2012 (abstr 673);ASH 2012 (abstr 48)	1.0									Acute myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	ITD (codified as inframe) in Juxtamembrane domain	01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	FLT3		AML	Acute myeloid leukemia	PMID:19389879;PMID:22368270	1.0									Acute myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	ITD (codified as inframe) in Juxtamembrane domain	01/16	RDientsmann	Sorafenib;Azacytidine	Pan-TK inhibitor;Chemotherapy	Sorafenib + Azacytidine (Pan-TK inhibitor + Chemotherapy)		Early trials	FLT3		AML	Acute myeloid leukemia	PMID:23613521	1.0									Acute myeloid leukemia
NF1:.	MUT		Not Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Cediranib	ALK inhibitor	Cediranib (ALK inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	NCT00326872	1.0									Plexiform neurofibroma
ALK:G1123S	MUT		Resistant	ALK (G1123S)		09/15	EArriola	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:26134233	1.0		c.3367G>A	chr2:g.29445466C>T	ALK:G1123S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr2:g.29445464_29445466delGCCinsACT,chr2:g.29445465_29445466delCCinsGA,chr2:g.29445464_29445466delGCCinsAGA,chr2:g.29445464_29445466delGCCinsCGA,chr2:g.29445464_29445466delGCCinsTGA;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_21]	-	ENST00000389048	Lung adenocarcinoma
G6PD:S218F	MUT		Increased Toxicity (Haemolytic Anemia)	G6PD (S218F)		01/16	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD		CANCER	Any cancer type	FDA	1.0		c.653C>T	chrX:g.153762634G>A	G6PD:S218F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chrX:g.153762633_153762634delGGinsAA;aliases=ENSP00000377192;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000393562	Any cancer type
GATA3:.	MUT		Responsive	GATA3 oncogenic mutation			RDientsmann	[]	[Aromatase ihibitor]	Aromatase ihibitors		Pre-clinical	GATA3		BRCA	Breast adenocarcinoma	PMID:24758297	1.0									Breast adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)		07/17	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.5957C>A	chr6:g.117639399G>T	ROS1:S1986Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAT;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)		07/17	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.5957C>T	chr6:g.117639399G>A	ROS1:S1986F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAA;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)		01/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNA11		CM	Cutaneous melanoma	PMID:22733540;PMID:22808163	1.0		c.626A>T	chr19:g.3118942A>T	GNA11:Q209L	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)		01/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNA11		CM	Cutaneous melanoma	PMID:22733540;PMID:22808163	1.0		c.626A>C	chr19:g.3118942A>C	GNA11:Q209P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)		01/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNA11		CM	Cutaneous melanoma	ASCO 2013 (abstr CRA9003)	1.0		c.626A>T	chr19:g.3118942A>T	GNA11:Q209L	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)		01/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNA11		CM	Cutaneous melanoma	ASCO 2013 (abstr CRA9003)	1.0		c.626A>C	chr19:g.3118942A>C	GNA11:Q209P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)		01/16	RDientsmann	Vorinostat	HDAC inhibitor	Vorinostat (HDAC inhibitor)		Pre-clinical	GNA11		CM	Cutaneous melanoma	NCT01587352	1.0		c.626A>T	chr19:g.3118942A>T	GNA11:Q209L	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)		01/16	RDientsmann	Vorinostat	HDAC inhibitor	Vorinostat (HDAC inhibitor)		Pre-clinical	GNA11		CM	Cutaneous melanoma	NCT01587352	1.0		c.626A>C	chr19:g.3118942A>C	GNA11:Q209P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)		01/16	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	GNAQ		CM	Cutaneous melanoma	NCT01587352	1.0									Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)		01/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNAQ		CM	Cutaneous melanoma	PMID:22733540;PMID:22808163	1.0									Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)		01/16	RDientsmann	[]	[PKC inhibitor]	PKC inhibitors		Pre-clinical	GNAQ		CM	Cutaneous melanoma	PMID:22653968;PMID:22253748	1.0									Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)		01/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNAQ		CM	Cutaneous melanoma	ASCO 2013 (abstr CRA9003)	1.0									Cutaneous melanoma
GNAS:R201.	MUT		Responsive	GNAS (R201)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	GNAS		CANCER	Any cancer type	PMID:21835143	1.0									Any cancer type
BRAF:V600E	MUT		Resistant	BRAF (V600E)			RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	BRAF		COREAD	Colorectal adenocarcinoma	PMID:20619739;PMID:21163703;PMID:23325582	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
HRAS:.	MUT		Responsive	HRAS oncogenic mutation			RDientsmann	[]	[MEK inhibitor +/- MTOR inhibitor]	MEK inhibitor +/- MTOR inhibitors		Pre-clinical	HRAS		AML	Acute myeloid leukemia	PMID:22399013;PMID:22507781	1.0									Acute myeloid leukemia
HRAS:.	MUT		Responsive	HRAS oncogenic mutation		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	HRAS		CESC	Cervical squamous cell carcinoma	PMID:22345164	1.0									Cervical squamous cell carcinoma
HRAS:.	MUT		Responsive	HRAS oncogenic mutation			RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	HRAS		CER	Cervical carcinoma	PMID:15950068	1.0									Cervical carcinoma
HRAS:.	MUT		Responsive	HRAS oncogenic mutation		01/16	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	HRAS		CANCER	Any cancer type	NCT02383927	1.0									Any cancer type
HRAS:.	MUT		Responsive	HRAS oncogenic mutation		11/15	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)	Clinical Trials	Early trials	HRAS		CANCER	Any cancer type	NCT02383927	1.0									Any cancer type
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation		01/16	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	IDH1		AML	Acute myeloid leukemia	PMID:25599133	1.0									Acute myeloid leukemia
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation		01/16	RDientsmann	[]	[IDH1 inhibitor]	IDH1 inhibitors		Early trials	IDH1		AML	Acute myeloid leukemia	ENA 2014 (abstr 1LBA)	1.0									Acute myeloid leukemia
IDH1:R132.	MUT		Responsive	IDH1 (R132)		07/17	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	IDH1		CANCER	Any cancer type	PMID:28148839	1.0									Any cancer type
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation		09/15	MMartínez;RDientsmann;CRubio-Perez	AG-120	IDH1 inhibitor	AG-120 (IDH1 inhibitor)	Clinical Trials	Early trials	IDH1		G	Glioma	NCT02073994;PMID:23558169	1.0	Direct								Glioma
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation			CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Clinical Trials	Early trials	IDH1		CH	Cholangiocarcinoma	NCT02428855	1.0	Indirect								Cholangiocarcinoma
IDH1:R132.	MUT		Responsive	IDH1 (R132)		07/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	IDH1		BT	Biliary tract cancer	PMID:27231123	1.0									Biliary tract cancer
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	ITD (codified as inframe) in Juxtamembrane domain	10/16	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	IDH1		AML	Acute myeloid leukemia	PMID:27520294	1.0									Acute myeloid leukemia
IDH2:R140K,R172K	MUT		Responsive	IDH2 (R140K,R172K)			RDientsmann	AG-221	IDH2 inhibitor	AG-221 (IDH2 inhibitor)	Clinical Trials	Early trials	IDH2		HEMATO	Hematologic malignancies	AACR 2014 (abstr CT103)	1.0	Direct	c.418_419delCGinsAA	chr15:g.90631934_90631935delCGinsTT	IDH2:R140K	CSQN=Missense;reference_codon=CGG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.90631933_90631935delCCGinsTTT;aliases=ENSP00000331897;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000330062	Hematologic malignancies
IDH2:R140K,R172K	MUT		Responsive	IDH2 (R140K,R172K)			RDientsmann	AG-221	IDH2 inhibitor	AG-221 (IDH2 inhibitor)	Clinical Trials	Early trials	IDH2		HEMATO	Hematologic malignancies	AACR 2014 (abstr CT103)	1.0	Direct	c.515G>A	chr15:g.90631838C>T	IDH2:R172K	CSQN=Missense;reference_codon=AGG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.90631837_90631838delCCinsTT;aliases=ENSP00000331897;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000330062	Hematologic malignancies
IDH2:.	MUT		Responsive	IDH2 oncogenic mutation			CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Clinical Trials	Early trials	IDH2		CH	Cholangiocarcinoma	NCT02428855	1.0	Indirect								Cholangiocarcinoma
IDH2:R172.	MUT		Responsive	IDH2 (R172)		07/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	IDH2		BT	Biliary tract cancer	PMID:27231123	1.0									Biliary tract cancer
IDH2:.	MUT		Responsive	IDH2 oncogenic mutation	ITD (codified as inframe) in Juxtamembrane domain	10/16	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	IDH2		AML	Acute myeloid leukemia	PMID:27520294	1.0									Acute myeloid leukemia
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)			RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	Colorectal adenocarcinoma	PMID:25623215	1.0		c.1391C>T	chr7:g.55227924C>T	EGFR:S464L	CSQN=Missense;reference_codon=TCA;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.55227923_55227924delTCinsCT,chr7:g.55227924_55227925delCAinsTG,chr7:g.55227923_55227925delTCAinsCTT,chr7:g.55227923_55227925delTCAinsCTG,chr7:g.55227923_55227925delTCAinsCTC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)			RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	Colorectal adenocarcinoma	PMID:25623215	1.0		c.1393G>A	chr7:g.55227926G>A	EGFR:G465R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)			RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	Colorectal adenocarcinoma	PMID:25623215	1.0		c.1473A>G	chr7:g.55228006A>G	EGFR:I491M	CSQN=Missense;reference_codon=ATA;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)		07/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	Colorectal adenocarcinoma	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	1.0		c.1476C>G	chr7:g.55228009C>G	EGFR:S492R	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)		07/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	Colorectal adenocarcinoma	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	1.0		c.1393G>A	chr7:g.55227926G>A	EGFR:G465R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)		07/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	Colorectal adenocarcinoma	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	1.0		c.1351C>T	chr7:g.55227884C>T	EGFR:R451C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55227884_55227886delCGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)		07/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	Colorectal adenocarcinoma	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	1.0		c.1400A>C	chr7:g.55227933A>C	EGFR:K467T	CSQN=Missense;reference_codon=AAA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.55227933_55227934delAAinsCG,chr7:g.55227933_55227934delAAinsCT,chr7:g.55227933_55227934delAAinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
INPP4B:.	MUT		Responsive	INPP4B oncogenic mutation			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	INPP4B		BRCA	Breast adenocarcinoma	PMID:23551093	1.0									Breast adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation		01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	KRAS		CANCER	Any cancer type	PMID:26552009	1.0									Any cancer type
KRAS:.	MUT		Resistant	KRAS oncogenic mutation			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	KRAS		ED	Endometrial carcinoma	PMID:22662154	1.0									Endometrial carcinoma
JAK1:S646F;R683.	MUT		Responsive	JAK1 (S646F;R683)		01/16	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	JAK1		ALL	Acute lymphoblastic leukemia	PMID:22955920;PMID:18805579	1.0									Acute lymphoblastic leukemia
JAK2:V617F	MUT		Responsive	JAK2 (V617F)		01/16	RDientsmann	[]	[JAK inhibitor (alone or in combination)]	JAK inhibitor (alone or in combination)s		Pre-clinical	JAK2		AML	Acute myeloid leukemia	PMID:22829971	1.0		c.1849G>T	chr9:g.5073770G>T	JAK2:V617F	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000381652	Acute myeloid leukemia
NRAS:.12.,.13.,.59.,.61.,.117.,.146.	MUT		Resistant	NRAS (12,13,59,61,117,146)			RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	NRAS		COREAD	Colorectal adenocarcinoma	FDA guidelines	1.0									Colorectal adenocarcinoma
JAK2:V617F	MUT		Responsive	JAK2 (V617F)		01/16	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Early trials	JAK2		AML	Acute myeloid leukemia	PMID:22422826	1.0		c.1849G>T	chr9:g.5073770G>T	JAK2:V617F	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000381652	Acute myeloid leukemia
JAK2:V617F	MUT		Responsive	JAK2 (V617F)			RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)	Approved	FDA guidelines	JAK2		MY	Myelofibrosis	FDA	1.0		c.1849G>T	chr9:g.5073770G>T	JAK2:V617F	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000381652	Myelofibrosis
JAK3:A572V,A573V	MUT		Responsive	JAK3 (A572V,A573V)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		LY	Lymphoma	PMID:22705984	1.0		c.1715C>T	chr19:g.17948009G>A	JAK3:A572V	CSQN=Missense;reference_codon=GCA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.17948008_17948009delTGinsGA,chr19:g.17948008_17948009delTGinsCA,chr19:g.17948008_17948009delTGinsAA;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000458235	Lymphoma
JAK3:A572V,A573V	MUT		Responsive	JAK3 (A572V,A573V)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		LY	Lymphoma	PMID:22705984	1.0		c.1718C>T	chr19:g.17948006G>A	JAK3:A573V	CSQN=Missense;reference_codon=GCG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.17948005_17948006delCGinsTA,chr19:g.17948005_17948006delCGinsGA,chr19:g.17948005_17948006delCGinsAA;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000458235	Lymphoma
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	Megakaryoblastic leukemia	PMID:18397343	1.0		c.1970G>A	chr19:g.17945969C>T	JAK3:R657Q	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr19:g.17945968_17945969delCCinsTT;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000458235	Megakaryoblastic leukemia
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	Megakaryoblastic leukemia	PMID:18397343	1.0		c.260T>C	chr19:g.17954634A>G	JAK3:I87T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr19:g.17954633_17954634delGAinsTG,chr19:g.17954633_17954634delGAinsCG,chr19:g.17954633_17954634delGAinsAG;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000458235	Megakaryoblastic leukemia
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	Megakaryoblastic leukemia	PMID:18397343	1.0		c.1503G>T	chr19:g.17949138C>A	JAK3:Q501H	CSQN=Missense;reference_codon=CAG;candidate_codons=CAT,CAC;candidate_snv_variants=chr19:g.17949138C>G;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000458235	Megakaryoblastic leukemia
KCNJ5:L168R	MUT	Cell line	Responsive	KCNJ5 (L168R)			ECampo	Amiloride	Na-Ca chanel blocker	Amiloride (Na-Ca chanel blocker)	Approved	Pre-clinical	KCNJ5		AA	Adrenal adenoma	PMID:24506072	1.0	Indirect	c.503T>G	chr11:g.128781671T>G	KCNJ5:L168R	CSQN=Missense;reference_codon=CTC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.128781671_128781672delTCinsGA,chr11:g.128781671_128781672delTCinsGG,chr11:g.128781671_128781672delTCinsGT,chr11:g.128781670_128781672delCTCinsAGG,chr11:g.128781670_128781672delCTCinsAGA;aliases=ENSP00000433295;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000529694	Adrenal adenoma
KCNJ5:L168R	MUT	Cell line	Responsive	KCNJ5 (L168R)			ECampo	Verapamil	Na-Ca chanel blocker	Verapamil (Na-Ca chanel blocker)	Approved	Pre-clinical	KCNJ5		AA	Adrenal adenoma	PMID:24506072	1.0	Indirect	c.503T>G	chr11:g.128781671T>G	KCNJ5:L168R	CSQN=Missense;reference_codon=CTC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.128781671_128781672delTCinsGA,chr11:g.128781671_128781672delTCinsGG,chr11:g.128781671_128781672delTCinsGT,chr11:g.128781670_128781672delCTCinsAGG,chr11:g.128781670_128781672delCTCinsAGA;aliases=ENSP00000433295;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000529694	Adrenal adenoma
KDR:A1065T	MUT		Responsive	KDR (A1065T)			RDientsmann	[]	[VEGFR inhibitor]	VEGFR inhibitors		Pre-clinical	KDR		CANCER	Any cancer type	PMID:24569783	1.0		c.3193G>A	chr4:g.55955969C>T	KDR:A1065T	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr4:g.55955967_55955969delAGCinsTGT,chr4:g.55955967_55955969delAGCinsCGT,chr4:g.55955967_55955969delAGCinsGGT;aliases=ENSP00000263923;source=Ensembl	inside_[cds_in_exon_24]	-	ENST00000263923	Any cancer type
KIT:550-592	MUT		Responsive	KIT mutation in exon 11		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	KIT		GIST	Gastrointestinal stromal	PMID:22898035	1.0									Gastrointestinal stromal
KIT:788-828,449-514	MUT		Responsive	KIT mutation in exon 9 or 17		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:21737509	1.0									Gastrointestinal stromal
KIT::wildtype:.	MUT		Responsive	KIT wildtype		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:16397263	1.0									Gastrointestinal stromal
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	Cutaneous melanoma	PMID:19671763	1.0									Cutaneous melanoma
KIT:D816V	MUT		Responsive	KIT (D816V)		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		SM	Systemic mastocytosis	PMID:18559612	1.0		c.2447A>T	chr4:g.55599321A>T	KIT:D816V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Systemic mastocytosis
KIT:D816V	MUT		Responsive	KIT (D816V)		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		AML	Acute myeloid leukemia	PMID:18986703	1.0		c.2447A>T	chr4:g.55599321A>T	KIT:D816V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Acute myeloid leukemia
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)			CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	Any cancer type	PMID:16397263	1.0		c.2446G>T	chr4:g.55599320G>T	KIT:D816Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599320_55599322delGACinsTAT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Any cancer type
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)			CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	Any cancer type	PMID:16397263	1.0		c.2446_2447delGAinsTT	chr4:g.55599320_55599321delGAinsTT	KIT:D816F	CSQN=Missense;reference_codon=GAC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr4:g.55599320_55599322delGACinsTTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Any cancer type
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)			CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	Any cancer type	PMID:16397263	1.0		c.2447A>T	chr4:g.55599321A>T	KIT:D816V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Any cancer type
KIT:N822K	MUT		Responsive	KIT (N822K)			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		AML	Acute myeloid leukemia	PMID:23149070	1.0		c.2466T>G	chr4:g.55599340T>G	KIT:N822K	CSQN=Missense;reference_codon=AAT;candidate_codons=AAG,AAA;candidate_snv_variants=chr4:g.55599340T>A;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Acute myeloid leukemia
KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422	MUT		Responsive	KIT inframe deletion (416-422),inframe insertion (416-422)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		AML	Acute myeloid leukemia	PMID:15618474	1.0									Acute myeloid leukemia
KIT::consequence::inframe_deletion:V560.	MUT		Responsive	KIT inframe deletion (V560)		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		THYM	Thymic carcinoma	PMID:15201427	1.0									Thymic carcinoma
PIK3CA:.	MUT		Resistant	PIK3CA oncogenic mutation		01/16	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	PIK3CA		COREAD	Colorectal adenocarcinoma	PMID:19223544;PMID:20619739	1.0									Colorectal adenocarcinoma
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17			CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	Gastrointestinal stromal	FDA	1.0									Gastrointestinal stromal
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		CM	Cutaneous melanoma	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	1.0									Cutaneous melanoma
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	KIT		CM	Cutaneous melanoma	NCCN	1.0									Cutaneous melanoma
TP53:.	MUT		Resistant	TP53 oncogenic mutation		12/16	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	TP53		FGCT;MGCT	Female germ cell tumor;Male germ cell tumor	PMID:27646943	1.0									Female germ cell tumor;Male germ cell tumor
ALK::consequence::inframe_insertion:.1151T.	MUT		Resistant	ALK inframe insertion (1151T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784	1.0									Lung adenocarcinoma
KIT:D820Y	MUT		Responsive	KIT (D820Y)		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		CM	Cutaneous melanoma	PMID:23775962	1.0		c.2458G>T	chr4:g.55599332G>T	KIT:D820Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599332_55599334delGATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Cutaneous melanoma
ALK:.	MUT		Resistant	ALK oncogenic mutation		09/15	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Clinical trials	ALK		NSCLC	Non-small cell lung cancer	PMID:22235099	1.0									Non-small cell lung cancer
KIT:Y553N	MUT		Responsive	KIT (Y553N)		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		THYM	Thymic carcinoma	PMID:21969494	1.0		c.1657T>A	chr4:g.55593591T>A	KIT:Y553N	CSQN=Missense;reference_codon=TAT;candidate_codons=AAC,AAT;candidate_mnv_variants=chr4:g.55593591_55593593delTATinsAAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000288135	Thymic carcinoma
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17		01/16	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		CM	Cutaneous melanoma	PMID:22068222;PMID:25695690	1.0									Cutaneous melanoma
KIT:788-828	MUT		Responsive	KIT mutation in exon 17		01/16	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		GIST	Gastrointestinal stromal	PMID:22119758;PMID:21456006	1.0									Gastrointestinal stromal
KIT:D820Y	MUT		Responsive	KIT (D820Y)		01/16	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	Cutaneous melanoma	PMID:25695690	1.0		c.2458G>T	chr4:g.55599332G>T	KIT:D820Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599332_55599334delGATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Cutaneous melanoma
KIT:788-828,829-860,550-592	MUT		Responsive	KIT (788-828,829-860,550-592)		01/16	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Early trials	KIT		GIST	Gastrointestinal stromal	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	1.0									Gastrointestinal stromal
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)			RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:25239608	1.0		c.2485G>C	chr4:g.55602664G>C	KIT:A829P	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr4:g.55602664_55602666delGCTinsCCG,chr4:g.55602664_55602666delGCTinsCCA,chr4:g.55602664_55602666delGCTinsCCC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000288135	Gastrointestinal stromal
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)			RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:25239608	1.0		c.1961T>C	chr4:g.55594258T>C	KIT:V654A	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55594258_55594259delTGinsCA,chr4:g.55594258_55594259delTGinsCC,chr4:g.55594258_55594259delTGinsCT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000288135	Gastrointestinal stromal
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)			RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:25239608	1.0		c.2009C>T	chr4:g.55595519C>T	KIT:T670I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55595519_55595520delCAinsTC,chr4:g.55595519_55595520delCAinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Gastrointestinal stromal
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	Exon 9,11,14,17		RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	Gastrointestinal stromal	FDA	1.0									Gastrointestinal stromal
KIT::consequence::inframe_deletion:577-579	MUT		Responsive	KIT inframe deletion (577-579)		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		THYM	Thymic carcinoma	PMID:20970876	1.0									Thymic carcinoma
KIT::wildtype:.	MUT		Responsive	KIT wildtype		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	KIT		GIST	Gastrointestinal stromal	ASCO 2011 (abstr 10009)	1.0									Gastrointestinal stromal
KIT:550-592,449-514	MUT		Responsive	KIT mutation in exon 9 or 11		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	KIT		GIST	Gastrointestinal stromal	PMID:22270258	1.0									Gastrointestinal stromal
KIT:550-592,627-664,788-828,829-860	MUT		Responsive	KIT (550-592,627-664,788-828,829-860)		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		CM	Cutaneous melanoma	PMID:18936790;PMID:20372153	1.0									Cutaneous melanoma
KIT:788-828	MUT		Responsive	KIT mutation in exon 17		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:23840364	1.0									Gastrointestinal stromal
KIT:D820E	MUT		Responsive	KIT (D820E)		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		THYM	Thymic carcinoma	PMID:19461405	1.0		c.2460T>G	chr4:g.55599334T>G	KIT:D820E	CSQN=Missense;reference_codon=GAT;candidate_codons=GAG,GAA;candidate_snv_variants=chr4:g.55599334T>A;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Thymic carcinoma
KIT::wildtype:.	MUT		Responsive	KIT wildtype		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		GIST	Gastrointestinal stromal	PMID:18955458	1.0									Gastrointestinal stromal
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17			RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	Gastrointestinal stromal	FDA	1.0									Gastrointestinal stromal
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		CM	Cutaneous melanoma	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	1.0									Cutaneous melanoma
ALK:C1156Y,L1196M	MUT		Resistant	ALK (C1156Y,L1196M)		09/15	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ALK		NSCLC	Non-small cell lung cancer	PMID:20979473	1.0		c.3467G>A	chr2:g.29445258C>T	ALK:C1156Y	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Non-small cell lung cancer
ALK:C1156Y,L1196M	MUT		Resistant	ALK (C1156Y,L1196M)		09/15	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ALK		NSCLC	Non-small cell lung cancer	PMID:20979473	1.0		c.3586C>A	chr2:g.29443631G>T	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Non-small cell lung cancer
ALK:F1174L	MUT		Resistant	ALK (F1174L)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	Glioma	PMID:22072639	1.0		c.3520T>C	chr2:g.29443697A>G	ALK:F1174L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Glioma
KIT:H697Y	MUT		Responsive	KIT (H697Y)		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		THYM	Thymic carcinoma	PMID:19861435	1.0		c.2089C>T	chr4:g.55595599C>T	KIT:H697Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Thymic carcinoma
KIT:H697Y	MUT		Responsive	KIT (H697Y)			RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		THYM	Thymic carcinoma	PMID:19861435	1.0		c.2089C>T	chr4:g.55595599C>T	KIT:H697Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Thymic carcinoma
KIT:Y553N	MUT		Responsive	KIT (Y553N)		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Case report	KIT		THYM	Thymic carcinoma	PMID:23375402	1.0		c.1657T>A	chr4:g.55593591T>A	KIT:Y553N	CSQN=Missense;reference_codon=TAT;candidate_codons=AAC,AAT;candidate_mnv_variants=chr4:g.55593591_55593593delTATinsAAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000288135	Thymic carcinoma
KRAS:.12.,.13.,.59.,.61.,.117.,.146.	MUT		Resistant	KRAS (12,13,59,61,117,146)			CRubio-Perez;RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	KRAS		COREAD	Colorectal adenocarcinoma	FDA guidelines	1.0									Colorectal adenocarcinoma
KRAS:G12.	MUT		Resistant	KRAS (G12)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KRAS		GIST	Gastrointestinal stromal	PMID:24687822	1.0									Gastrointestinal stromal
KRAS:.	MUT		Resistant	KRAS oncogenic mutation			RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		NCCN guidelines	KRAS		COREAD	Colorectal adenocarcinoma	NCCN guidelines	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation			RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		NCCN guidelines	KRAS		COREAD	Colorectal adenocarcinoma	NCCN guidelines	1.0									Colorectal adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3586C>A	chr2:g.29443631G>T	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3455T>G	chr2:g.29445270A>C	ALK:L1152R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr2:g.29445270_29445271delAGinsCT,chr2:g.29445269_29445270delCAinsTC,chr2:g.29445269_29445270delCAinsGC,chr2:g.29445269_29445270delCAinsAC,chr2:g.29445269_29445271delCAGinsTCT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3467G>A	chr2:g.29445258C>T	ALK:C1156Y	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3520T>C	chr2:g.29443697A>G	ALK:F1174L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3604G>A	chr2:g.29443613C>T	ALK:G1202R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.29443613C>G;candidate_mnv_variants=chr2:g.29443611_29443613delTCCinsCCT,chr2:g.29443611_29443613delTCCinsGCG,chr2:g.29443611_29443613delTCCinsCCG,chr2:g.29443611_29443613delTCCinsACG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3617C>A	chr2:g.29443600G>T	ALK:S1206Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29443599_29443600delGGinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3806G>C	chr2:g.29432682C>G	ALK:G1269A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29432681_29432682delTCinsGG,chr2:g.29432681_29432682delTCinsCG,chr2:g.29432681_29432682delTCinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_25]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784;PMID:25228534	1.0		c.3512T>C	chr2:g.29445213A>G	ALK:I1171T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
MET:Y1230C;Y1235D	MUT		Resistant	MET (Y1230C;Y1235D)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	Any cancer type	PMID:17483355	1.0									Any cancer type
KRAS:.	MUT		Resistant	KRAS oncogenic mutation			RDientsmann	[]	[EGFR inhibitor]	EGFR inhibitors		NCCN guidelines	KRAS		L	Lung carcinoma	NCCN guidelines	1.0									Lung carcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation		01/16	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Late trials	KRAS		COREAD	Colorectal adenocarcinoma	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	1.0									Colorectal adenocarcinoma
ROS1:G2032R	MUT		Resistant	ROS1 (G2032R)			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:23724914;PMID:25688157	1.0		c.6094G>A	chr6:g.117638347C>T	ROS1:G2032R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr6:g.117638347C>G;candidate_mnv_variants=chr6:g.117638345_117638347delTCCinsCCT,chr6:g.117638345_117638347delTCCinsGCG,chr6:g.117638345_117638347delTCCinsCCG,chr6:g.117638345_117638347delTCCinsACG;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_38]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)		07/17	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.5957C>A	chr6:g.117639399G>T	ROS1:S1986Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAT;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)		07/17	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.5957C>T	chr6:g.117639399G>A	ROS1:S1986F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAA;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	KRAS		L	Lung carcinoma	PMID:23129625;PMID:24045185	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[CDK4 inhibitor]	CDK4 inhibitors		Pre-clinical	KRAS		L	Lung carcinoma	PMID:20609353	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/17	RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors		Early trials	KRAS		L	Lung carcinoma	AACR 2017 (abstr CT046)	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/17	RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors		Pre-clinical	KRAS		CESC	Cervical squamous cell carcinoma	PMID:27167191	1.0									Cervical squamous cell carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[EGFR mAb inhibitor;MEK inhibitor]	EGFR mAb inhibitor + MEK inhibitors		Pre-clinical	KRAS		COREAD	Colorectal adenocarcinoma	PMID:24553387	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	KRAS		COREAD	Colorectal adenocarcinoma	PMID:23614898	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	KRAS		L	Lung carcinoma	PMID:23358651	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[FAS inhibitor]	FAS inhibitors		Case report	KRAS		L	Lung carcinoma	AACR 2016	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		06/16	RDientsmann	[]	[FAS inhibitor]	FAS inhibitors		Case report	KRAS		L	Lung carcinoma	AACR 2016 (abstr LB214)	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[HSP90 inhibitor (in combination)]	HSP90 inhibitor (in combination)s		Pre-clinical	KRAS		L	Lung carcinoma	PMID:23012248;PMID:21907929	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[JAK/TBK1/IKKε inhibitor]	JAK/TBK1/IKKε inhibitors		Pre-clinical	KRAS		L	Lung carcinoma	PMID:24444711	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[MEK inhibitor;BCL-XL inhibitor]	MEK inhibitor + BCL-XL inhibitors		Pre-clinical	KRAS		COREAD	Colorectal adenocarcinoma	PMID:23245996	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[MEK inhibitor;IGF1R inhibitor]	MEK inhibitor + IGF1R inhibitors		Pre-clinical	KRAS		COREAD	Colorectal adenocarcinoma	PMID:24045180	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[MEK inhibitor;PI3K pathway inhibitor]	MEK inhibitor + PI3K pathway inhibitors		Pre-clinical	KRAS		COREAD	Colorectal adenocarcinoma	PMID:22392911	1.0									Colorectal adenocarcinoma
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Has to be rechecked	12/15	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Has to be rechecked	12/15	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.943A>G	chr9:g.133748282A>G	ABL1:T315A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Has to be rechecked	12/15	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>C	chr9:g.133748288T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Has to be rechecked	12/15	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>G	chr9:g.133748288T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Has to be rechecked	12/15	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>A	chr9:g.133748288T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	Has to be rechecked	12/15	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.950T>G	chr9:g.133748289T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Early trials	KRAS		L;BT	Lung carcinoma;Biliary tract cancer	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555	1.0									Lung carcinoma;Biliary tract cancer
KRAS:.	MUT		Responsive	KRAS oncogenic mutation			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	KRAS		AML;CER;OV	Acute myeloid leukemia;Cervical carcinoma;Ovarian carcinoma	PMID:22507781;PMID:22169769;PMID:19018267	1.0									Acute myeloid leukemia;Cervical carcinoma;Ovarian carcinoma
NF1:.	MUT		Resistant	NF1 oncogenic mutation		07/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		L	Lung carcinoma	PMID:24296828	1.0									Lung carcinoma
KRAS:G12.	MUT		Responsive	KRAS (G12)		01/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	KRAS		ALL	Acute lymphoblastic leukemia	PMID:18701506	1.0									Acute lymphoblastic leukemia
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)			RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	Endometrial carcinoma	PMID:23908597	1.0									Endometrial carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	[]	[MTOR inhibitor;BH3 mimetics]	MTOR inhibitor + BH3 mimeticss		Pre-clinical	KRAS		COREAD	Colorectal adenocarcinoma	PMID:24163374	1.0									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/17	RDientsmann	[]	[pan-RAF inhibitor]	pan-RAF inhibitors		Early trials	KRAS		L	Lung carcinoma	AACR 2017 (abstr  CT002)	1.0									Lung carcinoma
AR:F877L	MUT		Resistant	AR (F877L)	REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge.	09/15	RDientsmann;ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Case report	AR	PRAD	PRAD	Prostate adenocarcinoma	PMID:23779130	1.0		c.2629T>C	chrX:g.66943549T>C	AR:F877L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chrX:g.66943551C>A,chrX:g.66943551C>G;candidate_mnv_variants=chrX:g.66943549_66943551delTTCinsCTT,chrX:g.66943549_66943551delTTCinsCTG,chrX:g.66943549_66943551delTTCinsCTA;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/17	RDientsmann	[]	[pan-RAF inhibitor]	pan-RAF inhibitors		Case report	KRAS		ED	Endometrial carcinoma	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	1.0									Endometrial carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/17	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	KRAS		ED	Endometrial carcinoma	PMID:21984976;PMID:22662154	1.0									Endometrial carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		04/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Early trials	KRAS		L	Lung carcinoma	PMID:25516890	1.0									Lung carcinoma
EGFR:S720.	MUT		Not Responsive	EGFR (S720)		12/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	Lung carcinoma	PMID:26773740	1.0									Lung carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/17	RDientsmann;DTamborero;CRubio-Perez	Abemaciclib	CDK4/6 inhibitor	Abemaciclib (CDK4/6 inhibitor)		Early trials	KRAS		L	Lung carcinoma	PMID:27217383	1.0									Lung carcinoma
NF1:.	MUT		Resistant	NF1 oncogenic mutation		07/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	NF1		L	Lung carcinoma	PMID:24535670	1.0									Lung carcinoma
NF2:.	MUT		Not Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Early trials	NF2		SCHW	Schwannoma	PMID:20736812	1.0									Schwannoma
MTOR:F2108L	MUT		Resistant	MTOR (F2108L)	Metastatic THCA with superresponse putatively assoiated with TSC2 nonsense mutation developing resistance associated with MTOR mutation after 18months		DTamborero;RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		THCA	Thyroid carcinoma	PMID:25295501	1.0		c.6322T>C	chr1:g.11187096A>G	MTOR:F2108L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr1:g.11187094G>T,chr1:g.11187094G>C;candidate_mnv_variants=chr1:g.11187094_11187096delGAAinsAAG,chr1:g.11187094_11187096delGAAinsCAG,chr1:g.11187094_11187096delGAAinsTAG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_45]	-	ENST00000361445	Thyroid carcinoma
MAP2K1:F129L,L215P,I103N,P124.	MUT		Responsive	MAP2K1 (F129L,L215P,I103N,P124)		01/16	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CANCER	Any cancer type	PMID:23614898	1.0									Any cancer type
MAP2K1:P124.	MUT		Responsive	MAP2K1 (P124)		01/16	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CM	Cutaneous melanoma	PMID:25370473	1.0									Cutaneous melanoma
NF1:.	MUT		Not Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF1		MPN	Malignant peripheral nerve sheat tumor	NCT01365468	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Not Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Everolimus;Bevacizumab	MTOR inhibitor;VEGFR mAb inhibitor	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)		Early trials	NF1		MPN	Malignant peripheral nerve sheat tumor	ASCO 2016 (abstr 11053)	1.0									Malignant peripheral nerve sheat tumor
MAP2K1:C121S	MUT		Responsive	MAP2K1 (C121S)		01/16	RDientsmann	[]	[novel MEK inhibitor]	novel MEK inhibitors		Pre-clinical	MAP2K1		CM	Cutaneous melanoma	PMID:24448821	1.0		c.361T>A	chr15:g.66729153T>A	MAP2K1:C121S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr15:g.66729154G>C;candidate_mnv_variants=chr15:g.66729153_66729155delTGCinsAGT,chr15:g.66729154_66729155delGCinsCT,chr15:g.66729154_66729155delGCinsCG,chr15:g.66729154_66729155delGCinsCA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:K57T	MUT		Responsive	MAP2K1 (K57T)		04/16	RDientsmann	Panitumumab;Trametinib	EGFR mAb inhibitor;MEK inhibitor	Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor)		Case report	MAP2K1		COREAD	Colorectal adenocarcinoma	PMID:26644315	1.0		c.170A>C	chr15:g.66727454A>C	MAP2K1:K57T	CSQN=Missense;reference_codon=AAG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr15:g.66727454_66727455delAGinsCA,chr15:g.66727454_66727455delAGinsCT,chr15:g.66727454_66727455delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Colorectal adenocarcinoma
MAP2K1::consequence::inframe_deletion:56-60	MUT		Responsive	MAP2K1 inframe deletion (56-60)		01/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	MAP2K1		OV	Ovarian carcinoma	PMID:26324360	1.0									Ovarian carcinoma
MAP2K1:Q56P	MUT		Responsive	MAP2K1 (Q56P)		04/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	MAP2K1		CANCER	Any cancer type	PMID:26582713	1.0		c.167A>C	chr15:g.66727451A>C	MAP2K1:Q56P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Any cancer type
NF1:.	MUT		Not Responsive	NF1 oncogenic mutation		07/16	RDientsmann	Everolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	Glioma	PMID:24634382	1.0									Glioma
ESR1:.	MUT		Resistant	ESR1 oncogenic mutation		06/16	RDientsmann	Exemestane	Hormonal therapy	Exemestane (Hormonal therapy)		Late trials	ESR1		BRCA	Breast adenocarcinoma	PMID:27269946	1.0									Breast adenocarcinoma
AR:T878A	MUT		Resistant	AR (T878A)	REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.	09/15	RDientsmann;ARodriguez-Vida	Flutamide	AR inhibitor	Flutamide (AR inhibitor)		Case report	AR	PRAD	PRAD	Prostate adenocarcinoma	PMID:2260966	1.0		c.2632A>G	chrX:g.66943552A>G	AR:T878A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
ESR1:Y537S	MUT		Resistant	ESR1 (Y537S)		07/17	RDientsmann	Fulvestrant	Hormonal therapy	Fulvestrant (Hormonal therapy)		Pre-clinical	ESR1		BRCA	Breast adenocarcinoma	PMID:27986707	1.0		c.1610A>C	chr6:g.152419923A>C	ESR1:Y537S	CSQN=Missense;reference_codon=TAT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr6:g.152419922_152419923delTAinsAG,chr6:g.152419923_152419924delATinsCG,chr6:g.152419923_152419924delATinsCC,chr6:g.152419923_152419924delATinsCA,chr6:g.152419922_152419924delTATinsAGC;aliases=ENSP00000405330;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000440973	Breast adenocarcinoma
EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS	MUT		Not Responsive	EGFR inframe deletion (L747),inframe insertion (P753PS)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		HNC	Head and neck cancer	PMID:21274259	1.0									Head and neck cancer
MET:1078-1345	MUT		Responsive	MET kinase domain mutation		07/17	RDientsmann	Savolitinib	MET inhibitor	Savolitinib (MET inhibitor)		Early trials	MET		R	Renal carcinoma	PMID:28644771	1.0									Renal carcinoma
EGFR:V843I	MUT		Not Responsive	EGFR (V843I)			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		HNC	Head and neck cancer	PMID:21274259	1.0		c.2527G>A	chr7:g.55259469G>A	EGFR:V843I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55259469_55259471delGTAinsATC,chr7:g.55259469_55259471delGTAinsATT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Head and neck cancer
SLC29A1:.	MUT		Resistant	SLC29A1 oncogenic mutation	SLC29A1 is HENT1 used symbol	09/15	ARodriguez-Vida	Gemcitabine	Chemotherapy	Gemcitabine (Chemotherapy)		Pre-clinical	SLC29A1	BLCA	BLCA	Bladder carcinoma	PMID:21166756	1.0									Bladder carcinoma
BTK:C481.	MUT		Resistant	BTK (C481)			RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		Case report	BTK		MCL	Mantle cell lymphoma	PMID:25082755	1.0									Mantle cell lymphoma
MET:H1112R	MUT		Responsive	MET (H1112R)	REMAP:H1094r changed to H1112R	01/16	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Early trials	MET		R	Renal carcinoma	PMID:23213094	1.0		c.3335A>G	chr7:g.116417464A>G	MET:H1112R	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.116417464_116417465delATinsGA,chr7:g.116417464_116417465delATinsGC,chr7:g.116417464_116417465delATinsGG,chr7:g.116417463_116417465delCATinsAGG,chr7:g.116417463_116417465delCATinsAGA;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Renal carcinoma
MET:M1268T	MUT		Responsive	MET (M1268T)		01/16	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		R	Renal carcinoma	PMID:23610116	1.0		c.3803T>C	chr7:g.116423474T>C	MET:M1268T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.116423474_116423475delTGinsCA,chr7:g.116423474_116423475delTGinsCT,chr7:g.116423474_116423475delTGinsCC;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000318493	Renal carcinoma
MET:H1112L	MUT		Responsive	MET (H1112L)			RDientsmann	[Crizotinib]	[MET inhibitor]	MET inhibitors (Crizotinib,etc)		Pre-clinical	MET		CANCER	Any cancer type	AACR 2012 (abstr 1786)	1.0		c.3335A>T	chr7:g.116417464A>T	MET:H1112L	CSQN=Missense;reference_codon=CAT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.116417464_116417465delATinsTG,chr7:g.116417464_116417465delATinsTA,chr7:g.116417464_116417465delATinsTC,chr7:g.116417463_116417465delCATinsTTA,chr7:g.116417463_116417465delCATinsTTG;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Any cancer type
MET:1132-1330	MUT		Responsive	MET mutation in exon 16-19	EXON 16-19	06/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	MET		R	Renal carcinoma	AACR 2016 (abstr CT2006)	1.0									Renal carcinoma
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)		RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	Any cancer type	PMID:17483355	1.0		c.3328G>A	chr7:g.116417457G>A	MET:V1110I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.116417457_116417459delGTAinsATC,chr7:g.116417457_116417459delGTAinsATT;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)		RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	Any cancer type	PMID:17483355	1.0		c.3335A>G	chr7:g.116417464A>G	MET:H1112R	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.116417464_116417465delATinsGA,chr7:g.116417464_116417465delATinsGC,chr7:g.116417464_116417465delATinsGG,chr7:g.116417463_116417465delCATinsAGG,chr7:g.116417463_116417465delCATinsAGA;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)		RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	Any cancer type	PMID:17483355	1.0		c.3803T>C	chr7:g.116423474T>C	MET:M1268T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.116423474_116423475delTGinsCA,chr7:g.116423474_116423475delTGinsCT,chr7:g.116423474_116423475delTGinsCC;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)		RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	Any cancer type	PMID:17483355	1.0		c.2962C>T	chr7:g.116411923C>T	MET:R988C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.116411923_116411925delCGCinsTGT;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)		RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	Any cancer type	PMID:17483355	1.0		c.3029C>T	chr7:g.116411990C>T	MET:T1010I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.116411990_116411991delCTinsTC,chr7:g.116411990_116411991delCTinsTA;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000318493	Any cancer type
BTK:C481S	MUT		Resistant	BTK (C481S)			RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		Early trials	BTK		CLL	Chronic lymphocytic leukemia	PMID:24869598;PMID:27199251	1.0		c.1441T>A	chrX:g.100611165A>T	BTK:C481S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chrX:g.100611164C>G;candidate_mnv_variants=chrX:g.100611163_100611165delGCAinsACT,chrX:g.100611163_100611164delGCinsAG,chrX:g.100611163_100611164delGCinsCG,chrX:g.100611163_100611164delGCinsTG;aliases=ENSP00000308176;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000308731	Chronic lymphocytic leukemia
PLCG2:R665W,L845F	MUT		Resistant	PLCG2 (R665W,L845F)			RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)	Approved	Early trials	PLCG2		CLL	Chronic lymphocytic leukemia	PMID:24869598	1.0		c.1993C>T	chr16:g.81946260C>T	PLCG2:R665W	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000352336;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000359376	Chronic lymphocytic leukemia
PLCG2:R665W,L845F	MUT		Resistant	PLCG2 (R665W,L845F)			RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)	Approved	Early trials	PLCG2		CLL	Chronic lymphocytic leukemia	PMID:24869598	1.0		c.2535A>T	chr16:g.81962183A>T	PLCG2:L845F	CSQN=Missense;reference_codon=TTA;candidate_codons=TTT,TTC;candidate_snv_variants=chr16:g.81962183A>C;aliases=ENSP00000352336;source=Ensembl	inside_[cds_in_exon_24]	+	ENST00000359376	Chronic lymphocytic leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.725T>C	chr9:g.133738325T>C	ABL1:I242T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133738325_133738326delTCinsCA,chr9:g.133738325_133738326delTCinsCG,chr9:g.133738325_133738326delTCinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.730A>G	chr9:g.133738330A>G	ABL1:M244V	CSQN=Missense;reference_codon=ATG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738330_133738332delATGinsGTA,chr9:g.133738330_133738332delATGinsGTC,chr9:g.133738330_133738332delATGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.740A>G	chr9:g.133738340A>G	ABL1:K247R	CSQN=Missense;reference_codon=AAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133738340_133738341delAGinsGA,chr9:g.133738339_133738340delAAinsCG,chr9:g.133738339_133738341delAAGinsCGA,chr9:g.133738339_133738341delAAGinsCGC,chr9:g.133738339_133738341delAAGinsCGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.742C>G	chr9:g.133738342C>G	ABL1:L248V	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738342_133738344delCTGinsGTA,chr9:g.133738342_133738344delCTGinsGTC,chr9:g.133738342_133738344delCTGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.749G>A	chr9:g.133738349G>A	ABL1:G250E	CSQN=Missense;reference_codon=GGG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr9:g.133738349_133738350delGGinsAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.748G>A	chr9:g.133738348G>A	ABL1:G250R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr9:g.133738348G>C;candidate_mnv_variants=chr9:g.133738348_133738350delGGGinsAGA,chr9:g.133738348_133738350delGGGinsCGA,chr9:g.133738348_133738350delGGGinsCGC,chr9:g.133738348_133738350delGGGinsCGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.755A>G	chr9:g.133738355A>G	ABL1:Q252R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133738354_133738355delCAinsAG,chr9:g.133738355_133738356delAGinsGA,chr9:g.133738355_133738356delAGinsGC,chr9:g.133738355_133738356delAGinsGT,chr9:g.133738354_133738356delCAGinsAGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.756G>T	chr9:g.133738356G>T	ABL1:Q252H	CSQN=Missense;reference_codon=CAG;candidate_codons=CAT,CAC;candidate_snv_variants=chr9:g.133738356G>C;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.758A>T	chr9:g.133738358A>T	ABL1:Y253F	CSQN=Missense;reference_codon=TAC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.133738358_133738359delACinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.757T>C	chr9:g.133738357T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.763G>A	chr9:g.133738363G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.764A>T	chr9:g.133738364A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.709A>G	chr9:g.133738309A>G	ABL1:M237V	CSQN=Missense;reference_codon=ATG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738309_133738311delATGinsGTA,chr9:g.133738309_133738311delATGinsGTC,chr9:g.133738309_133738311delATGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.774G>C	chr9:g.133738374G>C	ABL1:E258D	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr9:g.133738374G>T;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.782G>T	chr9:g.133738382G>T	ABL1:W261L	CSQN=Missense;reference_codon=TGG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr9:g.133738381_133738382delTGinsCT,chr9:g.133738382_133738383delGGinsTA,chr9:g.133738381_133738383delTGGinsCTT,chr9:g.133738381_133738383delTGGinsCTA,chr9:g.133738381_133738383delTGGinsCTC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.817T>A	chr9:g.133738417T>A	ABL1:L273M	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.823G>A	chr9:g.133747516G>A	ABL1:E275K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133747516_133747518delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.823G>C	chr9:g.133747516G>C	ABL1:E275Q	CSQN=Missense;reference_codon=GAG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133747516_133747518delGAGinsCAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.827A>G	chr9:g.133747520A>G	ABL1:D276G	CSQN=Missense;reference_codon=GAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133747520_133747521delACinsGT,chr9:g.133747520_133747521delACinsGG,chr9:g.133747520_133747521delACinsGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.829A>G	chr9:g.133747522A>G	ABL1:T277A	CSQN=Missense;reference_codon=ACC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747522_133747524delACCinsGCA,chr9:g.133747522_133747524delACCinsGCG,chr9:g.133747522_133747524delACCinsGCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.835G>A	chr9:g.133747528G>A	ABL1:E279K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133747528_133747530delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.839T>C	chr9:g.133747532T>C	ABL1:V280A	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747532_133747533delTGinsCA,chr9:g.133747532_133747533delTGinsCC,chr9:g.133747532_133747533delTGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.866T>C	chr9:g.133747559T>C	ABL1:V289A	CSQN=Missense;reference_codon=GTC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747559_133747560delTCinsCA,chr9:g.133747559_133747560delTCinsCG,chr9:g.133747559_133747560delTCinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.865G>A	chr9:g.133747558G>A	ABL1:V289I	CSQN=Missense;reference_codon=GTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133747558_133747560delGTCinsATA,chr9:g.133747558_133747560delGTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.875A>T	chr9:g.133747568A>T	ABL1:E292V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747568_133747569delAGinsTA,chr9:g.133747568_133747569delAGinsTC,chr9:g.133747568_133747569delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.874G>C	chr9:g.133747567G>C	ABL1:E292Q	CSQN=Missense;reference_codon=GAG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133747567_133747569delGAGinsCAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.877A>G	chr9:g.133747570A>G	ABL1:I293V	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747570_133747572delATCinsGTA,chr9:g.133747570_133747572delATCinsGTG,chr9:g.133747570_133747572delATCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.892C>G	chr9:g.133747585C>G	ABL1:L298V	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747585_133747587delCTGinsGTA,chr9:g.133747585_133747587delCTGinsGTC,chr9:g.133747585_133747587delCTGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.895G>C	chr9:g.133747588G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.931T>C	chr9:g.133748270T>C	ABL1:F311L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748272C>A,chr9:g.133748272C>G;candidate_mnv_variants=chr9:g.133748270_133748272delTTCinsCTT,chr9:g.133748270_133748272delTTCinsCTG,chr9:g.133748270_133748272delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.931T>A	chr9:g.133748270T>A	ABL1:F311I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748270_133748272delTTCinsATA,chr9:g.133748270_133748272delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.944C>T	chr9:g.133748283C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>C	chr9:g.133748288T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>G	chr9:g.133748288T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.949T>A	chr9:g.133748288T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.950T>G	chr9:g.133748289T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.959A>G	chr9:g.133748298A>G	ABL1:Y320C	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748298_133748299delACinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.971T>A	chr9:g.133748310T>A	ABL1:L324Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133748310_133748311delTGinsAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1024T>C	chr9:g.133748363T>C	ABL1:Y342H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133748363_133748365delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1028T>C	chr9:g.133748367T>C	ABL1:M343T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133748367_133748368delTGinsCA,chr9:g.133748367_133748368delTGinsCT,chr9:g.133748367_133748368delTGinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1031C>T	chr9:g.133748370C>T	ABL1:A344V	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748370_133748371delCCinsTA,chr9:g.133748370_133748371delCCinsTG,chr9:g.133748370_133748371delCCinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1049C>T	chr9:g.133748388C>T	ABL1:A350V	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748388_133748389delCCinsTA,chr9:g.133748388_133748389delCCinsTG,chr9:g.133748388_133748389delCCinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1052T>C	chr9:g.133748391T>C	ABL1:M351T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133748391_133748392delTGinsCA,chr9:g.133748391_133748392delTGinsCT,chr9:g.133748391_133748392delTGinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1065G>C	chr9:g.133748404G>C	ABL1:E355D	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr9:g.133748404G>T;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1064A>G	chr9:g.133748403A>G	ABL1:E355G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133748403_133748404delAGinsGT,chr9:g.133748403_133748404delAGinsGA,chr9:g.133748403_133748404delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1064A>C	chr9:g.133748403A>C	ABL1:E355A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748403_133748404delAGinsCA,chr9:g.133748403_133748404delAGinsCC,chr9:g.133748403_133748404delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>G	chr9:g.133748414T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>A	chr9:g.133748414T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1076T>G	chr9:g.133748415T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>C	chr9:g.133748414T>C	ABL1:F359L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748416C>A,chr9:g.133748416C>G;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsCTT,chr9:g.133748414_133748416delTTCinsCTG,chr9:g.133748414_133748416delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1087G>T	chr9:g.133750256G>T	ABL1:D363Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr9:g.133750256_133750258delGATinsTAC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1090C>A	chr9:g.133750259C>A	ABL1:L364I	CSQN=Missense;reference_codon=CTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133750259_133750261delCTTinsATC,chr9:g.133750259_133750261delCTTinsATA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1094C>T	chr9:g.133750263C>T	ABL1:A365V	CSQN=Missense;reference_codon=GCT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750263_133750264delCTinsTA,chr9:g.133750263_133750264delCTinsTC,chr9:g.133750263_133750264delCTinsTG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1097C>G	chr9:g.133750266C>G	ABL1:A366G	CSQN=Missense;reference_codon=GCC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133750266_133750267delCCinsGT,chr9:g.133750266_133750267delCCinsGG,chr9:g.133750266_133750267delCCinsGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1109T>C	chr9:g.133750278T>C	ABL1:L370P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750278_133750279delTGinsCT,chr9:g.133750278_133750279delTGinsCA,chr9:g.133750278_133750279delTGinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1112T>C	chr9:g.133750281T>C	ABL1:V371A	CSQN=Missense;reference_codon=GTA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133750281_133750282delTAinsCC,chr9:g.133750281_133750282delTAinsCG,chr9:g.133750281_133750282delTAinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1117G>A	chr9:g.133750286G>A	ABL1:E373K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133750286_133750288delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1135G>A	chr9:g.133750304G>A	ABL1:V379I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133750304_133750306delGTAinsATC,chr9:g.133750304_133750306delGTAinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1138G>A	chr9:g.133750307G>A	ABL1:A380T	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133750307_133750309delGCTinsACA,chr9:g.133750307_133750309delGCTinsACG,chr9:g.133750307_133750309delGCTinsACC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1144T>C	chr9:g.133750313T>C	ABL1:F382L	CSQN=Missense;reference_codon=TTT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133750315T>A,chr9:g.133750315T>G;candidate_mnv_variants=chr9:g.133750313_133750315delTTTinsCTG,chr9:g.133750313_133750315delTTTinsCTA,chr9:g.133750313_133750315delTTTinsCTC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1150C>A	chr9:g.133750319C>A	ABL1:L384M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1159T>A	chr9:g.133750328T>A	ABL1:L387M	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1161G>T	chr9:g.133750330G>T	ABL1:L387F	CSQN=Missense;reference_codon=TTG;candidate_codons=TTT,TTC;candidate_snv_variants=chr9:g.133750330G>C;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1159T>G	chr9:g.133750328T>G	ABL1:L387V	CSQN=Missense;reference_codon=TTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750328_133750330delTTGinsGTA,chr9:g.133750328_133750330delTTGinsGTC,chr9:g.133750328_133750330delTTGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1162A>C	chr9:g.133750331A>C	ABL1:M388L	CSQN=Missense;reference_codon=ATG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133750331A>T;candidate_mnv_variants=chr9:g.133750331_133750333delATGinsCTT,chr9:g.133750331_133750333delATGinsCTA,chr9:g.133750331_133750333delATGinsCTC,chr9:g.133750331_133750333delATGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1178A>G	chr9:g.133750347A>G	ABL1:Y393C	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133750347_133750348delACinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1187A>C	chr9:g.133750356A>C	ABL1:H396P	CSQN=Missense;reference_codon=CAT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750356_133750357delATinsCG,chr9:g.133750356_133750357delATinsCA,chr9:g.133750356_133750357delATinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1187A>G	chr9:g.133750356A>G	ABL1:H396R	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133750356_133750357delATinsGA,chr9:g.133750356_133750357delATinsGC,chr9:g.133750356_133750357delATinsGG,chr9:g.133750355_133750357delCATinsAGG,chr9:g.133750355_133750357delCATinsAGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1186_1187delCAinsGC	chr9:g.133750355_133750356delCAinsGC	ABL1:H396A	CSQN=Missense;reference_codon=CAT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133750355_133750357delCATinsGCA,chr9:g.133750355_133750357delCATinsGCC,chr9:g.133750355_133750357delCATinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1189G>C	chr9:g.133750358G>C	ABL1:A397P	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750358_133750360delGCTinsCCG,chr9:g.133750358_133750360delGCTinsCCA,chr9:g.133750358_133750360delGCTinsCCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1250C>T	chr9:g.133750419C>T	ABL1:S417F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.133750419_133750420delCCinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1250C>A	chr9:g.133750419C>A	ABL1:S417Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr9:g.133750419_133750420delCCinsAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1253T>G	chr9:g.133750422T>G	ABL1:I418S	CSQN=Missense;reference_codon=ATC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr9:g.133750422_133750423delTCinsGT,chr9:g.133750421_133750422delATinsTC,chr9:g.133750421_133750423delATCinsTCT,chr9:g.133750421_133750423delATCinsTCG,chr9:g.133750421_133750423delATCinsTCA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1252A>G	chr9:g.133750421A>G	ABL1:I418V	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750421_133750423delATCinsGTA,chr9:g.133750421_133750423delATCinsGTG,chr9:g.133750421_133750423delATCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1297G>A	chr9:g.133753828G>A	ABL1:A433T	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133753828_133753830delGCTinsACA,chr9:g.133753828_133753830delGCTinsACG,chr9:g.133753828_133753830delGCTinsACC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1313C>G	chr9:g.133753844C>G	ABL1:S438C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133753844_133753845delCCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1348G>A	chr9:g.133753879G>A	ABL1:E450K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753879_133753881delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1349A>G	chr9:g.133753880A>G	ABL1:E450G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsGT,chr9:g.133753880_133753881delAGinsGA,chr9:g.133753880_133753881delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1349A>C	chr9:g.133753880A>C	ABL1:E450A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsCA,chr9:g.133753880_133753881delAGinsCC,chr9:g.133753880_133753881delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1349A>T	chr9:g.133753880A>T	ABL1:E450V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsTA,chr9:g.133753880_133753881delAGinsTC,chr9:g.133753880_133753881delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1357G>A	chr9:g.133753888G>A	ABL1:E453K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753888_133753890delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1358A>G	chr9:g.133753889A>G	ABL1:E453G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsGT,chr9:g.133753889_133753890delAGinsGA,chr9:g.133753889_133753890delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1358A>C	chr9:g.133753889A>C	ABL1:E453A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsCA,chr9:g.133753889_133753890delAGinsCC,chr9:g.133753889_133753890delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1358A>T	chr9:g.133753889A>T	ABL1:E453V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsTA,chr9:g.133753889_133753890delAGinsTC,chr9:g.133753889_133753890delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1375G>A	chr9:g.133753906G>A	ABL1:E459K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753906_133753908delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1376A>G	chr9:g.133753907A>G	ABL1:E459G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsGT,chr9:g.133753907_133753908delAGinsGA,chr9:g.133753907_133753908delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1376A>C	chr9:g.133753907A>C	ABL1:E459A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsCA,chr9:g.133753907_133753908delAGinsCC,chr9:g.133753907_133753908delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1376A>T	chr9:g.133753907A>T	ABL1:E459V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsTA,chr9:g.133753907_133753908delAGinsTC,chr9:g.133753907_133753908delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1416G>C	chr9:g.133753947G>C	ABL1:M472I	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr9:g.133753947G>A,chr9:g.133753947G>T;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1439C>T	chr9:g.133755470C>T	ABL1:P480L	CSQN=Missense;reference_codon=CCC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr9:g.133755470_133755471delCCinsTT,chr9:g.133755470_133755471delCCinsTG,chr9:g.133755470_133755471delCCinsTA,chr9:g.133755469_133755471delCCCinsTTA,chr9:g.133755469_133755471delCCCinsTTG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1457T>C	chr9:g.133755488T>C	ABL1:F486S	CSQN=Missense;reference_codon=TTT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr9:g.133755487_133755488delTTinsAG,chr9:g.133755488_133755489delTTinsCG,chr9:g.133755488_133755489delTTinsCC,chr9:g.133755488_133755489delTTinsCA,chr9:g.133755487_133755489delTTTinsAGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)		12/15	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1520A>G	chr9:g.133755893A>G	ABL1:E507G	CSQN=Missense;reference_codon=GAA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133755893_133755894delAAinsGT,chr9:g.133755893_133755894delAAinsGG,chr9:g.133755893_133755894delAAinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000318560	Chronic myeloid leukemia
KIT::wildtype:.	MUT		Resistant	KIT wildtype			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	Gastrointestinal stromal	PMID:18955458	1.0									Gastrointestinal stromal
KIT:627-664,664-714,449-514	MUT		Resistant	KIT (627-664,664-714,449-514)		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	Gastrointestinal stromal	PMID:18955458;PMID:18955451;PMID:16624552	1.0									Gastrointestinal stromal
KIT:788-828	MUT		Resistant	KIT mutation in exon 17		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:23840364	1.0									Gastrointestinal stromal
KIT:788-828,829-860	MUT		Resistant	KIT mutation in exon 17 or 18			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	Cutaneous melanoma	PMID:21690468;PMID:21642685	1.0									Cutaneous melanoma
KIT:D816.	MUT		Resistant	KIT (D816)			CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST;MDS;MDPS;HES;ECL;CML;ALL;SM	Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis	FDA	1.0									Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis
KIT:T670I	MUT		Resistant	KIT (T670I)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		GIST	Gastrointestinal stromal	PMID:24687822	1.0		c.2009C>T	chr4:g.55595519C>T	KIT:T670I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55595519_55595520delCAinsTC,chr4:g.55595519_55595520delCAinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Gastrointestinal stromal
MLL2:.	MUT		Responsive	MLL2 oncogenic mutation		07/16	RDientsmann	Bicalutamide	AR inhibitor	Bicalutamide (AR inhibitor)		Pre-clinical	MLL2		LUSC	Squamous cell lung carcinoma	PMID:27397505	1.0									Squamous cell lung carcinoma
MPL:W515F	MUT		Responsive	MPL (W515F)			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	MPL		MDPS	Myelodisplasic proliferative syndrome	PMID:16834459	1.0		c.1544_1545delGGinsTT	chr1:g.43815009_43815010delGGinsTT	MPL:W515F	CSQN=Missense;reference_codon=TGG;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.43815009_43815010delGGinsTC;aliases=ENSP00000361548;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000372470	Myelodisplasic proliferative syndrome
MSH3:.	MUT		Responsive	MSH3 oncogenic mutation			RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	MSH3		CANCER	Any cancer type	PMID:24556366	1.0									Any cancer type
MTOR:F2108L	MUT		Responsive	MTOR (F2108L)		01/16	RDientsmann	[]	[MTOR kinase inhibitor]	MTOR kinase inhibitors		Pre-clinical	MTOR		CANCER	Any cancer type	PMID:25295501	1.0		c.6322T>C	chr1:g.11187096A>G	MTOR:F2108L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr1:g.11187094G>T,chr1:g.11187094G>C;candidate_mnv_variants=chr1:g.11187094_11187096delGAAinsAAG,chr1:g.11187094_11187096delGAAinsCAG,chr1:g.11187094_11187096delGAAinsTAG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_45]	-	ENST00000361445	Any cancer type
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	Bladder carcinoma	PMID:24625776	1.0		c.6040G>A	chr1:g.11187857C>T	MTOR:E2014K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11187855_11187857delCTCinsTTT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_44]	-	ENST00000361445	Bladder carcinoma
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	Bladder carcinoma	PMID:24625776	1.0		c.7255G>A	chr1:g.11174420C>T	MTOR:E2419K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11174418_11174420delTTCinsCTT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_53]	-	ENST00000361445	Bladder carcinoma
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	Bladder carcinoma	PMID:24625776	1.0		c.4261A>G	chr1:g.11227567T>C	MTOR:N1421D	CSQN=Missense;reference_codon=AAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr1:g.11227565_11227567delATTinsGTC;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_29]	-	ENST00000361445	Bladder carcinoma
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:23582185;PMID:21689725;PMID:17259998	1.0									Gastrointestinal stromal
MTOR:I1973F	MUT		Responsive	MTOR (I1973F)		06/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		AS;R	Angiosarcoma;Renal carcinoma	ASCO 2015 (abstr 11010);PMID:26859683	1.0		c.5917A>T	chr1:g.11188177T>A	MTOR:I1973F	CSQN=Missense;reference_codon=ATC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.11188175_11188177delGATinsAAA;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_43]	-	ENST00000361445	Angiosarcoma;Renal carcinoma
MTOR:K1771R	MUT		Responsive	MTOR (K1771R)		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		ST;AG	Gastric carcinoma;Anaplastic oligodendroglioma	ASCO 2015 (abstr 11010);PMID:26859683	1.0		c.5312A>G	chr1:g.11193189T>C	MTOR:K1771R	CSQN=Missense;reference_codon=AAA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr1:g.11193188_11193189delTTinsCC,chr1:g.11193189_11193190delTTinsCG,chr1:g.11193188_11193190delTTTinsGCG,chr1:g.11193188_11193190delTTTinsCCG,chr1:g.11193188_11193190delTTTinsACG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_38]	-	ENST00000361445	Gastric carcinoma;Anaplastic oligodendroglioma
MTOR:N1421D	MUT		Responsive	MTOR (N1421D)		06/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		ST	Gastric carcinoma	PMID:26859683	1.0		c.4261A>G	chr1:g.11227567T>C	MTOR:N1421D	CSQN=Missense;reference_codon=AAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr1:g.11227565_11227567delATTinsGTC;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_29]	-	ENST00000361445	Gastric carcinoma
MTOR:Q2223K	MUT		Responsive	MTOR (Q2223K)		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		R	Renal carcinoma	PMID:24622468	1.0		c.6667C>A	chr1:g.11182179G>T	MTOR:Q2223K	CSQN=Missense;reference_codon=CAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11182177_11182179delCTGinsTTT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_48]	-	ENST00000361445	Renal carcinoma
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)			RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	Any cancer type	PMID:24631838	1.0		c.4379T>C	chr1:g.11217299A>G	MTOR:L1460P	CSQN=Missense;reference_codon=CTT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr1:g.11217298_11217299delAAinsCG,chr1:g.11217298_11217299delAAinsTG,chr1:g.11217298_11217299delAAinsGG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_30]	-	ENST00000361445	Any cancer type
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)			RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	Any cancer type	PMID:24631838	1.0		c.6644C>A	chr1:g.11184573G>T	MTOR:S2215Y	CSQN=Missense;reference_codon=TCT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr1:g.11184572_11184573delAGinsGT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_47]	-	ENST00000361445	Any cancer type
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)			RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	Any cancer type	PMID:24631838	1.0		c.7514G>C	chr1:g.11169361C>G	MTOR:R2505P	CSQN=Missense;reference_codon=CGA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr1:g.11169360_11169361delTCinsAG,chr1:g.11169360_11169361delTCinsCG,chr1:g.11169360_11169361delTCinsGG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_56]	-	ENST00000361445	Any cancer type
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	Decitabine;BCL2 inhibitor	Chemotherapy;BCL2 inhibitor	Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)		Pre-clinical	KRAS		OV	Ovarian carcinoma	PMID:25968887	1.0									Ovarian carcinoma
MYD88:L265P	MUT		Responsive	MYD88 (L265P)		12/16	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		FDA guidelines	MYD88		WM	Waldenstroem macroglobulinemia	PMID:25853747	1.0				MYD88:L265P					Waldenstroem macroglobulinemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:24373973	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	[]	[BRD4 inhibitor]	BRD4 inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:24373973	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	[]	[KIT inhibitor;MTOR inhibitor]	KIT inhibitor + MTOR inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:24718867	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:23221341	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		G;LK	Glioma;Leukemia	PMID:22573716;PMID:19727076	1.0									Glioma;Leukemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	[]	[MTOR inhibitor;HSP90 inhibitor]	MTOR inhibitor + HSP90 inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:21907929	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF1		G;MPN;LK	Glioma;Malignant peripheral nerve sheat tumor;Leukemia	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	1.0									Glioma;Malignant peripheral nerve sheat tumor;Leukemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	[]	[Pan-RAF inhibitor;MEK inhibitor]	Pan-RAF inhibitor + MEK inhibitors		Pre-clinical	NF1		CM	Cutaneous melanoma	PMID:26351322	1.0									Cutaneous melanoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	NF1		CM	Cutaneous melanoma	ASCO 2016 (abstr 105)	1.0									Cutaneous melanoma
PDGFRA::wildtype:.	MUT		Resistant	PDGFRA wildtype			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	PDGFRA		GIST	Gastrointestinal stromal	PMID:14645423;PMID:18955458	1.0									Gastrointestinal stromal
PDGFRA:D842V	MUT		Resistant	PDGFRA (D842V)		01/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials,Pre-clinical	PDGFRA		GIST	Gastrointestinal stromal	PMID:22718859;PMID:16638875	1.0		c.2525A>T	chr4:g.55152093A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Case report	NF1		G	Glioma	PMID:24232489;PMID:2485933	1.0									Glioma
PDGFRA:T674I	MUT		Resistant	PDGFRA (T674I)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	PDGFRA		HES	Hyper eosinophilic advanced snydrome	PMID:12660384	1.0		c.2021C>T	chr4:g.55144547C>T	PDGFRA:T674I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55144547_55144548delCAinsTC,chr4:g.55144547_55144548delCAinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_15]	+	ENST00000257290	Hyper eosinophilic advanced snydrome
ERBB2:K753E	MUT		Resistant	ERBB2 (K753E)		12/16	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:27697991	1.0		c.2257A>G	chr17:g.37880213A>G	ERBB2:K753E	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37880213_37880215delAAAinsGAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
NTRK1:G595R	MUT		Resistant	NTRK1 (G595R)		07/17	RDientsmann	Larotrectinib	Topomyosine kinase inhibitor	Larotrectinib (Topomyosine kinase inhibitor)		Pre-clinical	NTRK1		CANCER	Any cancer type	PMID:28578312	1.0		c.1783G>A	chr1:g.156846342G>A	NTRK1:G595R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.156846342G>C;candidate_mnv_variants=chr1:g.156846342_156846344delGGGinsAGA,chr1:g.156846342_156846344delGGGinsCGA,chr1:g.156846342_156846344delGGGinsCGC,chr1:g.156846342_156846344delGGGinsCGT;aliases=ENSP00000431418;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000524377	Any cancer type
NTRK3:G623R	MUT		Resistant	NTRK3 (G623R)		07/17	RDientsmann	Larotrectinib	Topomyosine kinase inhibitor	Larotrectinib (Topomyosine kinase inhibitor)		Pre-clinical	NTRK3		CANCER	Any cancer type	PMID:28578312	1.0		c.1867G>A	chr15:g.88476265C>T	NTRK3:G623R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr15:g.88476265C>G;candidate_mnv_variants=chr15:g.88476263_88476265delTCCinsCCT,chr15:g.88476263_88476265delTCCinsGCG,chr15:g.88476263_88476265delTCCinsCCG,chr15:g.88476263_88476265delTCCinsACG;aliases=ENSP00000354207;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000360948	Any cancer type
CRBN:.	MUT		Resistant	CRBN oncogenic mutation	. other mutation disrupting IMID - CRBN or CRBN - ubiqutin complex may confer IMiD resistance		DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:25108355	1.0									Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	REMAP:Q99 changed to Q100 (meaning that i change from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A)		DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:23480694	1.0		c.298C>T	chr3:g.3215822G>A	CRBN:Q100*	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.3215820_3215822delCTGinsTTA,chr3:g.3215820_3215822delCTGinsTCA;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000231948	Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	REMAP:Q99 changed to Q100 (meaning that i change from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A)		DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:23480694	1.0		c.848G>A	chr3:g.3195747C>T	CRBN:R283K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr3:g.3195746_3195747delTCinsCT;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000231948	Myeloma
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC;SG	Head and neck cancer;Salivary glands tumor	PMID:26859683;ASCO 2016 (abstr e17557)	1.0									Head and neck cancer;Salivary glands tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	benign	09/15	MMartínez	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Late trials	NF1		NF	Neurofibroma	NCT01365468	1.0	Indirect								Neurofibroma
NF1:D1644A	MUT		Responsive	NF1 (D1644A)		06/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC	Head and neck cancer	ASCO 2015 (abstr 11010);PMID:26859683	1.0		c.4931A>C	chr17:g.29652933A>C	NF1:D1644A	CSQN=Missense;reference_codon=GAC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.29652933_29652934delACinsCA,chr17:g.29652933_29652934delACinsCG,chr17:g.29652933_29652934delACinsCT;aliases=ENSP00000351015;source=Ensembl	inside_[cds_in_exon_37]	+	ENST00000358273	Head and neck cancer
LRP1B:.	MUT		Resistant	LRP1B oncogenic mutation			RDientsmann	Liposomal Doxorubicin	Chemotherapy	Liposomal Doxorubicin (Chemotherapy)		Early trials	LRP1B		OV	Ovarian carcinoma	PMID:22896685	1.0									Ovarian carcinoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	Everolimus;Pazopanib	MTOR inhibitor;VEGFR inhibitor	Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)		Case report	NF1		HC	Hepatic carcinoma	PMID:24931142	1.0									Hepatic carcinoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	PMID:23099009	1.0									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		PLEN;MPN	Plexiform neurofibroma;Malignant peripheral nerve sheat tumor	PMID:24173684	1.0									Plexiform neurofibroma;Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	PLX3397	Pan-TK inhibitor	PLX3397 (Pan-TK inhibitor)		Pre-clinical	NF1		PLEN	Plexiform neurofibroma	PMID:23099891	1.0									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	ASCO 2014 (abstr 10018)	1.0									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	PMID:25314964	1.0									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline, rampamycin = sirolimus	07/16	RDientsmann	Sirolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	Glioma	PMID:22434731	1.0									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Sorafenib;Sirolimus	Pan-TK inhibitor;MTOR inhibitor	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:25810463	1.0									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:21075781	1.0									Malignant peripheral nerve sheat tumor
ERBB2:T798I	MUT		Resistant	ERBB2 (T798I)		07/17	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA	Breast adenocarcinoma	PMID:28274957	1.0		c.2393C>T	chr17:g.37881064C>T	ERBB2:T798I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881064_37881065delCAinsTC,chr17:g.37881064_37881065delCAinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)		12/15	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.763G>A	chr9:g.133738363G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)		12/15	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.764A>T	chr9:g.133738364A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)		12/15	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.757T>C	chr9:g.133738357T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)		12/15	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>G	chr9:g.133748414T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)		12/15	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1076T>G	chr9:g.133748415T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)		12/15	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	Chronic myeloid leukemia	PMID:21562040	1.0		c.1075T>A	chr9:g.133748414T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		G	Glioma	PMID:26936308	1.0									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation		07/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	NF1		CM	Cutaneous melanoma	PMID:24576830;PMID:2524381	1.0									Cutaneous melanoma
EGFR:C797S	MUT		Resistant	EGFR (C797S)		07/17	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Early trials	EGFR		L	Lung carcinoma	PMID:25939061	1.0		c.2389T>A	chr7:g.55249091T>A	EGFR:C797S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr7:g.55249092G>C;candidate_mnv_variants=chr7:g.55249091_55249093delTGCinsAGT,chr7:g.55249092_55249093delGCinsCT,chr7:g.55249092_55249093delGCinsCG,chr7:g.55249092_55249093delGCinsCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
EGFR:L718.	MUT		Resistant	EGFR (L718)		07/17	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Early trials	EGFR		L	Lung carcinoma	ASCO 2017 (abstr 2572)	1.0									Lung carcinoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Vinblastine	Chemotherapy	Vinblastine (Chemotherapy)		Early trials	NF1		G	Glioma	ASCO 2016 (abstr 2019)	1.0									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Vinblastine;Nilotinib	Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)		Case report	NF1		G	Glioma	ASCO 2016 (abstr 10555)	1.0									Glioma
EGFR:L792.	MUT		Resistant	EGFR (L792)		07/17	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Early trials	EGFR		L	Lung carcinoma	ASCO 2017 (abstr 2572)	1.0									Lung carcinoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation		07/16	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Early trials	NF2		MESO	Mesothelioma	ENA 2012 (abstr 610)	1.0									Mesothelioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation		07/16	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	NF2		MESO;OV	Mesothelioma;Ovarian carcinoma	PMID:24848258;PMID:24786638	1.0									Mesothelioma;Ovarian carcinoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NF2		MEN	Meningioma	PMID:23714726	1.0									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation		07/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF2		TH	Thyroid carcinoma	PMID:26359368	1.0									Thyroid carcinoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation		07/18	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF2		MEN	Meningioma	PMID:19451225;PMID:2242646	1.0									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	NF2		SCHW;MEN	Schwannoma;Meningioma	PMID:23960073;PMID:25596744	1.0									Schwannoma;Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	[]	[PDK1 inhibitor]	PDK1 inhibitors		Pre-clinical	NF2		SCHW	Schwannoma	PMID:19359162	1.0									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Pre-clinical	NF2		SCHW	Schwannoma	PMID:21778190	1.0									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline,minor response	07/16	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Early trials	NF2		MEN	Meningioma	ASCO 2016 (abstr 2558)	1.0									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Early trials	NF2		SCHW	Schwannoma	PMID:19587327;PMID:22805104;PMID:26022982	1.0									Schwannoma
BRAF:V600E	MUT		Resistant	BRAF (V600E)			RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Late trials	BRAF		COREAD	Colorectal adenocarcinoma	PMID:20619739;PMID:21163703;PMID:23325582	1.0		c.1799T>A	chr7:g.140453136A>T	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
EGFR:G465R	MUT		Resistant	EGFR (G465R)		01/16	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	Colorectal adenocarcinoma	PMID:26059438	1.0		c.1393G>A	chr7:g.55227926G>A	EGFR:G465R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline, minor responsiv	07/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF2		SCHW	Schwannoma	PMID:24311643	1.0									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation		07/16	RDientsmann	Everolimus;Octreotide	MTOR inhibitor;Somatostatin analog	Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)		Pre-clinical	NF2		MEN	Meningioma	PMID:26015296	1.0									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	NF2		SCHW	Schwannoma	PMID:19509233;PMID:2290085	1.0									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	germline	07/16	RDientsmann;MMartínez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	NF2		SCHW;NF	Schwannoma;Neurofibroma	PMID:22844108;NCT00973739	1.0									Schwannoma;Neurofibroma
NF2:.	MUT		Responsive	NF2 oncogenic mutation		07/16	RDientsmann	Tensirolimus;Chemotherapy	MTOR inhibitor;Chemotherapy	Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)		Case report	NF2		BRCA	Breast adenocarcinoma	PMID:25878190	1.0									Breast adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	Gemcitabine;MEK inhibitor	Chemotherapy;MEK inhibitor	Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)		Early trials	KRAS		PA	Pancreatic carcinoma	PMID:23583440	1.0									Pancreatic carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		09/15	EArriola	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)	Clinical Trials	Early trials	KRAS		NSCLC	Non-small cell lung cancer	NCT00890825	1.0									Non-small cell lung cancer
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain		01/16	RDientsmann	[]	[Gamma secretase inhibitor;CDK4 inhibitor]	Gamma secretase inhibitor + CDK4 inhibitors		Pre-clinical	NOTCH1		ALL	Acute lymphoblastic leukemia	PMID:19318552	1.0									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain		01/16	RDientsmann	[]	[Gamma secretase inhibitor;MTOR inhibitor]	Gamma secretase inhibitor + MTOR inhibitors		Pre-clinical	NOTCH1		ALL	Acute lymphoblastic leukemia	PMID:19246562	1.0									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain		01/16	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Early trials	NOTCH1		ALL	Acute lymphoblastic leukemia	ASCO 2006 (abstr 6585)	1.0									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain		01/16	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		ALL	Acute lymphoblastic leukemia	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	1.0									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain			RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		BRCA	Breast adenocarcinoma	PMID:25564152	1.0									Breast adenocarcinoma
NOTCH1:.	MUT		Responsive	NOTCH1 oncogenic mutation			RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		MCL	Mantle cell lymphoma	PMID:22210878	1.0									Mantle cell lymphoma
NOTCH1::consequence::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)		07/17	RDientsmann	[]	[NOTCH1 inhibitor]	NOTCH1 inhibitors		Case report	NOTCH1		ADCC	Adenoid cystic carcinoma	PMID:27870570	1.0									Adenoid cystic carcinoma
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain			ECampo	[Ro4929097,Pf-03084014,Mk-0752]	[Gamma secretase inhibitor]	Gamma secretase inhibitors (Ro4929097,Pf-03084014,Mk-0752,etc)	Clinical Trials	Early trials	NOTCH1		CANCER	Any cancer type	NCT01703572;NCT01778439;NCT01098344;NCT01981551	1.0	Indirect								Any cancer type
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain			ECampo	OMP-52M51	NOTCH1 inhibitor	OMP-52M51 (NOTCH1 inhibitor)	Clinical Trials	Early trials	NOTCH1		CANCER	Any cancer type	NCT01703572;NCT01778439	1.0	Direct								Any cancer type
NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	MUT		Responsive	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)			KKarube;RDientsmann	Mk-0752	Gamma secretase inhibitor	Mk-0752 (Gamma secretase inhibitor)	Clinical Trials	Early trials	NOTCH2		BRCA;AML;ALL	Breast adenocarcinoma;Acute myeloid leukemia;Acute lymphoblastic leukemia	PMID:25564152	1.0	Direct								Breast adenocarcinoma;Acute myeloid leukemia;Acute lymphoblastic leukemia
NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	MUT		Responsive	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)			ECampo	OMP-59R5	NOTCH2 inhibitor	OMP-59R5 (NOTCH2 inhibitor)	Clinical Trials	Early trials	NOTCH2		SOLID	Solid tumors	NCT01859741;NCT01277146	1.0	Direct								Solid tumors
NPM1:.	MUT		Responsive	NPM1 oncogenic mutation		12/16	RDientsmann	[]	[DOT1L inhibitors;MLL1 inhibitors]	DOT1L inhibitors + MLL1 inhibitors		Pre-clinical	NPM1		AML	Acute myeloid leukemia	PMID:27535106	1.0									Acute myeloid leukemia
NPM1:.	MUT		Responsive	NPM1 oncogenic mutation			RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	NPM1		AML	Acute myeloid leukemia	PMID:22417203	1.0									Acute myeloid leukemia
EGFR:T790M	MUT		Resistant	EGFR (T790M)		01/16	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)		NCCN/CAP guidelines	EGFR		L	Lung carcinoma	NCCN	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation			DTamborero;CRubio-Perez;RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors	Approved	Early trials	NRAS		CM	Cutaneous melanoma	PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	1.0	Indirect								Cutaneous melanoma
NRAS:G12C	MUT		Responsive	NRAS (G12C)			RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	NRAS		CANCER	Any cancer type	PMID:23614898	1.0		c.34G>T	chr1:g.115258748C>A	NRAS:G12C	CSQN=Missense;reference_codon=GGT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.115258746_115258748delACCinsGCA;aliases=ENSP00000358548;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000369535	Any cancer type
NRAS:.	MUT		Responsive	NRAS oncogenic mutation		07/17	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Case report	NRAS		CM	Cutaneous melanoma	ASCO 2017 (abstr 2508)	1.0									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation		07/17	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NRAS		CM	Cutaneous melanoma	PMID:23538902	1.0									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation		01/16	RDientsmann	[]	[MEK inhibitor +/- PI3K pathway inhibitor]	MEK inhibitor +/- PI3K pathway inhibitors		Pre-clinical	NRAS		COREAD	Colorectal adenocarcinoma	PMID:23274911;PMID:22392911	1.0									Colorectal adenocarcinoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NRAS		AML;LUAD;ALL	Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia	PMID:22507781;PMID:23515407;PMID:18701506	1.0									Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia
NRAS:Q61.	MUT		Responsive	NRAS (Q61)		06/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Late trials	NRAS		CM	Cutaneous melanoma	PMID:23414587;ASCO 2016 (abstr 9500)	1.0									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation		07/17	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Case report	NRAS		CM	Cutaneous melanoma	ESMO 2015 (abstract 300);AACR 2017 (abstr CT002)	1.0									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation			RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	NRAS		MYMA	Myeloma	PMID:22985491	1.0									Myeloma
CRBN:.	MUT		Resistant	CRBN oncogenic mutation	IMiD-compound pocket in TBD of the CRBN is formed by three tryptophan residues, Trp380, Trp386 and Trp400		DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:25108355	1.0									Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	REMAP:Q99 changed to Q100 (meaning that i changed from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A)		DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:23480694	1.0		c.298C>T	chr3:g.3215822G>A	CRBN:Q100*	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.3215820_3215822delCTGinsTTA,chr3:g.3215820_3215822delCTGinsTCA;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000231948	Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	REMAP:Q99 changed to Q100 (meaning that i changed from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A)		DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:23480694	1.0		c.848G>A	chr3:g.3195747C>T	CRBN:R283K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr3:g.3195746_3195747delTCinsCT;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000231948	Myeloma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation		01/16	RDientsmann	Sorafenib;MEK inhibitor	Pan-TK inhibitor;MEK inhibitor	Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)		Early Trials,Case Report	NRAS		HC	Hepatic carcinoma	PMID:25294897	1.0									Hepatic carcinoma
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation		01/16	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	PALB2		PRAD	Prostate adenocarcinoma	AACR 2015 (abstr CT322);PMID:26510020	1.0									Prostate adenocarcinoma
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation		01/16	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	PALB2		PA	Pancreatic carcinoma	PMID:25263539;NCT01585805	1.0									Pancreatic carcinoma
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation		01/16	RDientsmann	Mytomycin C	Chemotherapy	Mytomycin C (Chemotherapy)		Case report	PALB2		PA	Pancreatic carcinoma	PMID:21135251	1.0									Pancreatic carcinoma
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation		01/16	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	PALB2		PA	Pancreatic carcinoma	PMID:25719666	1.0									Pancreatic carcinoma
PBRM1:.	MUT		Responsive	PBRM1 oncogenic mutation		01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	PBRM1		CANCER	Any cancer type	PMID:26552009	1.0									Any cancer type
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	PDGFRA		GIST	Gastrointestinal stromal	PMID:18794084	1.0		c.2525A>T	chr4:g.55152093A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
FLT3:D835.,Y842.	MUT		Resistant	FLT3 (D835,Y842)		01/16	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FLT3		AML	Acute myeloid leukemia	PMID:23430109	1.0									Acute myeloid leukemia
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)		12/16	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Early trials	PDGFRA		GIST	Gastrointestinal stromal	ASCO 2016 (abstr 11010)	1.0		c.2525A>T	chr4:g.55152093A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)			RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.1973T>C	chr4:g.55144144T>C	PDGFRA:V658A	CSQN=Missense;reference_codon=GTA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55144144_55144145delTAinsCC,chr4:g.55144144_55144145delTAinsCG,chr4:g.55144144_55144145delTAinsCT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)			RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.1729C>T	chr4:g.55141083C>T	PDGFRA:P577S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr4:g.55141083_55141085delCCGinsTCT,chr4:g.55141083_55141085delCCGinsTCC,chr4:g.55141083_55141085delCCGinsTCA,chr4:g.55141083_55141085delCCGinsAGC,chr4:g.55141083_55141085delCCGinsAGT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)			RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.2522G>A	chr4:g.55152090G>A	PDGFRA:R841K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr4:g.55152090_55152091delGAinsAG;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)			RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.2533C>T	chr4:g.55152101C>T	PDGFRA:H845Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55152101_55152103delCATinsTAC;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)			RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.2558G>A	chr4:g.55152126G>A	PDGFRA:G853D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55152126_55152127delGCinsAT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA::wildtype:.	MUT		Responsive	PDGFRA wildtype		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	PDGFRA		GIST	Gastrointestinal stromal	PMID:16397263	1.0									Gastrointestinal stromal
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	PDGFRA		GIST	Gastrointestinal stromal	PMID:18794084	1.0		c.2525A>T	chr4:g.55152093A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PDGFRA::consequence::inframe_deletion:I843.	MUT		Responsive	PDGFRA inframe deletion (I843)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	Gastrointestinal stromal	NCCN guidelines	1.0									Gastrointestinal stromal
RET:I788N	MUT		Resistant	RET (I788N)		07/17	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	RET		LUAD	Lung adenocarcinoma	PMID:28615362	1.0		c.2363T>A	chr10:g.43613899T>A	RET:I788N	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr10:g.43613899_43613900delTCinsAT;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000355710	Lung adenocarcinoma
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	Gastrointestinal stromal	NCCN guidelines	1.0									Gastrointestinal stromal
FLT3:F691.,D835.,N676.,Y842.	MUT		Resistant	FLT3 (F691,D835,N676,Y842)			RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	Acute myeloid leukemia	PMID:22504184;PMID:23878140	1.0									Acute myeloid leukemia
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.1729C>T	chr4:g.55141083C>T	PDGFRA:P577S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr4:g.55141083_55141085delCCGinsTCT,chr4:g.55141083_55141085delCCGinsTCC,chr4:g.55141083_55141085delCCGinsTCA,chr4:g.55141083_55141085delCCGinsAGC,chr4:g.55141083_55141085delCCGinsAGT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.2522G>A	chr4:g.55152090G>A	PDGFRA:R841K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr4:g.55152090_55152091delGAinsAG;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.2533C>T	chr4:g.55152101C>T	PDGFRA:H845Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55152101_55152103delCATinsTAC;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	Cutaneous melanoma	PMID:24132921	1.0		c.2558G>A	chr4:g.55152126G>A	PDGFRA:G853D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55152126_55152127delGCinsAT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
EGFR:T790M	MUT		Resistant	EGFR (T790M)		01/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		NCCN/CAP guidelines	EGFR		L	Lung carcinoma	NCCN	1.0		c.2369C>T	chr7:g.55249071C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung carcinoma
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	Mutation exon 12,14,18		RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	Gastrointestinal stromal	NCCN guidelines	1.0									Gastrointestinal stromal
PDGFRA::wildtype:.	MUT		Responsive	PDGFRA wildtype		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	PDGFRA		GIST	Gastrointestinal stromal	ASCO 2011 (abstr 10009)	1.0									Gastrointestinal stromal
PDGFRA::wildtype:.	MUT		Responsive	PDGFRA wildtype		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	PDGFRA		GIST	Gastrointestinal stromal	PMID:18955458	1.0									Gastrointestinal stromal
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	Mutation exon 12,14,18		RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	Gastrointestinal stromal	NCCN guidelines	1.0									Gastrointestinal stromal
EGFR:L798I	MUT		Resistant	EGFR (L798I)		07/16	RDientsmann	Rociletinib	EGFR inhibitor	Rociletinib (EGFR inhibitor)		Case report	EGFR		LUAD	Lung adenocarcinoma	PMID:27283993	1.0		c.2392C>A	chr7:g.55249094C>A	EGFR:L798I	CSQN=Missense;reference_codon=CTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249094_55249096delCTCinsATA,chr7:g.55249094_55249096delCTCinsATT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung adenocarcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		01/16	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Early trials	PIK3CA		BRCA	Breast adenocarcinoma	ASCO 2015 (abstr 2500)	1.0									Breast adenocarcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor (alone or in combination)]	PI3K pathway inhibitor (alone or in combination)s		Pre-clinical	PIK3CA		L;COREAD	Lung carcinoma;Colorectal adenocarcinoma	PMID:23136191;PMID:23475782;PMID:22392911	1.0									Lung carcinoma;Colorectal adenocarcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CA		BLCA;HNC;L	Bladder carcinoma;Head and neck cancer;Lung carcinoma	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	1.0									Bladder carcinoma;Head and neck cancer;Lung carcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Early trials	PIK3CA		BRCA;OV;CESC;ED	Breast adenocarcinoma;Ovarian carcinoma;Cervical squamous cell carcinoma;Endometrial carcinoma	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	1.0									Breast adenocarcinoma;Ovarian carcinoma;Cervical squamous cell carcinoma;Endometrial carcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		07/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CA		HNSC	Head and neck squamous cell carcinoma	PMID:26787751;PMID:26763254	1.0									Head and neck squamous cell carcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CA		G;THCA	Glioma;Thyroid carcinoma	PMID:19671762;PMID:21289267	1.0									Glioma;Thyroid carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		01/16	RDientsmann	Sorafenib;MEK inhibitor	Pan-TK inhibitor;MEK inhibitor	Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)		Early Trials,Case Report	KRAS		HC	Hepatic carcinoma	PMID:25294897	1.0									Hepatic carcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		07/17	RDientsmann	[]	[PIK3CA inhibitor]	PIK3CA inhibitors		Early trials	PIK3CA		BRCA	Breast adenocarcinoma	PMID:28331003	1.0									Breast adenocarcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation		01/16	RDientsmann	[]	[PIK3CA inhibitor]	PIK3CA inhibitors		Case report	PIK3CA		ST	Gastric carcinoma	ASCO 2015 (abstr 2501)	1.0									Gastric carcinoma
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation		04/16	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3CB		HNSC	Head and neck squamous cell carcinoma	PMID:23619167	1.0									Head and neck squamous cell carcinoma
PIK3CB:D1067Y	MUT		Responsive	PIK3CB (D1067Y)		04/16	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3CB		BRCA	Breast adenocarcinoma	PMID:26759240	1.0		c.3199G>T	chr3:g.138374245C>A	PIK3CB:D1067Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000477593	Breast adenocarcinoma
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation		04/16	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Pre-clinical	PIK3CB		HNSC	Head and neck squamous cell carcinoma	PMID:23619167	1.0									Head and neck squamous cell carcinoma
PIK3CB:D1067Y	MUT		Responsive	PIK3CB (D1067Y)		04/16	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Pre-clinical	PIK3CB		BRCA	Breast adenocarcinoma	PMID:26759240	1.0		c.3199G>T	chr3:g.138374245C>A	PIK3CB:D1067Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000477593	Breast adenocarcinoma
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CB		HNSC	Head and neck squamous cell carcinoma	PMID:23619167	1.0									Head and neck squamous cell carcinoma
PIK3R1:.	MUT		Responsive	PIK3R1 oncogenic mutation			RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3R1		G	Glioma	PMID:23166678	1.0									Glioma
PIK3R1:.	MUT		Responsive	PIK3R1 oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3R1		ED	Endometrial carcinoma	ASCO 2015 (abstr 11075)	1.0									Endometrial carcinoma
PIK3R2:A171V,N561D	MUT		Responsive	PIK3R2 (A171V,N561D)			RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	PIK3R2		ED	Endometrial carcinoma	PMID:21984976;PMID:19962665	1.0		c.512C>T	chr19:g.18271909C>T	PIK3R2:A171V	CSQN=Missense;reference_codon=GCT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.18271909_18271910delCTinsTA,chr19:g.18271909_18271910delCTinsTC,chr19:g.18271909_18271910delCTinsTG;aliases=ENSP00000222254;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000222254	Endometrial carcinoma
PIK3R2:A171V,N561D	MUT		Responsive	PIK3R2 (A171V,N561D)			RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	PIK3R2		ED	Endometrial carcinoma	PMID:21984976;PMID:19962665	1.0		c.1681A>G	chr19:g.18278061A>G	PIK3R2:N561D	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.18278061_18278063delAACinsGAT;aliases=ENSP00000222254;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000222254	Endometrial carcinoma
POLE:268-471	MUT		Responsive	POLE (268-471)	Mutations in exonuclease domain. Domain coordinates from (PMID:23528559)	06/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	POLE		G;ED	Glioma;Endometrial carcinoma	PMID:27001570;PMID:27683556;PMID:27159395	1.0									Glioma;Endometrial carcinoma
POLE:.	MUT		Responsive	POLE oncogenic mutation		07/17	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	POLE		COREAD	Colorectal adenocarcinoma	PMID:28188185	1.0									Colorectal adenocarcinoma
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation		10/16	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors	Approved	Pre-clinical	PTCH1		MB	Medulloblastoma	PMID:24651015 	1.0									Medulloblastoma
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation		01/16	RDientsmann	Foretinib	MET inhibitor	Foretinib (MET inhibitor)		Pre-clinical	PTCH1		MB	Medulloblastoma	PMID:25391241	1.0									Medulloblastoma
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation			RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)	Approved	FDA guidelines	PTCH1		BCC;MB	Basal cell carcinoma;Medulloblastoma	PMID:19726763;PMID:19726761	1.0									Basal cell carcinoma;Medulloblastoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Case report	PTEN		PA	Pancreatic carcinoma	PMID:22025163	1.0									Pancreatic carcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		07/16	RDientsmann	[]	[ATM inhibitor]	ATM inhibitors		Pre-clinical	PTEN		BRCA	Breast adenocarcinoma	PMID:27397505	1.0									Breast adenocarcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	(low estrogen)		RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	PTEN		ED	Endometrial carcinoma	PMID:21468130;PMID:20944090	1.0									Endometrial carcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		06/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	PTEN		CM	Cutaneous melanoma	PMID:26645196	1.0									Cutaneous melanoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor;AR antagonist]	PI3K pathway inhibitor + AR antagonists		Pre-clinical	PTEN		PRAD	Prostate adenocarcinoma	PMID:21575859	1.0									Prostate adenocarcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	PTEN		OV	Ovarian carcinoma	PMID:21632463	1.0									Ovarian carcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PTEN		TH;G;L;OV;BRCA;CANCER;ED	Thyroid carcinoma;Glioma;Lung carcinoma;Ovarian carcinoma;Breast adenocarcinoma;Any cancer type;Endometrial carcinoma	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	1.0									Thyroid carcinoma;Glioma;Lung carcinoma;Ovarian carcinoma;Breast adenocarcinoma;Any cancer type;Endometrial carcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	[]	[PIK3CB inhibitor]	PIK3CB inhibitors		Case report	PTEN		PRAD	Prostate adenocarcinoma	ASCO 2014 (abstr 2514)	1.0									Prostate adenocarcinoma
KIT:550-592	MUT		Resistant	KIT mutation in exon 11		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		GIST	Gastrointestinal stromal	PMID:18955458	1.0									Gastrointestinal stromal
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	PTEN		PRAD	Prostate adenocarcinoma	PMID:23582881	1.0									Prostate adenocarcinoma
KIT:788-828	MUT		Resistant	KIT mutation in exon 17		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		GIST	Gastrointestinal stromal	PMID:23840364	1.0									Gastrointestinal stromal
PTEN:.	MUT		Responsive	PTEN oncogenic mutation		01/16	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	PTEN		CANCER	Any cancer type	ASCO 2013 (abstr 2532)	1.0									Any cancer type
PDGFRA:D842V	MUT		Resistant	PDGFRA (D842V)		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials,Pre-clinical	PDGFRA		GIST	Gastrointestinal stromal	PMID:22718859;PMID:16638875	1.0		c.2525A>T	chr4:g.55152093A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)			RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	Breast adenocarcinoma	PMID:24185512;PMID:24185510;PMID:24398047	1.0									Breast adenocarcinoma
NF1:.	MUT		Not Responsive	NF1 oncogenic mutation	germline	07/16	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	PMID:24500418	1.0									Plexiform neurofibroma
PTPRD:.	MUT		Responsive	PTPRD oncogenic mutation		12/16	RDientsmann	[]	[IGF1R inhibitor]	IGF1R inhibitors		Case report	PTPRD		S	Sarcoma	PMID:23800680	1.0									Sarcoma
NF1:.	MUT		Not Responsive	NF1 oncogenic mutation		07/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		OS	Osteosarcoma	PMID:26325560	1.0									Osteosarcoma
RAD51C:.	MUT		Responsive	RAD51C oncogenic mutation		01/16	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	RAD51C		OV	Ovarian carcinoma	ASCO 2015 (abstr 5508)	1.0									Ovarian carcinoma
RAD51C:.	MUT		Responsive	RAD51C oncogenic mutation		04/16	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	RAD51C		OV	Ovarian carcinoma	ASCO 2015 (abstr 5508)	1.0									Ovarian carcinoma
RB1:.	MUT		Responsive	RB1 oncogenic mutation		01/16	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	RB1		RB	Retinoblastoma	PMID:18483379	1.0									Retinoblastoma
RB1:.	MUT		Responsive	RB1 oncogenic mutation			RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	RB1		RB	Retinoblastoma	PMID:17080083;PMID:21515735	1.0									Retinoblastoma
RB1:.	MUT		Responsive	RB1 oncogenic mutation			ARodriguez-Vida;RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	RB1	BLCA	BLCA	Bladder carcinoma	PMID:26238431	1.0	Indirect								Bladder carcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)		01/16	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:23056499	1.0		c.1902C>G	chr10:g.43609950C>G	RET:C634W	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000355710	Thyroid carcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)		01/16	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:23056499	1.0		c.2753T>C	chr10:g.43617416T>C	RET:M918T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000355710	Thyroid carcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)		01/16	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:21470995	1.0		c.1902C>G	chr10:g.43609950C>G	RET:C634W	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000355710	Thyroid carcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)		01/16	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:21470995	1.0		c.2753T>C	chr10:g.43617416T>C	RET:M918T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000355710	Thyroid carcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:21470995	1.0		c.1902C>G	chr10:g.43609950C>G	RET:C634W	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000355710	Thyroid carcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:21470995	1.0		c.2753T>C	chr10:g.43617416T>C	RET:M918T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000355710	Thyroid carcinoma
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)			RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	Thyroid carcinoma	PMID:20065189;PMID:22025146	1.0									Thyroid carcinoma
RNF43:.	MUT		Responsive	RNF43 oncogenic mutation		11/15	RDientsmann	[]	[Porcupine inhibitor]	Porcupine inhibitors		Case report	RNF43		COREAD	Colorectal adenocarcinoma	ENA 2015 (abstr C45)	1.0									Colorectal adenocarcinoma
ROS1:G2032R	MUT		Responsive	ROS1 (G2032R)		01/16	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	ROS1		LUAD	Lung adenocarcinoma	PMID:25351743	1.0		c.6094G>A	chr6:g.117638347C>T	ROS1:G2032R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr6:g.117638347C>G;candidate_mnv_variants=chr6:g.117638345_117638347delTCCinsCCT,chr6:g.117638345_117638347delTCCinsGCG,chr6:g.117638345_117638347delTCCinsCCG,chr6:g.117638345_117638347delTCCinsACG;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_38]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Responsive	ROS1 (S1986Y,S1986F)		07/17	RDientsmann	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.5957C>A	chr6:g.117639399G>T	ROS1:S1986Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAT;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Responsive	ROS1 (S1986Y,S1986F)		07/17	RDientsmann	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27401242	1.0		c.5957C>T	chr6:g.117639399G>A	ROS1:S1986F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAA;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
SERPINB3:.	MUT		Responsive	SERPINB3 oncogenic mutation		12/16	RDientsmann	[]	[CTLA4 inhibitor]	CTLA4 inhibitors		Early trials	SERPINB3		CM	Cutaneous melanoma	PMID:27668655	1.0									Cutaneous melanoma
SETD2:.	MUT		Responsive	SETD2 oncogenic mutation			RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	SETD2		CANCER	Any cancer type	ENA 2014 (abstr 211)	1.0									Any cancer type
SF3B1:K700E,K666N	MUT		Responsive	SF3B1 (K700E,K666N)			RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SF3B1		CANCER	Any cancer type	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	1.0		c.2098A>G	chr2:g.198266834T>C	SF3B1:K700E	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr2:g.198266832_198266834delTTTinsCTC;aliases=ENSP00000335321;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000335508	Any cancer type
SF3B1:K700E,K666N	MUT		Responsive	SF3B1 (K700E,K666N)			RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SF3B1		CANCER	Any cancer type	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	1.0		c.1998G>C	chr2:g.198267359C>G	SF3B1:K666N	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr2:g.198267359C>A;aliases=ENSP00000335321;source=Ensembl	inside_[cds_in_exon_14]	-	ENST00000335508	Any cancer type
SH2B3:.	MUT		Responsive	SH2B3 oncogenic mutation			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	SH2B3		MDPS	Myelodisplasic proliferative syndrome	PMID:20404132	1.0									Myelodisplasic proliferative syndrome
SMARCA1:.	MUT		Responsive	SMARCA1 oncogenic mutation		01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	SMARCA1		CANCER	Any cancer type	PMID:26552009	1.0									Any cancer type
SMARCA4:.	MUT		Responsive	SMARCA4 oncogenic mutation		11/15	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCA4		OV	Ovarian carcinoma	ESMO 2015 (abstract 302)	1.0									Ovarian carcinoma
SMARCB1:.	MUT		Responsive	SMARCB1 oncogenic mutation	INI1 gene symbol: SMARCB1	01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCB1		MRT	Malignant rhabdoid tumor	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	1.0									Malignant rhabdoid tumor
SMARCB1:.	MUT		Responsive	SMARCB1 oncogenic mutation		07/16	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	SMARCB1		MRT	Malignant rhabdoid tumor	PMID:26920892	1.0									Malignant rhabdoid tumor
KRAS:.	MUT		Responsive	KRAS oncogenic mutation		07/16	RDientsmann	Trametinib;Ponatinib	MEK inhibitor;BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KRAS		LUAD	Lung adenocarcinoma	PMID:27338794	1.0									Lung adenocarcinoma
SMO:P641A	MUT		Responsive	SMO (P641A)		07/17	RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		L	Lung carcinoma	ASCO 2017 (abstr 9062)	1.0		c.1921C>G	chr7:g.128851596C>G	SMO:P641A	CSQN=Missense;reference_codon=CCT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.128851596_128851598delCCTinsGCA,chr7:g.128851596_128851598delCCTinsGCC,chr7:g.128851596_128851598delCCTinsGCG;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000249373	Lung carcinoma
SRSF2:.	MUT		Responsive	SRSF2 oncogenic mutation		06/16	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SRSF2		AML	Acute myeloid leukemia	PMID:27135740	1.0									Acute myeloid leukemia
STAG2:.	MUT		Responsive	STAG2 oncogenic mutation			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	STAG2		G	Glioma	PMID:24356817	1.0									Glioma
BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.	MUT		Resistant	BRAF inframe deletion (L485),inframe deletion (P490)		04/16	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Pre-clinical	BRAF		CANCER	Any cancer type	PMID:26732095	1.0									Any cancer type
STK11:.	MUT		Responsive	STK11 oncogenic mutation			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	STK11		LUAD	Lung adenocarcinoma	PMID:19165201	1.0									Lung adenocarcinoma
STK11:.	MUT		Responsive	STK11 oncogenic mutation			RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	STK11		CANCER	Any cancer type	PMID:19541609	1.0									Any cancer type
STK11:.	MUT		Responsive	STK11 oncogenic mutation		01/16	RDientsmann	[]	[SRC inhibitor;PI3K/MEK inhibitor]	SRC inhibitor + PI3K/MEK inhibitors		Pre-clinical	STK11		LUAD	Lung adenocarcinoma	PMID:20541700	1.0									Lung adenocarcinoma
STK11:D194E	MUT		Responsive	STK11 (D194E)		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	STK11		PA	Pancreatic carcinoma	PMID:21189378	1.0		c.582C>G	chr19:g.1220489C>G	STK11:D194E	CSQN=Missense;reference_codon=GAC;candidate_codons=GAG,GAA;candidate_snv_variants=chr19:g.1220489C>A;aliases=ENSP00000324856;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000326873	Pancreatic carcinoma
STK11:.	MUT		Responsive	STK11 oncogenic mutation		01/16	RDientsmann	Phenformin	Anti-diabetic	Phenformin (Anti-diabetic)		Pre-clinical	STK11		LUAD	Lung adenocarcinoma	PMID:23352126	1.0									Lung adenocarcinoma
BRAF:V600.	MUT		Not Responsive	BRAF (V600)			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		COREAD	Colorectal adenocarcinoma	PMID:26287849	1.0									Colorectal adenocarcinoma
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)			RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:23569304	1.0		c.607G>A	chr15:g.66774131G>A	MAP2K1:E203K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.66774131_66774133delGAGinsAAA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)			RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:23569304	1.0		c.167A>C	chr15:g.66727451A>C	MAP2K1:Q56P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)			RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	Cutaneous melanoma	PMID:23569304	1.0		c.169A>G	chr15:g.66727453A>G	MAP2K1:K57E	CSQN=Missense;reference_codon=AAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr15:g.66727453_66727455delAAGinsGAA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
SUZ12:.	MUT		Responsive	SUZ12 oncogenic mutation			RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	SUZ12		CANCER	Any cancer type	PMID:25119042	1.0									Any cancer type
TERT::consequence::promoters_core:.	MUT		Responsive	TERT promoters core		02/17	CRubio-Perez	Eribulin	Macrocyclic analog	Eribulin (Macrocyclic analog)		Pre-clinical	TERT		GBM	Glioblastoma multiforme	PMID:25375122;Neuro Oncology Oct 2016	1.0									Glioblastoma multiforme
TP53::wildtype:.	MUT		Responsive	TP53 wildtype		07/17	RDientsmann	[]	[HDM2 inhibitor]	HDM2 inhibitors		Early trials	TP53		AML	Acute myeloid leukemia	AACR 2017 (abstr CT152)	1.0									Acute myeloid leukemia
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)		04/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	Any cancer type	PMID:26009011	1.0		c.743G>A	chr17:g.7577538C>T	TP53:R248Q	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr17:g.7577537_7577538delCCinsTT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000269305	Any cancer type
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)		04/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	Any cancer type	PMID:26009011	1.0		c.524G>A	chr17:g.7578406C>T	TP53:R175H	CSQN=Missense;reference_codon=CGC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.7578405_7578406delGCinsAT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000269305	Any cancer type
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	REMAP:R172H changed to R175H it was not the human mutation		RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	Any cancer type	PMID:26009011	1.0		c.743G>A	chr17:g.7577538C>T	TP53:R248Q	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr17:g.7577537_7577538delCCinsTT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000269305	Any cancer type
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	REMAP:R172H changed to R175H it was not the human mutation		RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	Any cancer type	PMID:26009011	1.0		c.524G>A	chr17:g.7578406C>T	TP53:R175H	CSQN=Missense;reference_codon=CGC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.7578405_7578406delGCinsAT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000269305	Any cancer type
TP53:.	MUT		Responsive	TP53 oncogenic mutation			RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	TP53		HNC	Head and neck cancer	PMID:25125259	1.0									Head and neck cancer
TP53:.	MUT		Responsive	TP53 oncogenic mutation			ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	TP53		BCL	B cell lymphoma	NCT01955668;ASH 2014	1.0	Indirect								B cell lymphoma
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	there is also some report in real patients with resistance, but not clear association		DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Pre-clinical	NRAS		CM	Cutaneous melanoma	PMID:20179705	1.0									Cutaneous melanoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation		12/16	RDientsmann	Decitabine	Chemotherapy	Decitabine (Chemotherapy)		Early trials	TP53		AML;MDPS	Acute myeloid leukemia;Myelodisplasic proliferative syndrome	PMID:27959731	1.0									Acute myeloid leukemia;Myelodisplasic proliferative syndrome
TP53:.	MUT		Responsive	TP53 oncogenic mutation		07/16	RDientsmann	Doxorubicin	Anthracycline antitumor antibiotic	Doxorubicin (Anthracycline antitumor antibiotic)		Pre-clinical	TP53		BLCA	Bladder carcinoma	PMID:27397505	1.0									Bladder carcinoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation		07/16	RDientsmann	Gemcitabine	Chemotherapy	Gemcitabine (Chemotherapy)		Pre-clinical	TP53		BLCA	Bladder carcinoma	PMID:27397505	1.0									Bladder carcinoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation		07/16	RDientsmann	Mitomycin C	Chemotherapy	Mitomycin C (Chemotherapy)		Pre-clinical	TP53		BLCA	Bladder carcinoma	PMID:27397505	1.0									Bladder carcinoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation			KKarube;RDientsmann;DTamborero	[]	[WEE1 inhibitor]	WEE1 inhibitors	Clinical Trials	Early trials	TP53		OV	Ovarian carcinoma	PMID:27998224	1.0	Indirect								Ovarian carcinoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation			RDientsmann	Pramlintide	Amylin analogue	Pramlintide (Amylin analogue)		Pre-clinical	TP53		THYM	Thymic carcinoma	PMID:25409149	1.0									Thymic carcinoma
TPMT::consequence::splice_acceptor_variant:.	MUT		Increased Toxicity (Ototoxicity)	TPMT splice acceptor variant		01/16	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0									Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.238G>C	chr6:g.18143955C>G	TPMT:A80P	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.719A>G	chr6:g.18130918T>C	TPMT:Y240C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_9]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.460G>A	chr6:g.18139228C>T	TPMT:A154T	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.500C>G	chr6:g.18134115G>C	TPMT:A167G	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000309983	Any cancer type
TPMT::consequence::splice_acceptor_variant:.	MUT		Increased Toxicity (Myelosupression)	TPMT splice acceptor variant		01/16	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0									Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.238G>C	chr6:g.18143955C>G	TPMT:A80P	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.719A>G	chr6:g.18130918T>C	TPMT:Y240C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_9]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.460G>A	chr6:g.18139228C>T	TPMT:A154T	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.500C>G	chr6:g.18134115G>C	TPMT:A167G	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000309983	Any cancer type
TPMT::consequence::splice_acceptor_variant:.	MUT		Increased Toxicity (Myelosupression)	TPMT splice acceptor variant		01/16	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0									Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.238G>C	chr6:g.18143955C>G	TPMT:A80P	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.719A>G	chr6:g.18130918T>C	TPMT:Y240C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_9]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.460G>A	chr6:g.18139228C>T	TPMT:A154T	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)		01/16	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0		c.500C>G	chr6:g.18134115G>C	TPMT:A167G	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000309983	Any cancer type
NTRK3:G623R	MUT		Responsive	NTRK3 (G623R)		07/17	RDientsmann	[]	[novel TRK inhibitor]	novel TRK inhibitors		Case report	NTRK3		CANCER	Any cancer type	PMID:28578312	1.0		c.1867G>A	chr15:g.88476265C>T	NTRK3:G623R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr15:g.88476265C>G;candidate_mnv_variants=chr15:g.88476263_88476265delTCCinsCCT,chr15:g.88476263_88476265delTCCinsGCG,chr15:g.88476263_88476265delTCCinsCCG,chr15:g.88476263_88476265delTCCinsACG;aliases=ENSP00000354207;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000360948	Any cancer type
FLT3::consequence::inframe_variant:572-603	MUT		Resistant	FLT3-ITD	ITD (codified as inframe) in Juxtamembrane domain	10/16	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	FLT3		AML	Acute myeloid leukemia	PMID:27520294	1.0									Acute myeloid leukemia
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	TSC1		RA	Renal angiomyolipoma	PMID:23312829;PMID:21525172;PMID:20048174	1.0									Renal angiomyolipoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	TSC1 or TSC2 mutated	01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Early trials	TSC1		BLCA	Bladder carcinoma	PMID:22923433	1.0	Indirect								Bladder carcinoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	TSC1		R	Renal carcinoma	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	1.0									Renal carcinoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	Tuberous sclerosis complex in 80% of cases = mutations in TSC1 or TSC2	04/16	DTamborero	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC1		GCA	Giant cell astrocytoma	FDA	1.0									Giant cell astrocytoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation		06/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Case report	TSC1		S;ST	Sarcoma;Gastric carcinoma	PMID:26859683	1.0									Sarcoma;Gastric carcinoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	TSC positive.Renal angilypoma is benign tumor	09/15	ARodriguez-Vida	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC1	RA	RA	Renal angiomyolipoma	FDA	1.0									Renal angiomyolipoma
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	TSC2		RA	Renal angiomyolipoma	PMID:23312829;PMID:21525172;PMID:20048174	1.0									Renal angiomyolipoma
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation			RDientsmann	[]	[SRC inhibitor]	SRC inhibitors		Pre-clinical	TSC2		LAM	Lymphangioleiomyomatosis	PMID:24691995	1.0									Lymphangioleiomyomatosis
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	TSC1 or TSC2 mutated	01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Early trials	TSC2		BLCA	Bladder carcinoma	PMID:22923433	1.0	Indirect								Bladder carcinoma
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	TSC positive.Renal angilypoma is benign tumor	04/16	ARodriguez-Vida;DTamborero	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC2	RA	RA;GCA	Renal angiomyolipoma;Giant cell astrocytoma	FDA	1.0									Renal angiomyolipoma;Giant cell astrocytoma
TSC2:Q1178*	MUT		Responsive	TSC2 (Q1178*)		01/16	CRubio-Perez;RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Case report	TSC2		THCA	Thyroid carcinoma	PMID:25295501	1.0	Indirect	c.3532C>T	chr16:g.2130300C>T	TSC2:Q1178*	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr16:g.2130300_2130302delCAGinsTAA,chr16:g.2130300_2130302delCAGinsTGA;aliases=ENSP00000219476;source=Ensembl	inside_[cds_in_exon_30]	+	ENST00000219476	Thyroid carcinoma
TSC2:E66K	MUT		Responsive	TSC2 (E66K)		07/16	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Case report	TSC2		ED	Endometrial carcinoma	PMID:27016228	1.0		c.196G>A	chr16:g.2100458G>A	TSC2:E66K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr16:g.2100458_2100460delGAAinsAAG;aliases=ENSP00000219476;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000219476	Endometrial carcinoma
SMO:D473H	MUT		Resistant	SMO (D473H)			RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		MB	Medulloblastoma	PMID:19726788;PMID:25759019	1.0		c.1417G>C	chr7:g.128849189G>C	SMO:D473H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Medulloblastoma
U2AF1:.	MUT		Responsive	U2AF1 oncogenic mutation		07/16	RDientsmann	[]	[FLT3 inhibitor]	FLT3 inhibitors		Pre-clinical	U2AF1		CANCER	Any cancer type	PMID:27397505	1.0									Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity	UGT1A1 (G71R,P229Q)		01/16	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0		c.211G>A	chr2:g.234669144G>A	UGT1A1:G71R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.234669144G>C;candidate_mnv_variants=chr2:g.234669144_234669146delGGAinsAGG,chr2:g.234669144_234669146delGGAinsCGC,chr2:g.234669144_234669146delGGAinsCGG,chr2:g.234669144_234669146delGGAinsCGT;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity	UGT1A1 (G71R,P229Q)		01/16	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0		c.686C>A	chr2:g.234669619C>A	UGT1A1:P229Q	CSQN=Missense;reference_codon=CCG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.234669619_234669620delCGinsAA;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 (G71R,P229Q)		01/16	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0		c.211G>A	chr2:g.234669144G>A	UGT1A1:G71R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.234669144G>C;candidate_mnv_variants=chr2:g.234669144_234669146delGGAinsAGG,chr2:g.234669144_234669146delGGAinsCGC,chr2:g.234669144_234669146delGGAinsCGG,chr2:g.234669144_234669146delGGAinsCGT;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 (G71R,P229Q)		01/16	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0		c.686C>A	chr2:g.234669619C>A	UGT1A1:P229Q	CSQN=Missense;reference_codon=CCG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.234669619_234669620delCGinsAA;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
VHL:.	MUT	Retrospective analysis	Responsive	VHL oncogenic mutation		09/15	ARodriguez-Vida	[Sorafenib,Sunitinib,Bevacizumab,Axitinib]	[VEGFR inhibitor]	VEGFR inhibitors (Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc)	Approved	Pre-clinical	VHL		R	Renal carcinoma	PMID:18635227	1.0	Indirect								Renal carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.1417G>C	chr7:g.128849189G>C	SMO:D473H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.1418A>G	chr7:g.128849190A>G	SMO:D473G	CSQN=Missense;reference_codon=GAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.128849190_128849191delACinsGT,chr7:g.128849190_128849191delACinsGG,chr7:g.128849190_128849191delACinsGA;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.1604G>T	chr7:g.128850341G>T	SMO:W535L	CSQN=Missense;reference_codon=TGG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.128850340_128850341delTGinsCT,chr7:g.128850341_128850342delGGinsTA,chr7:g.128850340_128850342delTGGinsCTT,chr7:g.128850340_128850342delTGGinsCTA,chr7:g.128850340_128850342delTGGinsCTC;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.1234C>T	chr7:g.128846398C>T	SMO:L412F	CSQN=Missense;reference_codon=CTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr7:g.128846398_128846400delCTCinsTTT;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.843G>T	chr7:g.128845546G>T	SMO:W281C	CSQN=Missense;reference_codon=TGG;candidate_codons=TGT,TGC;candidate_snv_variants=chr7:g.128845546G>C;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.1429C>G	chr7:g.128849201C>G	SMO:Q477E	CSQN=Missense;reference_codon=CAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.128849201_128849203delCAGinsGAA;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)		04/16	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	Basal cell carcinoma	PMID:25759020;PMID:25306392	1.0		c.1489G>T	chr7:g.128850226G>T	SMO:G497W	CSQN=Missense;reference_codon=GGG;candidate_codons=TGG;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000249373	Basal cell carcinoma
ZNRF3:.	MUT		Responsive	ZNRF3 oncogenic mutation			RDientsmann	[]	[Porcupine inhibitor]	Porcupine inhibitors		Pre-clinical	ZNRF3		COREAD	Colorectal adenocarcinoma	PMID:26023187	1.0									Colorectal adenocarcinoma
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion			CRubio-Perez;DTamborero;RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	FDA guidelines	ABL1		CML	Chronic myeloid leukemia	FDA	1.0									Chronic myeloid leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion			CRubio-Perez;DTamborero;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	ABL1		CML;ALL	Chronic myeloid leukemia;Acute lymphoblastic leukemia	FDA	1.0									Chronic myeloid leukemia;Acute lymphoblastic leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion		12/16	RDientsmann	Dasatinib;Venetoclax	BCR-ABL inhibitor 2nd gen;BCL2 inhibitor	Dasatinib + Venetoclax (BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)		Pre-clinical	ABL1		ALL	Acute lymphoblastic leukemia	PMID:27582059	1.0									Acute lymphoblastic leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf		CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	Chronic myeloid leukemia;Acute lymphoblastic leukemia	EMA	1.0									Chronic myeloid leukemia;Acute lymphoblastic leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion			CRubio-Perez;DTamborero;RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	ABL1		CML	Chronic myeloid leukemia	FDA	1.0									Chronic myeloid leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion			CRubio-Perez;DTamborero;RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	Chronic myeloid leukemia;Acute lymphoblastic leukemia	FDA	1.0									Chronic myeloid leukemia;Acute lymphoblastic leukemia
AKT2:amp	CNA		Responsive	AKT2 amplification			RDientsmann	MK2206	Allosteric AKT inhibitor	MK2206 (Allosteric AKT inhibitor)	Clinical Trials	Pre-clinical	AKT2		CANCER	Any cancer type	ENA 2014 (abstr 373)	1.0									Any cancer type
AKT3__.	FUS	Cell line	Responsive	AKT3 fusion		09/15	JAlbanell;ARovira;RDientsmann	[AZD5363,GSK2141795]	[ATP competitive AKT inhibitor]	ATP competitive AKT inhibitors (AZD5363,GSK2141795,etc)	Clinical Trials;Clinical Trials	Pre-clinical	AKT3		BRCA	Breast adenocarcinoma	PMID:22722202	1.0	Direct								Breast adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		01/16	RDientsmann	[]	[ALK inhibitor;IGF1R inhibitor]	ALK inhibitor + IGF1R inhibitors		Pre-clinical	ALK		LUAD	Lung adenocarcinoma	PMID:25173427	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		01/16	RDientsmann	[]	[ALK inhibitor;MEK inhibitor]	ALK inhibitor + MEK inhibitors		Pre-clinical	ALK		LUAD	Lung adenocarcinoma	PMID:26301689	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		01/16	RDientsmann	[]	[ALK inhibitor;SRC inhibitor]	ALK inhibitor + SRC inhibitors		Pre-clinical	ALK		LUAD	Lung adenocarcinoma	PMID:25394791	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		01/16	RDientsmann	[]	[ALK inhibitor]	ALK inhibitors		Case report	ALK		COREAD	Colorectal adenocarcinoma	PMID:26633560	1.0									Colorectal adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	ALK		LUAD	Lung adenocarcinoma	PMID:23553849	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		01/16	RDientsmann	[]	[novel ALK inhibitor]	novel ALK inhibitors		Early trials	ALK		LUAD	Lung adenocarcinoma	PMID:23639470	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		12/16	RDientsmann	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	Lung adenocarcinoma	FDA	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion			EArriola;CRubio-Perez	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)	Clinical_Trials	FDA guidelines	ALK		NSCLC	Non-small cell lung cancer	FDA	1.0									Non-small cell lung cancer
CCND1:amp	CNA		Resistant	CCND1 amplification			DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	CCND1		MB	Medulloblastoma	PMID:24951114	1.0									Medulloblastoma
ALK:amp	CNA		Responsive	ALK amplification		07/17	RDientsmann	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 9065)	1.0									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		12/16	CRubio-Perez;DTamborero;RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)	Approved	FDA guidelines	ALK		NSCLC;LUAD	Non-small cell lung cancer;Lung adenocarcinoma	FDA	1.0									Non-small cell lung cancer;Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		12/16	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ALK		COREAD;IM	Colorectal adenocarcinoma;Inflammatory myofibroblastic	PMID:26633560;PMID:26933125;PMID:27742657	1.0									Colorectal adenocarcinoma;Inflammatory myofibroblastic
ALK__.	FUS		Responsive	ALK fusion			ECampo	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)	Clinical Trials	Early trials	ALK		HEMATO	Hematologic malignancies	NCT02186821	1.0	Direct								Hematologic malignancies
ALK__.	FUS		Responsive	ALK fusion		09/15	MMartínez;RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	ALK		LY;GB	Lymphoma;Glioblastoma	PMID:24491302;NCT02270034	1.0									Lymphoma;Glioblastoma
ALK__.	FUS		Responsive	ALK fusion			CRubio-Perez;DTamborero;RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	FDA guidelines	ALK		NSCLC;LUAD	Non-small cell lung cancer;Lung adenocarcinoma	FDA	1.0									Non-small cell lung cancer;Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		IM;THCA	Inflammatory myofibroblastic;Thyroid carcinoma	PMID:20979472;PMID:24687827	1.0									Inflammatory myofibroblastic;Thyroid carcinoma
EGFR:amp	CNA		Not Responsive	EGFR amplification			RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	EGFR		G	Glioma	PMID:16282176;PMID:16278407	1.0									Glioma
EGFR:amp	CNA		Not Responsive	EGFR amplification			RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Early trials	EGFR		G	Glioma	PMID:16282176;PMID:16278407	1.0									Glioma
ALK__.	FUS		Responsive	ALK fusion		12/16	RDientsmann	Entrictinib	Pan-TK inhibitor	Entrictinib (Pan-TK inhibitor)		Case report	ALK		COREAD	Colorectal adenocarcinoma	PMID:26633560;PMID:26933125	1.0									Colorectal adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion		07/17	RDientsmann;CRubio-Perez	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Early trials	ALK		NSCLC	Non-small cell lung cancer	PMID:26951079 	1.0									Non-small cell lung cancer
ALK__.	FUS		Responsive	ALK fusion		07/17	RDientsmann;CRubio-Perez	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		FDA guidelines	ALK		NSCLC	Non-small cell lung cancer	FDA	1.0									Non-small cell lung cancer
EGFR:amp	CNA		Not Responsive	EGFR amplification			RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		G	Glioma	PMID:16282176;PMID:16278407	1.0									Glioma
AR:amp	CNA		Responsive	AR amplification			RDientsmann	[]	[AR inhibitor next gen]	AR inhibitor next gens		Pre-clinical	AR		PRAD	Prostate adenocarcinoma	PMID:23589709;PMID:21859989	1.0									Prostate adenocarcinoma
AR:over	EXPR		Responsive	AR overexpression		09/15	JAlbanell;ARovira	[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]	[AR inhibitor]	AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)	Clinical Trials	Early trials	AR		BRCA	Breast adenocarcinoma	ASCO 2015 (abstr 1003)	1.0	Direct								Breast adenocarcinoma
ERBB2:amp	CNA		Resistant	ERBB2 amplification		06/16	EArriola	[]	[EGFR inhibitor]	EGFR inhibitors		Pre-clinical	ERBB2		LUAD	Lung adenocarcinoma	PMID:22956644	1.0									Lung adenocarcinoma
ERBB2:amp	CNA		Resistant	ERBB2 amplification			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	ERBB2		COREAD	Colorectal adenocarcinoma	PMID:22586653;PMID:23348520	1.0									Colorectal adenocarcinoma
ERBB3:amp	CNA		Resistant	ERBB3 amplification			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	ERBB3		COREAD	Colorectal adenocarcinoma	PMID:25520391	1.0									Colorectal adenocarcinoma
ESR1__YAP1	FUS		Resistant	ESR1-YAP1 fusion			RDientsmann	[]	[ESR1 inhibitor]	ESR1 inhibitors		Pre-clinical	ESR1		BRCA	Breast adenocarcinoma	PMID:24055055	1.0									Breast adenocarcinoma
AR:over	EXPR		Responsive	AR overexpression		09/15	ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)	Approved	Early trials	AR	PRAD	PRAD	Prostate adenocarcinoma	PMID:24882673	1.0	Direct								Prostate adenocarcinoma
AR:F877L;AR:T878A	MUT;MUT		Responsive	AR (F877L) + AR (T878A)		12/16	RDientsmann	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Pre-clinical	AR;AR		PRAD	Prostate adenocarcinoma	PMID:27196756	1.0									Prostate adenocarcinoma
FBXW7:del	CNA		Resistant	FBXW7 deletion			RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	FBXW7		CANCER	Any cancer type	PMID:21368834	1.0									Any cancer type
FGFR2:N549H,V564F,K659M,L617V,K641R,R565A;FGFR2__.	MUT;FUS		Resistant	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2;FGFR2		CH	Cholangiocarcinoma	PMID:28034880;ASCO 2017 (abstr 2500)	1.0									Cholangiocarcinoma
AREG:amp	CNA		Responsive	AREG amplification		04/16	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	AREG		COREAD	Colorectal adenocarcinoma	PMID:19738126;PMID:26341080	1.0									Colorectal adenocarcinoma
GLI2:amp	CNA		Resistant	GLI2 amplification			DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	GLI2		MB	Medulloblastoma	PMID:24951114	1.0									Medulloblastoma
ATM:del	CNA		Responsive	ATM deletion		11/15	RDientsmann	[]	[ATR inhibitor]	ATR inhibitors		Case report	ATM		COREAD	Colorectal adenocarcinoma	ENA 2015 (abstr A48)	1.0									Colorectal adenocarcinoma
ATM:del	CNA		Responsive	ATM deletion		11/15	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	ATM		LY	Lymphoma	PMID:23761041	1.0									Lymphoma
ATM:del	CNA		Responsive	ATM deletion			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	ATM		ST	Gastric carcinoma	ENA 2014 (abstr 8LBA)	1.0									Gastric carcinoma
ATM:.	BIA		Responsive	ATM biallelic inactivation			ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	ATM		BCL	B cell lymphoma	NCT01955668;ASH 2014	1.0	Indirect								B cell lymphoma
ATM:del	CNA		Responsive	ATM deletion		09/15	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	ATM	BLCA	BLCA	Bladder carcinoma	PMID:26238431	1.0	Indirect								Bladder carcinoma
ATR:del	CNA	Cell line	Responsive	ATR deletion			CRubio-Perez;ECampo;RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Pre-clinical	ATR		OV;CANCER	Ovarian carcinoma;Any cancer type	PMID:23548269	1.0	Indirect								Ovarian carcinoma;Any cancer type
AURKA:amp	CNA		Responsive	AURKA amplification			RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	AURKA		PRAD;CANCER	Prostate adenocarcinoma;Any cancer type	PMID:22302096;PMID:22389870	1.0									Prostate adenocarcinoma;Any cancer type
IGF2:amp	CNA		Resistant	IGF2 amplification			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	IGF2		COREAD	Colorectal adenocarcinoma	PMID:25632036	1.0									Colorectal adenocarcinoma
BAP1:del	CNA		Responsive	BAP1 deletion		11/15	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	BAP1		MESO	Mesothelioma	PMID:26437366	1.0									Mesothelioma
BAP1:del	CNA		Responsive	BAP1 deletion			RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	BAP1		CM	Cutaneous melanoma	PMID:22038994	1.0									Cutaneous melanoma
BAP1:del	CNA		Responsive	BAP1 deletion			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BAP1		R;CANCER	Renal carcinoma;Any cancer type	PMID:22683710	1.0									Renal carcinoma;Any cancer type
BCL2:over	EXPR		Responsive	BCL2 overexpression		02/17	CRubio-Perez	Venetoclax;Bortezomib	BCL2 inhibitor;Proteasome inhibitor	Venetoclax + Bortezomib (BCL2 inhibitor + Proteasome inhibitor)		Early trials	BCL2		MM	Multiple myeloma	ASH 2015 (Blood 2015 126:2975)	1.0									Multiple myeloma
BCL2:amp	CNA		Responsive	BCL2 amplification			RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	BCL2		LY	Lymphoma	PMID:22649144	1.0									Lymphoma
BCL6:over	EXPR		Responsive	BCL6 overexpression		02/17	CRubio-Perez	Onalespib	HSP90 inhibitor	Onalespib (HSP90 inhibitor)		Early trials	BCL6		LY	Lymphoma	NCT02572453	1.0									Lymphoma
BRAF__.	FUS		Responsive	BRAF fusion		07/17	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	BRAF		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 9072)	1.0									Lung adenocarcinoma
BRAF__.	FUS		Responsive	BRAF fusion			RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Pre-clinical	BRAF		LUAD;CM;PRAD	Lung adenocarcinoma;Cutaneous melanoma;Prostate adenocarcinoma	PMID:24727320;PMID:24345920;PMID:20526349	1.0									Lung adenocarcinoma;Cutaneous melanoma;Prostate adenocarcinoma
BRAF__.	FUS		Responsive	BRAF fusion		01/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	BRAF		OV	Ovarian carcinoma	PMID:26324360	1.0									Ovarian carcinoma
BRAF__.	FUS		Responsive	BRAF fusion			RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM;LUAD;PRAD	Cutaneous melanoma;Lung adenocarcinoma;Prostate adenocarcinoma	PMID:238900088;PMID:20526349;PMID:24727320	1.0									Cutaneous melanoma;Lung adenocarcinoma;Prostate adenocarcinoma
KRAS:amp	CNA		Resistant	KRAS amplification			RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor]	BRAF inhibitor + EGFR mAb inhibitors		Case report	KRAS		COREAD	Colorectal adenocarcinoma	ENA 2014 (abstr 428)	1.0									Colorectal adenocarcinoma
BRAF:G469A;EGFR:.	MUT;MUT		Responsive	BRAF (G469A) + EGFR oncogenic mutation		01/16	RDientsmann	[]	[EGFR TK inhibitor;MEK inhibitor]	EGFR TK inhibitor + MEK inhibitors		Pre-clinical	BRAF;EGFR		LUAD	Lung adenocarcinoma	PMID:22773810	1.0									Lung adenocarcinoma
BRCA1:del	CNA		Responsive	BRCA1 deletion			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BRCA1		OV	Ovarian carcinoma	PMID:22392482	1.0									Ovarian carcinoma
BRCA2:del	CNA		Responsive	BRCA2 deletion			RDientsmann	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)		Pre-clinical	BRCA2		OV	Ovarian carcinoma	PMID:22392482	1.0									Ovarian carcinoma
KRAS:amp	CNA		Resistant	KRAS amplification			RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	KRAS		COREAD	Colorectal adenocarcinoma	ENA 2014 (abstr 428)	1.0									Colorectal adenocarcinoma
BRD4__C15orf55	FUS		Responsive	BRD4-C15orf55 fusion		11/15	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Case report	C15orf55		NMC	NUT midline carcinoma	ENA 2015 (abstr A49)	1.0									NUT midline carcinoma
CA9:over	EXPR	Cell line	Responsive	CA9 overexpression		09/15	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	CA9		R	Renal carcinoma	PMID:24086736	1.0	Indirect								Renal carcinoma
CCND1:amp	CNA		Responsive	CCND1 amplification			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CCND1		CM	Cutaneous melanoma	ASCO 2014 (abstr 2528)	1.0									Cutaneous melanoma
CCND1:amp	CNA		Responsive	CCND1 amplification			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND1		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CCND2:amp	CNA		Responsive	CCND2 amplification			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND2		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CCND2:amp	CNA		Responsive	CCND2 amplification			CRubio-Perez;DTamborero	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Approved	Early trials	CCND2		L	Lung carcinoma	NCT02154490	1.0	Indirect								Lung carcinoma
CCND3:amp	CNA		Responsive	CCND3 amplification			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND3		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CCNE1:amp	CNA		Responsive	CCNE1 amplification			RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CCNE1		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CD274:amp	CNA		Responsive	CD274 amplification		07/17	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	CD274		BCC	Basal cell carcinoma	PMID:27942391	1.0									Basal cell carcinoma
CD274:amp	CNA		Responsive	CD274 amplification			RDientsmann	[]	[PDL1 inhibitor]	PDL1 inhibitors		Pre-clinical	CD274		CANCER	Any cancer type	PMID:25079317	1.0									Any cancer type
CD274:over	EXPR		Responsive	CD274 overexpression		09/15	ARodriguez-Vida	Atezolizumab	PDL1 inhibitor	Atezolizumab (PDL1 inhibitor)	Clinical Trials	Early trials	CD274	BLCA	CM;R;CANCER	Cutaneous melanoma;Renal carcinoma;Any cancer type	NCT01375842;doi: 10.1093/annonc/mdu337.2	1.0	Direct								Cutaneous melanoma;Renal carcinoma;Any cancer type
CD274:over	EXPR		Responsive	CD274 overexpression		09/15	ARodriguez-Vida	Nivolumab	PD1 Ab inhibitor	Nivolumab (PD1 Ab inhibitor)	Clinical Trials	Early trials	CD274	R	R	Renal carcinoma	PMID:25452452	1.0	Indirect								Renal carcinoma
CD274:over	EXPR		Responsive	CD274 overexpression		09/15	ARodriguez-Vida	Pembrolizumab	PD1 Ab	Pembrolizumab (PD1 Ab)	Clinical Trials	Early trials	CD274	BLCA	BLCA	Bladder carcinoma	NCT01848834	1.0	Indirect								Bladder carcinoma
CD69:under	EXPR	Cell line	Responsive	CD69 undexpression	Ibrutinib and idelalisib as adjuvants (not added)	01/16	CRubio-Perez	Bendamustine	Alkylating agent	Bendamustine (Alkylating agent)	Approved	Pre-clinical	CD69		CLL	Chronic lymphocytic leukemia	PMID:26701728	1.0									Chronic lymphocytic leukemia
CDK12:amp	CNA		Responsive	CDK12 amplification		12/16	RDientsmann	[]	[PARP inhibitors]	PARP inhibitors		Pre-clinical	CDK12		OV	Ovarian carcinoma	PMID:24240700;PMID:24554720	1.0									Ovarian carcinoma
CDK4:amp	CNA		Responsive	CDK4 amplification			CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK4		LIP;LY;CANCER	Liposarcoma;Lymphoma;Any cancer type	NCT02187783;NCT01237236;ASCO 2011 (abstr 8061)	1.0	Direct								Liposarcoma;Lymphoma;Any cancer type
CDK4:amp;RB1:norm	CNA;EXPR		Responsive	CDK4 amplification + RB1 expression			RDientsmann	[]	[CDK4 inhibitor]	CDK4 inhibitors		Early trials	CDK4;RB1		LIP	Liposarcoma	PMID:23569312	1.0									Liposarcoma
CDK6:amp	CNA		Responsive	CDK6 amplification			RDientsmann	[]	[CDK6 inhibitor]	CDK6 inhibitors		Pre-clinical	CDK6		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CDK6:amp	CNA		Responsive	CDK6 amplification			CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK6		LIP;LY;CANCER	Liposarcoma;Lymphoma;Any cancer type	NCT02187783;NCT01237236;ASCO 2011 (abstr 8061)	1.0	Direct								Liposarcoma;Lymphoma;Any cancer type
CDKN1A:del	CNA		Responsive	CDKN1A deletion			RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1A		CANCER	Any cancer type	PMID:22471707;PMID:22997239	1.0									Any cancer type
CDKN1B:del	CNA		Responsive	CDKN1B deletion			RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1B		CANCER	Any cancer type	PMID:22471707	1.0									Any cancer type
CDKN2A:del	CNA		Responsive	CDKN2A deletion			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CDKN2A		CM	Cutaneous melanoma	ASCO 2013 (abstr 2500)	1.0									Cutaneous melanoma
CDKN2A:del	CNA		Responsive	CDKN2A deletion			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2A		G;CANCER	Glioma;Any cancer type	PMID:22471707;PMID:22586120;PMID:22711607	1.0									Glioma;Any cancer type
CDKN2A:del	CNA		Responsive	CDKN2A deletion			CRubio-Perez;DTamborero	Ilorasertib	AURKA-VEGF inhibitor	Ilorasertib (AURKA-VEGF inhibitor)	Clinical Trials	Early trials	CDKN2A		CANCER	Any cancer type	NCT02478320	1.0	Indirect								Any cancer type
CDKN2B:del	CNA		Responsive	CDKN2B deletion			RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2B		G;CANCER	Glioma;Any cancer type	PMID:22471707;PMID:22711607	1.0									Glioma;Any cancer type
CDKN2C:del	CNA		Responsive	CDKN2C deletion			RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CDKN2C		G;CANCER	Glioma;Any cancer type	PMID:22471707;PMID:22997239;PMID:22711607	1.0									Glioma;Any cancer type
CHEK2:del	CNA		Responsive	CHEK2 deletion			RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	CHEK2		PRAD	Prostate adenocarcinoma	AACR 2015 (abstr CT322)	1.0									Prostate adenocarcinoma
CRLF2__.	FUS		Responsive	CRLF2 fusion		01/16	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	CRLF2		ALL	Acute lymphoblastic leukemia	PMID:22904298	1.0									Acute lymphoblastic leukemia
CRLF2__.	FUS		Responsive	CRLF2 fusion		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	CRLF2		ALL	Acute lymphoblastic leukemia	PMID:22955920	1.0									Acute lymphoblastic leukemia
CYP17A1:norm	EXPR		Responsive	CYP17A1 expression		09/15	ARodriguez-Vida	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	CYP17A1	PRAD	PRAD	Prostate adenocarcinoma	PMID:22184395	1.0	Direct								Prostate adenocarcinoma
CYP17A1:norm	EXPR		Responsive	CYP17A1 expression		09/15	ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)	Approved	Early trials	CYP17A1	PRAD	PRAD	Prostate adenocarcinoma	PMID:24882673	1.0	Indirect								Prostate adenocarcinoma
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation		01/16	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0									Any cancer type
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation		01/16	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	Any cancer type	FDA	1.0									Any cancer type
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation		01/16	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	Any cancer type	PMID:23988873	1.0									Any cancer type
MCL1:amp	CNA		Resistant	MCL1 amplification			RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	MCL1		CANCER	Any cancer type	PMID:21368834	1.0									Any cancer type
MET:amp	CNA		Resistant	MET amplification			DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	MET		NSCLC;COREAD	Non-small cell lung cancer;Colorectal adenocarcinoma	PMID:22189054;PMID:23729478	1.0									Non-small cell lung cancer;Colorectal adenocarcinoma
MET:amp	CNA		Resistant	MET amplification			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	MET		COREAD	Colorectal adenocarcinoma	PMID:23729478	1.0									Colorectal adenocarcinoma
MET:amp;EGFR:.	CNA;MUT		Resistant	MET amplification + EGFR oncogenic mutation		01/16	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Early trials	MET;EGFR		LUAD	Lung adenocarcinoma	ASCO 2015 (abstr 8089)	1.0									Lung adenocarcinoma
MITF:amp	CNA		Resistant	MITF amplification		01/16	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MITF		CM	Cutaneous melanoma	PMID:24265153	1.0									Cutaneous melanoma
MITF:amp	CNA		Resistant	MITF amplification			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MITF		CM	Cutaneous melanoma	PMID:24265153	1.0									Cutaneous melanoma
MYCN:amp	CNA		Resistant	MYCN amplification			DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	MYCN		MB	Medulloblastoma	PMID:24951114	1.0									Medulloblastoma
EGFR:amp	CNA		Responsive	EGFR amplification		07/16	RDientsmann	[]	[EGFR inhibitor]	EGFR inhibitors		Case report	EGFR		HNSC	Head and neck squamous cell carcinoma	PMID:26763254	1.0									Head and neck squamous cell carcinoma
EGFR:amp	CNA		Responsive	EGFR amplification			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	EGFR		COREAD	Colorectal adenocarcinoma	PMID:18794099;PMID:17664472	1.0									Colorectal adenocarcinoma
NF1:del	CNA		Resistant	NF1 deletion		07/16	RDientsmann	[]	[Retinoic Acid]	Retinoic Acids		Pre-clinical	NF1		NB	Neuroblastoma	PMID:20655465	1.0									Neuroblastoma
EGFR:over	EXPR		Responsive	EGFR overexpression			CRubio-Perez	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	FDA guidelines	EGFR		COREAD	Colorectal adenocarcinoma	FDA	1.0									Colorectal adenocarcinoma
EGFR__RAD51	FUS		Responsive	EGFR-RAD51 fusion		06/16	EArriola	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		NSCLC	Non-small cell lung cancer	PMID:27102076	1.0									Non-small cell lung cancer
EGFR__RAD51	FUS		Responsive	EGFR-RAD51 fusion		07/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	Lung carcinoma	PMID:27102076	1.0									Lung carcinoma
PDGFRA:amp	CNA		Not Responsive	PDGFRA amplification			RDientsmann	[]	[PDGFR inhibitor]	PDGFR inhibitors		Pre-clinical	PDGFRA		G	Glioma	PMID:23544171	1.0									Glioma
PIK3CA:amp	CNA		Resistant	PIK3CA amplification			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CA		BRCA	Breast adenocarcinoma	PMID:24366379	1.0									Breast adenocarcinoma
EGFR:amp	CNA		Responsive	EGFR amplification			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Late trials	EGFR		ED	Endometrial carcinoma	PMID:24950987	1.0									Endometrial carcinoma
PTEN:del	CNA		Resistant	PTEN deletion			RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	PTEN		COREAD	Colorectal adenocarcinoma	PMID:21163703;PMID:19398573	1.0									Colorectal adenocarcinoma
PTEN:del	CNA		Not Responsive	PTEN deletion		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	PTEN		ED	Endometrial carcinoma	PMID:21788564;PMID:23238879	1.0									Endometrial carcinoma
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation		07/17	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	PTEN;BRAF		CM	Cutaneous melanoma	JCO Precision Oncology (PO.16.00054)	1.0									Cutaneous melanoma
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation		07/17	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	PTEN;BRAF		CM	Cutaneous melanoma	JCO Precision Oncology (PO.16.00054)	1.0									Cutaneous melanoma
EPHA2:amp	CNA		Responsive	EPHA2 amplification		01/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		CANCER	Any cancer type	PMID:18047674;PMID:19010823;PMID:19861960	1.0									Any cancer type
EPHA2:amp	CNA		Responsive	EPHA2 amplification			RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		CANCER	Any cancer type	PMID:18047674;PMID:19010823;PMID:19861960	1.0									Any cancer type
EPHA3:amp	CNA		Responsive	EPHA3 amplification		01/16	RDientsmann	[]	[EPHA3 inhibitor]	EPHA3 inhibitors		Pre-clinical	EPHA3		CANCER	Any cancer type	PMID:25125683	1.0									Any cancer type
EPHA3:amp	CNA		Responsive	EPHA3 amplification			RDientsmann	[]	[EPHA3 inhibitor]	EPHA3 inhibitors		Pre-clinical	EPHA3		CANCER	Any cancer type	PMID:25125683	1.0									Any cancer type
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation		01/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	PTEN;BRAF		CM	Cutaneous melanoma	PMID:23039341	1.0									Cutaneous melanoma
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation		01/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	PTEN;BRAF		CM	Cutaneous melanoma	PMID:23039341	1.0									Cutaneous melanoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann	[]	[ERBB2 inhibitor;CDK4/6 inhibitor]	ERBB2 inhibitor + CDK4/6 inhibitors		Pre-clinical	ERBB2		BRCA	Breast adenocarcinoma	PMID:26977878	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann	Ado-Trastuzumab Emtansine	EGFR mAb inhibitor	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)		FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression			CRubio-Perez	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		01/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB2		ST	Gastric carcinoma	AACR 2014 (abstr CT228)	1.0									Gastric carcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Late trials	ERBB2		BRCA	Breast adenocarcinoma	PMID:20142587;PMID:22418700;PMID:23632474	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		07/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB2		BLCA	Bladder carcinoma	PMID:27044931	1.0									Bladder carcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann;CRubio-Perez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		07/17	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	ERBB2		BT	Biliary tract cancer	PMID:26022204	1.0									Biliary tract cancer
RAC1:P29S;BRAF:.	MUT;MUT		Resistant	RAC1 (P29S) + BRAF oncogenic mutation		01/16	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	RAC1;BRAF		CM	Cutaneous melanoma	PMID:25056119	1.0									Cutaneous melanoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression			CRubio-Perez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		01/16	RDientsmann	Lapatinib;Chemotherapy	ERBB2 inhibitor;Chemotherapy	Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy)		Early trials	ERBB2		ST	Gastric carcinoma	PMID:25694417;NCT02015169	1.0									Gastric carcinoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression			DCasadevall	MK2206;Trastuzumab	Allosteric AKT inhibitor;ERBB2 mAb inhibitor	MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor)		Early trials	ERBB2		SOLID	Solid tumors	ASCO 2013 (abstr 2605);PMID:26104654	1.0									Solid tumors
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Late trials	ERBB2		BRCA	Breast adenocarcinoma	PMID:20142587;PMID:22418700;PMID:23632474	1.0									Breast adenocarcinoma
RAC1:P29S;BRAF:.	MUT;MUT		Resistant	RAC1 (P29S) + BRAF oncogenic mutation			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	RAC1;BRAF		CM	Cutaneous melanoma	PMID:25056119	1.0									Cutaneous melanoma
RAF1:S257P,G361A,P261P;BRAF:.	MUT;MUT		Resistant	RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation			RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	RAF1;BRAF		CM	Cutaneous melanoma	PMID:23737487	1.0									Cutaneous melanoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		01/16	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		ST	Gastric carcinoma	PMID:24960402	1.0									Gastric carcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann;CRubio-Perez	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		07/17	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		BT	Biliary tract cancer	PMID:26022204	1.0									Biliary tract cancer
ERBB2:over	EXPR		Responsive	ERBB2 overexpression			CRubio-Perez	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		ST;GEJA	Gastric carcinoma;Gastroesophageal junction adenocarcinoma	FDA	1.0									Gastric carcinoma;Gastroesophageal junction adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann;CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		07/17	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		BT	Biliary tract cancer	PMID:26022204	1.0									Biliary tract cancer
ERBB2:amp	CNA		Responsive	ERBB2 amplification			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Case report	ERBB2		HNC	Head and neck cancer	PMID:21380780	1.0									Head and neck cancer
ERBB2:amp	CNA		Responsive	ERBB2 amplification			RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		OV	Ovarian carcinoma	PMID:20003286;PMID:12525520	1.0									Ovarian carcinoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression			CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression			CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		ST;GEJA	Gastric carcinoma;Gastroesophageal junction adenocarcinoma	FDA	1.0									Gastric carcinoma;Gastroesophageal junction adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		07/17	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Case report	ERBB2		COREAD	Colorectal adenocarcinoma	JCO Precision Oncology (PO.16.00055)	1.0									Colorectal adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann	Trastuzumab;Everolimus;Chemotherapy	ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy	Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)		Early trials	ERBB2		BRCA	Breast adenocarcinoma	PMID:21107682;PMID:20975068	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		04/16	RDientsmann	Trastuzumab;HSP90 inhibitor	ERBB2 mAb inhibitor;HSP90 inhibitor	Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor)		Early trials	ERBB2		BRCA	Breast adenocarcinoma	PMID:21558407	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		01/16	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Late trials	ERBB2		COREAD	Colorectal adenocarcinoma	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	1.0									Colorectal adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification		01/16	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Pre-clinical	ERBB2		ED	Endometrial carcinoma	PMID:25294905	1.0									Endometrial carcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression		09/15	JAlbanell;ARovira	[Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist]	[Hormonal therapy]	Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression		04/16	DTamborero;CRubio-Perez	Abemaciclib	CDK4/6 inhibitor	Abemaciclib (CDK4/6 inhibitor)		Early trials	ERBB2;ESR1		BRCA	Breast adenocarcinoma	PMID:26658964	1.0									Breast adenocarcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	HER2- (not overexpressed and not amplified) and ER+ (>1% positive tumor cells)	09/15	JAlbanell;ARovira	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf		CRubio-Perez	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	Breast adenocarcinoma	FDA	1.0									Breast adenocarcinoma
STK11:.;KRAS:.	MUT;MUT		Resistant	STK11 oncogenic mutation + KRAS oncogenic mutation		07/17	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	STK11;KRAS		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 9016)	1.0									Lung adenocarcinoma
STK11:del;KRAS:.	CNA;MUT		Resistant	STK11 deletion + KRAS oncogenic mutation		07/17	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	STK11;KRAS		LUAD	Lung adenocarcinoma	ASCO 2017 (abstr 9016)	1.0									Lung adenocarcinoma
ERBB4__.	FUS		Responsive	ERBB4 fusion			RDientsmann	Lapatinib;Afatinib	ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen	Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)		Pre-clinical	ERBB4		LUAD	Lung adenocarcinoma	PMID:24727320	1.0									Lung adenocarcinoma
ERCC1:del	CNA		Responsive	ERCC1 deletion			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ERCC1		L	Lung carcinoma	PMID:23934192	1.0									Lung carcinoma
ERCC1:del	CNA		Responsive	ERCC1 deletion		01/16	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC1		L	Lung carcinoma	PMID:23275151;PMID:23934192	1.0									Lung carcinoma
EREG:amp	CNA		Responsive	EREG amplification		04/16	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	EREG		COREAD	Colorectal adenocarcinoma	PMID:19738126;PMID:26341080	1.0									Colorectal adenocarcinoma
ZBTB16:under	EXPR		Resistant	ZBTB16 undexpression		09/15	ARodriguez-Vida	[]	[LHRH analogues or antagonist]	LHRH analogues or antagonists		Pre-clinical	ZBTB16	PR	PRAD	Prostate adenocarcinoma	PMID:16637071	1.0									Prostate adenocarcinoma
FANCA:del	CNA		Responsive	FANCA deletion		01/16	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	FANCA		PRAD	Prostate adenocarcinoma	PMID:26510020	1.0									Prostate adenocarcinoma
FANCC:del	CNA		Responsive	FANCC deletion		09/15	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	FANCC	BLCA	BLCA	Bladder carcinoma	PMID:26238431	1.0	Indirect								Bladder carcinoma
FBXW7:del	CNA	Cell line	Responsive	FBXW7 deletion			CRubio-Perez	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)	Approved	Pre-clinical	FBXW7		COREAD	Colorectal adenocarcinoma	PMID:23558291	1.0	Indirect								Colorectal adenocarcinoma
FGF3:amp	CNA		Responsive	FGF3 amplification			RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Early trials	FGF3		BRCA	Breast adenocarcinoma	PMID:23658459	1.0									Breast adenocarcinoma
FGF3:amp	CNA		Responsive	FGF3 amplification		09/15	JAlbanell;ARovira	Lucitanib	FGFR inhibitor	Lucitanib (FGFR inhibitor)	Clinical Trials	Early trials	FGF3		BRCA	Breast adenocarcinoma	PMID:25193991	1.0	Indirect								Breast adenocarcinoma
FGF4:amp	CNA		Responsive	FGF4 amplification			RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Early trials	FGF4		BRCA	Breast adenocarcinoma	PMID:23658459	1.0									Breast adenocarcinoma
FGF4:amp	CNA		Responsive	FGF4 amplification		09/15	JAlbanell;ARovira	Lucitanib	FGFR inhibitor	Lucitanib (FGFR inhibitor)	Clinical Trials	Early trials	FGF4		BRCA	Breast adenocarcinoma	PMID:25193991	1.0	Indirect								Breast adenocarcinoma
FGFR1:amp	CNA		Responsive	FGFR1 amplification		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR1		LUSC	Squamous cell lung carcinoma	PMID:27870574	1.0									Squamous cell lung carcinoma
FGFR1:amp	CNA		Responsive	FGFR1 amplification		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR1		ED	Endometrial carcinoma	ASCO 2017 (abstr 2500)	1.0									Endometrial carcinoma
FGFR1:amp	CNA		Responsive	FGFR1 amplification			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR1		LUSC	Squamous cell lung carcinoma	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	1.0									Squamous cell lung carcinoma
FGFR1:amp	CNA		Responsive	FGFR1 amplification			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR1		HNC	Head and neck cancer	PMID:23418312	1.0									Head and neck cancer
FGFR1:amp	CNA		Responsive	FGFR1 amplification			RDientsmann;JAlbanell	[Lucitanib]	[FGFR inhibitor]	FGFR inhibitors (Lucitanib,etc)		Early trials	FGFR1		BRCA	Breast adenocarcinoma	PMID:25193991	1.0									Breast adenocarcinoma
AR:amp	CNA		Resistant	AR amplification		11/15	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	Prostate adenocarcinoma	PMID:26537258	1.0									Prostate adenocarcinoma
FGFR2__.	FUS		Responsive	FGFR2 fusion			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		BT	Biliary tract cancer	ASCO 2016 (abstr 109)	1.0									Biliary tract cancer
FGFR2:amp	CNA		Responsive	FGFR2 amplification		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		ST	Gastric carcinoma	ASCO 2015 (abstr 2508)	1.0									Gastric carcinoma
FGFR2:amp	CNA		Responsive	FGFR2 amplification		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR2		BRCA	Breast adenocarcinoma	PMID:25193991	1.0									Breast adenocarcinoma
EGFR:over	EXPR		Resistant	EGFR overexpression			CRubio-Perez;RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	EGFR		COREAD	Colorectal adenocarcinoma	FDA guidelines	1.0									Colorectal adenocarcinoma
FGFR2__.	FUS		Responsive	FGFR2 fusion		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		COREAD	Colorectal adenocarcinoma	ASCO 2017 (abstr 2500)	1.0									Colorectal adenocarcinoma
FGFR3__.	FUS		Responsive	FGFR3 fusion		01/16	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR3		G	Glioma	PMID:26324363	1.0									Glioma
FGFR3__.	FUS		Responsive	FGFR3 fusion		07/17	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR3		BLCA	Bladder carcinoma	PMID:26324363;ASCO 2017 (abstr 2500)	1.0									Bladder carcinoma
FGFR3__TACC3	FUS		Responsive	FGFR3-TACC3 fusion		06/16	EArriola		[FGFR inhibitor]	FGFR inhibitors (,etc)		Pre-clinical	FGFR3		NSCLC	Non-small cell lung cancer	PMID:25294908	1.0									Non-small cell lung cancer
FLCN:del	CNA		Responsive	FLCN deletion		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	FLCN		TH	Thyroid carcinoma	PMID:25295501	1.0									Thyroid carcinoma
VEGFR1:over	EXPR	Cell line	Responsive	FLT1 overexpression		09/15	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	FLT1		R	Renal carcinoma	PMID:24086736;PMID:21478036	1.0	Direct								Renal carcinoma
VEGFR2:over	EXPR	Cell line	Responsive	FLT1 overexpression		09/15	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	FLT1		R	Renal carcinoma	PMID:24086736;PMID:21478036	1.0	Direct								Renal carcinoma
PTEN:.	BIA		Resistant	PTEN biallelic inactivation			DTamborero	BYL719	PIK3CA inhibitor	BYL719 (PIK3CA inhibitor)	Clinical Trials	Case report	PTEN		BRCA	Breast adenocarcinoma	PMID:25409150	1.0									Breast adenocarcinoma
NF1:del	CNA		Not Responsive	NF1 deletion	germline NCT00326872 (trial results section)	07/16	RDientsmann	Cediranib	ALK inhibitor	Cediranib (ALK inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	NCT00326872	1.0									Plexiform neurofibroma
FOXA1:amp	CNA		Responsive	FOXA1 amplification		07/16	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	FOXA1		COREAD	Colorectal adenocarcinoma	PMID:27397505	1.0									Colorectal adenocarcinoma
FRS2:amp	CNA		Responsive	FRS2 amplification			RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FRS2		LIP	Liposarcoma	PMID:23393200	1.0									Liposarcoma
G6PD:.	BIA		Increased Toxicity (Haemolytic Anemia)	G6PD biallelic inactivation		01/16	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD		CANCER	Any cancer type	FDA	1.0									Any cancer type
G6PD:V98M;G6PD:N156D	MUT;MUT		Increased Toxicity (Haemolytic Anemia)	G6PD (V98M) + G6PD (N156D)		01/16	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD;G6PD		CANCER	Any cancer type	FDA	1.0									Any cancer type
HDAC2:.	BIA		Responsive	HDAC2 biallelic inactivation		01/16	RDientsmann;CRubio-Perez	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	HDAC2		PRAD	Prostate adenocarcinoma	PMID:26510020	1.0									Prostate adenocarcinoma
HGF:over	EXPR	Xenograft	Responsive	HGF overexpression			CRubio-Perez;ARodriguez-Vida	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)	Approved	Pre-clinical	HGF		UTC	Urinary tract carcinoma	PMID:25534569	1.0	Indirect								Urinary tract carcinoma
HIF1A:over	EXPR	Cell line	Responsive	HIF1A overexpression		09/15	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	HIF1A		R	Renal carcinoma	PMID:24086736	1.0	Indirect								Renal carcinoma
IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del	MUT;CNA		Responsive	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	IL7R;SH2B3		ALL	Acute lymphoblastic leukemia	PMID:22955920	1.0									Acute lymphoblastic leukemia
IL7R:S185C;SH2B3:del	MUT;CNA		Responsive	IL7R (S185C) + SH2B3 deletion		01/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	IL7R;SH2B3		ALL	Acute lymphoblastic leukemia	PMID:22955920	1.0									Acute lymphoblastic leukemia
IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del	MUT;CNA		Responsive	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion		01/16	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	IL7R;SH2B3		ALL	Acute lymphoblastic leukemia	PMID:22897847;PMID:22955920	1.0									Acute lymphoblastic leukemia
IL7R:S185C;SH2B3:del	MUT;CNA		Responsive	IL7R (S185C) + SH2B3 deletion		01/16	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	IL7R;SH2B3		ALL	Acute lymphoblastic leukemia	PMID:22897847;PMID:22955920	1.0									Acute lymphoblastic leukemia
INPP4B:del	CNA		Responsive	INPP4B deletion			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	INPP4B		BRCA	Breast adenocarcinoma	PMID:23551093	1.0									Breast adenocarcinoma
JAK2:amp	CNA		Responsive	JAK2 amplification		06/16	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK2		BRCA	Breast adenocarcinoma	PMID:27075627	1.0									Breast adenocarcinoma
JAK2__BRAF	FUS		Responsive	JAK2-BRAF fusion		01/16	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	JAK2		ALL	Acute lymphoblastic leukemia	PMID:22875628;PMID:22899477	1.0									Acute lymphoblastic leukemia
PTEN:.	BIA		Resistant	PTEN biallelic inactivation			DTamborero	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Case report	PTEN		COREAD	Colorectal adenocarcinoma	Caris molecular intelligence	1.0									Colorectal adenocarcinoma
ERCC1:over	EXPR		Resistant	ERCC1 overexpression		09/15	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Pre-clinical	ERCC1	BLCA	BLCA	Bladder carcinoma	PMID:20846399;PMID:21177407	1.0									Bladder carcinoma
MDM2:amp	CNA		Resistant	MDM2 amplification		12/16	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	MDM2		MGCT	Male germ cell tumor	PMID:27646943	1.0									Male germ cell tumor
ALK:amp	CNA		Resistant	ALK amplification		09/15	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Clinical trials	ALK		NSCLC	Non-small cell lung cancer	PMID:22235099	1.0									Non-small cell lung cancer
ALK:amp	CNA		Resistant	ALK amplification			RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	Lung adenocarcinoma	PMID:22277784	1.0									Lung adenocarcinoma
NF1:del	CNA		Resistant	NF1 deletion		07/16	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		L	Lung carcinoma	PMID:24296828	1.0									Lung carcinoma
EGFR:amp	CNA		Not Responsive	EGFR amplification			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		L	Lung carcinoma	ASCO 2015 (abstr 19028)	1.0									Lung carcinoma
IGF1R:amp	CNA		Resistant	IGF1R amplification			RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	IGF1R		LUAD	Lung adenocarcinoma	PMID:24458568	1.0									Lung adenocarcinoma
NF1:del	CNA		Resistant	NF1 deletion		07/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	NF1		L	Lung carcinoma	PMID:24535670	1.0									Lung carcinoma
NF2:del	CNA		Not Responsive	NF2 deletion	germline	07/16	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Early trials	NF2		SCHW	Schwannoma	PMID:20736812	1.0									Schwannoma
NF2:.;EGFR:.	MUT;MUT		Resistant	NF2 oncogenic mutation + EGFR oncogenic mutation	 In Egfr Mutant Tumors	07/16	RDientsmann	Erlotinib;Cetuximab	EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)		Case report	NF2;EGFR		L	Lung carcinoma	PMID:24813888	1.0									Lung carcinoma
NF2:del;EGFR:.	CNA;MUT		Resistant	NF2 deletion + EGFR oncogenic mutation	 In Egfr Mutant Tumors	07/16	RDientsmann	Erlotinib;Cetuximab	EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)		Case report	NF2;EGFR		L	Lung carcinoma	PMID:24813888	1.0									Lung carcinoma
NF1:del	CNA		Not Responsive	NF1 deletion	germline	07/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF1		MPN	Malignant peripheral nerve sheat tumor	NCT01365468	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Not Responsive	NF1 deletion	germline	07/16	RDientsmann	Everolimus;Bevacizumab	MTOR inhibitor;VEGFR mAb inhibitor	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)		Early trials	NF1		MPN	Malignant peripheral nerve sheat tumor	ASCO 2016 (abstr 11053)	1.0									Malignant peripheral nerve sheat tumor
MAP2K1:P124S,I111S;BRAF:.	MUT;MUT		Responsive	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation		01/16	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1;BRAF		CM	Cutaneous melanoma	PMID:22588879	1.0									Cutaneous melanoma
NF1:del	CNA		Not Responsive	NF1 deletion		07/16	RDientsmann	Everolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	Glioma	PMID:24634382	1.0									Glioma
MDM2:amp	CNA		Responsive	MDM2 amplification		01/16	RDientsmann	[]	[MDM2 inhibitor]	MDM2 inhibitors		Early trials	MDM2		LIP	Liposarcoma	PMID:23084521;ASCO 2015 (abstr 10564)	1.0									Liposarcoma
MDM4:amp	CNA		Responsive	MDM4 amplification			RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	MDM4		S	Sarcoma	PMID:24336067	1.0									Sarcoma
EGFR:amp	CNA		Not Responsive	EGFR amplification			RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		HNC	Head and neck cancer	PMID:21274259;PMID:22261807	1.0									Head and neck cancer
MET:amp	CNA		Responsive	MET amplification		07/16	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	MET		COREAD	Colorectal adenocarcinoma	PMID:27397505	1.0									Colorectal adenocarcinoma
MET:amp	CNA		Responsive	MET amplification		01/16	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		HC	Hepatic carcinoma	ENA 2015 (abstract A55)	1.0									Hepatic carcinoma
MET:amp	CNA		Responsive	MET amplification		01/16	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Pre-clinical	MET		ST	Gastric carcinoma	PMID:22729845;PMID:23327903	1.0									Gastric carcinoma
MET:amp	CNA		Responsive	MET amplification		06/16	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Early trials	MET		R	Renal carcinoma	PMID:23213094;AACR 2016 (abstr CT2006)	1.0									Renal carcinoma
MET:amp	CNA		Responsive	MET amplification		11/15	RDientsmann	Cabozantinib;Panitumumab	Pan-kinase inhibitor;EGFR mAb inhibitor	Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor)	Clinical Trials	Case report	MET		COREAD	Colorectal adenocarcinoma	ENA 2015 (abstr A52)	1.0									Colorectal adenocarcinoma
MET__.	FUS		Responsive	MET fusion		12/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	MET		G	Glioma	PMID:27748748	1.0									Glioma
MET:amp	CNA		Responsive	MET amplification		01/16	EArriola;CRubio-Perez	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Clinical Trials	Early trials	MET		NSCLC	Non-small cell lung cancer	NCT02499614;ASCO 2015 (abstr 2595)	1.0									Non-small cell lung cancer
MET:amp	CNA		Responsive	MET amplification		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	MET		LUAD;ST	Lung adenocarcinoma;Gastric carcinoma	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	1.0									Lung adenocarcinoma;Gastric carcinoma
MET:amp	CNA		Responsive	MET amplification		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	MET		G	Glioma	PMID:22162573	1.0									Glioma
MET:amp;BRAF:V600E	CNA;MUT		Responsive	MET amplification + BRAF (V600E)		12/16	RDientsmann	Crizotinib;Vemurafenib	ALK inhibitor;BRAF inhibitor	Crizotinib + Vemurafenib (ALK inhibitor + BRAF inhibitor)		Case report	MET;BRAF		COREAD	Colorectal adenocarcinoma	PMID:27325282	1.0									Colorectal adenocarcinoma
MET:amp;ERBB2:amp	CNA;CNA		Responsive	MET amplification + ERBB2 amplification		01/16	RDientsmann	Crizotinib;Trastuzumab	ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)		Case report	MET;ERBB2		ST	Gastric carcinoma	PMID:26432108	1.0									Gastric carcinoma
MET:amp;ERBB2:amp	CNA;CNA		Responsive	MET amplification + ERBB2 amplification		01/16	RDientsmann	Crizotinib;Trastuzumab	ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)		Case report	MET;ERBB2		ST	Gastric carcinoma	PMID:26432108	1.0									Gastric carcinoma
KIT:amp	CNA		Not Responsive	KIT amplification			RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	Cutaneous melanoma	PMID:23775962	1.0									Cutaneous melanoma
MKI67:over	EXPR	Cell line	Responsive	MKI67 overexpression		09/15	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	MKI67		R	Renal carcinoma	PMID:24086736	1.0	Indirect								Renal carcinoma
MLL__.	FUS		Responsive	MLL fusion		01/16	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	MLL		AML	Acute myeloid leukemia	PMID:21964340	1.0									Acute myeloid leukemia
MLL__.	FUS		Responsive	MLL fusion			ECampo;RDientsmann	Belinostat	HDAC inhibitor	Belinostat (HDAC inhibitor)	Approved	Early trials	MLL		AML	Acute myeloid leukemia	NCT00351975;NCT00357032;PMID:22015773	1.0	Indirect								Acute myeloid leukemia
MLL__.	FUS		Responsive	MLL fusion			RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	MLL		AML	Acute myeloid leukemia	PMID:22417203	1.0									Acute myeloid leukemia
MLL__.	FUS		Responsive	MLL fusion			ECampo;RDientsmann	EPZ-5676	DOTL1 inhibitor	EPZ-5676 (DOTL1 inhibitor)	Clinical Trials	Early trials	MLL		AML;ALL;MDS	Acute myeloid leukemia;Acute lymphoblastic leukemia;Myelodisplasic syndrome	NCT02141828;NCT01684150;PMID:21741596	1.0	Indirect								Acute myeloid leukemia;Acute lymphoblastic leukemia;Myelodisplasic syndrome
MYC:amp	CNA		Responsive	MYC amplification			RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	MYC		MYMA;NB	Myeloma;Neuroblastoma	PMID:21889194;PMID:23430699	1.0									Myeloma;Neuroblastoma
MYC:amp	CNA		Responsive	MYC amplification			RDientsmann	[]	[CDK7 inhibitor]	CDK7 inhibitors		Pre-clinical	MYC		NB	Neuroblastoma	PMID:25416950	1.0									Neuroblastoma
MYC:amp	CNA		Responsive	MYC amplification		11/15	RDientsmann	[]	[FACT inhibitor]	FACT inhibitors		Pre-clinical	MYC		NB	Neuroblastoma	PMID:26537256	1.0									Neuroblastoma
MYC:amp	CNA		Responsive	MYC amplification			RDientsmann	[]	[PIM inhibitor]	PIM inhibitors		Pre-clinical	MYC		PRAD	Prostate adenocarcinoma	PMID:25505253	1.0									Prostate adenocarcinoma
MYC:amp	CNA		Responsive	MYC amplification		07/16	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	MYC		COREAD	Colorectal adenocarcinoma	PMID:27397505	1.0									Colorectal adenocarcinoma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:24373973	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	[]	[BRD4 inhibitor]	BRD4 inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:24373973	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	[]	[KIT inhibitor;MTOR inhibitor]	KIT inhibitor + MTOR inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:24718867	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion		07/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:23221341	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion		07/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		G;LK	Glioma;Leukemia	PMID:22573716;PMID:19727076	1.0									Glioma;Leukemia
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	[]	[MTOR inhibitor;HSP90 inhibitor]	MTOR inhibitor + HSP90 inhibitors		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:21907929	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion		07/16	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF1		G;MPN;LK	Glioma;Malignant peripheral nerve sheat tumor;Leukemia	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	1.0									Glioma;Malignant peripheral nerve sheat tumor;Leukemia
NF1:del	CNA		Responsive	NF1 deletion		07/16	RDientsmann	[]	[Pan-RAF inhibitor;MEK inhibitor]	Pan-RAF inhibitor + MEK inhibitors		Pre-clinical	NF1		CM	Cutaneous melanoma	PMID:26351322	1.0									Cutaneous melanoma
NF1:del	CNA		Responsive	NF1 deletion	, PD1 expression higher in NF1 mutant melanoma (PMID 26960397)	07/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	NF1		CM	Cutaneous melanoma	ASCO 2016 (abstr 105)	1.0									Cutaneous melanoma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Case report	NF1		G	Glioma	PMID:24232489;PMID:2485933	1.0									Glioma
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification		01/16	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	MET;ERBB2		ST	Gastric carcinoma	PMID:22238368	1.0									Gastric carcinoma
CRBN:under	EXPR		Resistant	CRBN undexpression	several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression		DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:21860026	1.0									Myeloma
NF1:del	CNA		Responsive	NF1 deletion		07/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC;SG	Head and neck cancer;Salivary glands tumor	PMID:26859683;ASCO 2016 (abstr e17557)	1.0									Head and neck cancer;Salivary glands tumor
LRP1B:del	CNA		Resistant	LRP1B deletion			RDientsmann	Liposomal Doxorubicin	Chemotherapy	Liposomal Doxorubicin (Chemotherapy)		Early trials	LRP1B		OV	Ovarian carcinoma	PMID:22896685	1.0									Ovarian carcinoma
STK11:.;KRAS:.	MUT;MUT		Resistant	STK11 oncogenic mutation + KRAS oncogenic mutation		01/16	RDientsmann	MEK inhibitor;Docetaxel	MEK inhibitor;Chemotherapy	MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)		Pre-clinical	STK11;KRAS		LUAD	Lung adenocarcinoma	PMID:22425996	1.0									Lung adenocarcinoma
STK11:del;KRAS:.	CNA;MUT		Resistant	STK11 deletion + KRAS oncogenic mutation		01/16	RDientsmann	MEK inhibitor;Docetaxel	MEK inhibitor;Chemotherapy	MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)		Pre-clinical	STK11;KRAS		LUAD	Lung adenocarcinoma	PMID:22425996	1.0									Lung adenocarcinoma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	PMID:23099009	1.0									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		PLEN;MPN	Plexiform neurofibroma;Malignant peripheral nerve sheat tumor	PMID:24173684	1.0									Plexiform neurofibroma;Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	PLX3397	Pan-TK inhibitor	PLX3397 (Pan-TK inhibitor)		Pre-clinical	NF1		PLEN	Plexiform neurofibroma	PMID:23099891	1.0									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	ASCO 2014 (abstr 10018)	1.0									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	PMID:25314964	1.0									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	germline, rampamycin = sirolimus	07/16	RDientsmann	Sirolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	Glioma	PMID:22434731	1.0									Glioma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Sorafenib;Sirolimus	Pan-TK inhibitor;MTOR inhibitor	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:25810463	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Pre-clinical	NF1		MPN	Malignant peripheral nerve sheat tumor	PMID:21075781	1.0									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		G	Glioma	PMID:26936308	1.0									Glioma
NF1:del	CNA		Responsive	NF1 deletion		07/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	NF1		CM	Cutaneous melanoma	PMID:24576830;PMID:2524381	1.0									Cutaneous melanoma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Vinblastine	Chemotherapy	Vinblastine (Chemotherapy)		Early trials	NF1		G	Glioma	ASCO 2016 (abstr 2019)	1.0									Glioma
NF1:del	CNA		Responsive	NF1 deletion	germline	07/16	RDientsmann	Vinblastine;Nilotinib	Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)		Case report	NF1		G	Glioma	ASCO 2016 (abstr 10555)	1.0									Glioma
ERBB2:amp	CNA		Resistant	ERBB2 amplification		06/16	EArriola	Osimertinib	3rd generation EGFR inhibitor	Osimertinib (3rd generation EGFR inhibitor)	Approved	Case report	ERBB2		LUAD	Lung adenocarcinoma	PMID:27252416	1.0									Lung adenocarcinoma
MET:amp	CNA		Resistant	MET amplification		06/16	EArriola	Osimertinib	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Osimertinib,etc)	Approved	Case report	MET		LUAD	Lung adenocarcinoma	PMID:27252416	1.0									Lung adenocarcinoma
TUBB3:over	EXPR		Resistant	TUBB3 overexpression		09/15	ARodriguez-Vida	Paclitaxel	Taxane	Paclitaxel (Taxane)		Pre-clinical	TUBB3	BLCA	BLCA	Bladder carcinoma	PMID:23184177	1.0									Bladder carcinoma
CCND1:amp	CNA		Not Responsive	CCND1 amplification		07/17	RDientsmann	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)		Early trials	CCND1		L	Lung carcinoma	ASCO 2017 (abstr 9056)	1.0									Lung carcinoma
CDK4:amp	CNA		Not Responsive	CDK4 amplification		07/17	RDientsmann	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)		Early trials	CDK4		L	Lung carcinoma	ASCO 2017 (abstr 9056)	1.0									Lung carcinoma
NF2:del	CNA		Responsive	NF2 deletion		07/16	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Early trials	NF2		MESO	Mesothelioma	ENA 2012 (abstr 610)	1.0									Mesothelioma
NF2:del	CNA		Responsive	NF2 deletion		07/16	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	NF2		MESO;OV	Mesothelioma;Ovarian carcinoma	PMID:24848258;PMID:24786638	1.0									Mesothelioma;Ovarian carcinoma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NF2		MEN	Meningioma	PMID:23714726	1.0									Meningioma
NF2:del	CNA		Responsive	NF2 deletion		07/16	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF2		TH	Thyroid carcinoma	PMID:26359368	1.0									Thyroid carcinoma
NF2:del	CNA		Responsive	NF2 deletion		07/17	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF2		MEN	Meningioma	PMID:19451225;PMID:2242646	1.0									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	NF2		SCHW;MEN	Schwannoma;Meningioma	PMID:23960073;PMID:25596744	1.0									Schwannoma;Meningioma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann	[]	[PDK1 inhibitor]	PDK1 inhibitors		Pre-clinical	NF2		SCHW	Schwannoma	PMID:19359162	1.0									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Pre-clinical	NF2		SCHW	Schwannoma	PMID:21778190	1.0									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	germline,minor response	07/16	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Early trials	NF2		MEN	Meningioma	ASCO 2016 (abstr 2558)	1.0									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Early trials	NF2		SCHW	Schwannoma	PMID:19587327;PMID:22805104;PMID:26022982	1.0									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	germline, minor responsiv	07/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF2		SCHW	Schwannoma	PMID:24311643	1.0									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion		07/16	RDientsmann	Everolimus;Octreotide	MTOR inhibitor;Somatostatin analog	Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)		Pre-clinical	NF2		MEN	Meningioma	PMID:26015296	1.0									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	NF2		SCHW	Schwannoma	PMID:19509233;PMID:2290085	1.0									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	germline	07/16	RDientsmann;MMartínez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	NF2		SCHW;NF	Schwannoma;Neurofibroma	PMID:22844108;NCT00973739	1.0									Schwannoma;Neurofibroma
NF2:del	CNA		Responsive	NF2 deletion		07/16	RDientsmann	Tensirolimus;Chemotherapy	MTOR inhibitor;Chemotherapy	Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)		Case report	NF2		BRCA	Breast adenocarcinoma	PMID:25878190	1.0									Breast adenocarcinoma
NOTCH1__.	FUS		Responsive	NOTCH1 fusion		01/16	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		ALL	Acute lymphoblastic leukemia	PMID:16688224;PMID:23033986	1.0									Acute lymphoblastic leukemia
NOTCH1__.	FUS		Responsive	NOTCH1 fusion			RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		BRCA	Breast adenocarcinoma	PMID:22101766	1.0									Breast adenocarcinoma
NOTCH2__.	FUS		Responsive	NOTCH2 fusion			RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH2		BRCA	Breast adenocarcinoma	PMID:22101766	1.0									Breast adenocarcinoma
PTEN:.	BIA		Resistant	PTEN biallelic inactivation			DTamborero	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	PTEN		COREAD	Colorectal adenocarcinoma	Caris molecular intelligence	1.0									Colorectal adenocarcinoma
CRBN:under	EXPR		Resistant	CRBN undexpression	several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression		DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	Myeloma	PMID:21860026	1.0									Myeloma
NRG1__.	FUS		Responsive	NRG1 fusion		06/16	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	NRG1		LUAD	Lung adenocarcinoma	AACR 2016 (abstr 2631)	1.0									Lung adenocarcinoma
NRG1__.	FUS		Responsive	NRG1 fusion			RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	NRG1		LUAD	Lung adenocarcinoma	PMID:24727320	1.0									Lung adenocarcinoma
NTRK1__.	FUS		Responsive	NTRK1 fusion		01/16	RDientsmann	[]	[Pan-TK inhibitor]	Pan-TK inhibitors		Pre-clinical	NTRK1		LUAD	Lung adenocarcinoma	PMID:24162815	1.0									Lung adenocarcinoma
NTRK1__.	FUS		Responsive	NTRK1 fusion		07/17	RDientsmann	[]	[Pan-TKR inhibitor]	Pan-TKR inhibitors		Early trials	NTRK1		CANCER	Any cancer type	PMID:28183697;ASCO 2017 (LBA2501)	1.0									Any cancer type
NTRK1__.	FUS		Responsive	NTRK1 fusion		11/15	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	Colorectal adenocarcinoma	PMID:26546295	1.0									Colorectal adenocarcinoma
NTRK1__.	FUS		Responsive	NTRK1 fusion		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	NTRK1		LUAD	Lung adenocarcinoma	ASCO 2013 (abstr 8023)	1.0									Lung adenocarcinoma
NTRK3__.	FUS		Responsive	NTRK3 fusion			RDientsmann	[]	[IGF1R inhibitor]	IGF1R inhibitors		Pre-clinical	NTRK3		BRCA	Breast adenocarcinoma	PMID:21148487;PMID:23131561	1.0									Breast adenocarcinoma
NTRK3__.	FUS		Responsive	NTRK3 fusion			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	NTRK3		BRCA	Breast adenocarcinoma	PMID:21148487;PMID:23131561	1.0									Breast adenocarcinoma
NTRK3__.	FUS		Responsive	NTRK3 fusion			RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Pre-clinical	NTRK3		BRCA	Breast adenocarcinoma	PMID:21148487;PMID:23131561	1.0									Breast adenocarcinoma
PAK1:amp	CNA		Responsive	PAK1 amplification			RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	PAK1		CM	Cutaneous melanoma	PMID:23535073	1.0									Cutaneous melanoma
PALB2:del	CNA		Responsive	PALB2 deletion		01/16	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	PALB2		PRAD	Prostate adenocarcinoma	AACR 2015 (abstr CT322);PMID:26510020	1.0									Prostate adenocarcinoma
PALB2:del	CNA		Responsive	PALB2 deletion		01/16	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	PALB2		PA	Pancreatic carcinoma	PMID:25263539;NCT01585805	1.0									Pancreatic carcinoma
PALB2:del	CNA		Responsive	PALB2 deletion		01/16	RDientsmann	Mytomycin C	Chemotherapy	Mytomycin C (Chemotherapy)		Case report	PALB2		PA	Pancreatic carcinoma	PMID:21135251	1.0									Pancreatic carcinoma
PALB2:del	CNA		Responsive	PALB2 deletion		01/16	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	PALB2		PA	Pancreatic carcinoma	PMID:25719666	1.0									Pancreatic carcinoma
PBRM1:del	CNA		Responsive	PBRM1 deletion		01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	PBRM1		CANCER	Any cancer type	PMID:26552009	1.0									Any cancer type
PBRM1:under	EXPR	Cell line	Responsive	PBRM1 undexpression		09/15	ARodriguez-Vida	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Pre-clinical	PBRM1		R	Renal carcinoma	PMID:25997916	1.0									Renal carcinoma
PDGFRA__.	FUS		Responsive	PDGFRA fusion	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf		CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRA		MDS;MDPS	Myelodisplasic syndrome;Myelodisplasic proliferative syndrome	EMA	1.0									Myelodisplasic syndrome;Myelodisplasic proliferative syndrome
PDGFRA__FIP1L1	FUS		Responsive	PDGFRA-FIP1L1 fusion	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf		CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRA		HES;ECL	Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia	EMA	1.0									Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia
PDGFRA:over	EXPR	Cell line	Responsive	PDGFRA overexpression		09/15	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	PDGFRA		R	Renal carcinoma	PMID:24086736	1.0	Direct								Renal carcinoma
PDGFB__COL1A1	FUS		Responsive	PDGFB-COL1A1 fusion	http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf		CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFB		DFS	Dermatofibrosarcoma	FDA	1.0									Dermatofibrosarcoma
PDPK1:amp	CNA		Responsive	PDPK1 amplification			RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PDPK1		BRCA	Breast adenocarcinoma	PMID:19602588	1.0									Breast adenocarcinoma
ERBB2:amp	CNA		Resistant	ERBB2 amplification		06/16	EArriola	Rociletinib	3rd generation EGFR inhibitor	Rociletinib (3rd generation EGFR inhibitor)		Case report	ERBB2		LUAD	Lung adenocarcinoma	PMID:27252416	1.0									Lung adenocarcinoma
MET:amp	CNA		Resistant	MET amplification		06/16	EArriola	Rociletinib	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Rociletinib,etc)		Case report	MET		LUAD	Lung adenocarcinoma	PMID:27252416	1.0									Lung adenocarcinoma
NF1:.;BRAF:.	MUT;MUT		Resistant	NF1 oncogenic mutation + BRAF oncogenic mutation		07/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	NF1;BRAF		CM	Cutaneous melanoma	PMID:23444215	1.0									Cutaneous melanoma
PIK3CA:.;ERBB2:amp	MUT;CNA		Responsive	PIK3CA oncogenic mutation + ERBB2 amplification		01/16	RDientsmann	Everolimus;Trastuzumab;Chemotherapy	MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)		Late trials	PIK3CA;ERBB2		BRCA	Breast adenocarcinoma	PMID:27091708	1.0									Breast adenocarcinoma
NF1:del;BRAF:.	CNA;MUT		Resistant	NF1 deletion + BRAF oncogenic mutation		07/16	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	NF1;BRAF		CM	Cutaneous melanoma	PMID:23444215	1.0									Cutaneous melanoma
PML__RARA	FUS		Responsive	PML-RARA fusion		01/16	DTamborero;CRubio-Perez	Tretinoin	Retinoid	Tretinoin (Retinoid)	Approved	FDA guidelines	PML		APML	Acute promyelocytic leukemia	FDA	1.0									Acute promyelocytic leukemia
PML__RARA	FUS		Responsive	PML-RARA fusion	PML is the oncogene or rara??		RDientsmann	Tretinoin;Arsenic Trioxide	Retinoid;Chemotherapy	Tretinoin + Arsenic Trioxide (Retinoid + Chemotherapy)	Approved	FDA guidelines	PML		AML	Acute myeloid leukemia	FDA	1.0									Acute myeloid leukemia
PML__RARA	FUS		Responsive	PML-RARA fusion			ECampo	Volasertib	PLK1 inhibitor	Volasertib (PLK1 inhibitor)	Clinical Trials	Early trials	PML		AML	Acute myeloid leukemia	NCT02198482;NCT01662505	1.0	Indirect								Acute myeloid leukemia
PRKCH:amp;ABL1__BCR	CNA;FUS		Responsive	PRKCH amplification + ABL1-BCR fusion			RDientsmann	Trametinib;Imatinib	MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor	Trametinib + Imatinib (MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PRKCH;ABL1		CML	Chronic myeloid leukemia	PMID:25186176	1.0									Chronic myeloid leukemia
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Case report	PTEN		PA	Pancreatic carcinoma	PMID:22025163	1.0									Pancreatic carcinoma
PTEN:del	CNA		Responsive	PTEN deletion	(low estrogen)		RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	PTEN		ED	Endometrial carcinoma	PMID:21468130;PMID:20944090	1.0									Endometrial carcinoma
PTEN:del	CNA		Responsive	PTEN deletion		06/16	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	PTEN		CM	Cutaneous melanoma	PMID:26645196	1.0									Cutaneous melanoma
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	[]	[PI3K pathway inhibitor;AR antagonist]	PI3K pathway inhibitor + AR antagonists		Pre-clinical	PTEN		PRAD	Prostate adenocarcinoma	PMID:21575859	1.0									Prostate adenocarcinoma
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	PTEN		OV	Ovarian carcinoma	PMID:21632463	1.0									Ovarian carcinoma
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PTEN		TH;G;L;OV;BRCA;CANCER;ED	Thyroid carcinoma;Glioma;Lung carcinoma;Ovarian carcinoma;Breast adenocarcinoma;Any cancer type;Endometrial carcinoma	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669	1.0									Thyroid carcinoma;Glioma;Lung carcinoma;Ovarian carcinoma;Breast adenocarcinoma;Any cancer type;Endometrial carcinoma
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	[]	[PIK3CB inhibitor]	PIK3CB inhibitors		Case report	PTEN		PRAD	Prostate adenocarcinoma	ASCO 2014 (abstr 2514)	1.0									Prostate adenocarcinoma
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	PTEN		PRAD	Prostate adenocarcinoma	PMID:23582881	1.0									Prostate adenocarcinoma
PTEN:del	CNA		Responsive	PTEN deletion		01/16	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	PTEN		CANCER	Any cancer type	ASCO 2013 (abstr 2532)	1.0									Any cancer type
KIT:amp	CNA		Not Responsive	KIT amplification		01/16	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Early trials	KIT		CM	Cutaneous melanoma	PMID:22261812	1.0									Cutaneous melanoma
PTEN:.;ERBB2:amp	MUT;CNA		Responsive	PTEN oncogenic mutation + ERBB2 amplification		01/16	RDientsmann	Everolimus;Trastuzumab;Chemotherapy	MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)		Late trials	PTEN;ERBB2		BRCA	Breast adenocarcinoma	PMID:27091708	1.0									Breast adenocarcinoma
NF1:del	CNA		Not Responsive	NF1 deletion	germline	07/16	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	NF1		PLEN	Plexiform neurofibroma	PMID:24500418	1.0									Plexiform neurofibroma
RAD50:L1237F;ATM:del	MUT;CNA		Responsive	RAD50 (L1237F) + ATM deletion		01/16	RDientsmann	Irinotecan;CHK1/2 inhibitor	TOPO1 inhibitor;CHK1/2 inhibitor	Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor)		Case report	RAD50;ATM		CANCER	Any cancer type	PMID:24934408	1.0									Any cancer type
RAF1__.	FUS	Cell line	Responsive	RAF1 fusion		09/15	ARodriguez-Vida	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors	Pre-clinical	Pre-clinical	RAF1		PRAD	Prostate adenocarcinoma	PMID:20526349	1.0	Direct								Prostate adenocarcinoma
RAF1__.	FUS		Responsive	RAF1 fusion			RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	RAF1		PRAD	Prostate adenocarcinoma	PMID:20526349	1.0									Prostate adenocarcinoma
RAF1:over	EXPR	Cell line	Responsive	RAF1 overexpression		10/16	CdeTorres	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	RAF1		OS	Osteosarcoma	PMID:24375110	1.0									Osteosarcoma
RAF1__.	FUS	Cell line	Responsive	RAF1 fusion		09/15	ARodriguez-Vida	U0126	MEK inhibitor	U0126 (MEK inhibitor)	Approved	Pre-clinical	RAF1		PRAD	Prostate adenocarcinoma	PMID:20526349	1.0	Indirect								Prostate adenocarcinoma
NF1:del	CNA		Not Responsive	NF1 deletion		07/16	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		OS	Osteosarcoma	PMID:26325560	1.0									Osteosarcoma
RB1:del	CNA		Responsive	RB1 deletion		01/16	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	RB1		RB	Retinoblastoma	PMID:18483379	1.0									Retinoblastoma
RB1:del	CNA		Responsive	RB1 deletion			RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	RB1		RB	Retinoblastoma	PMID:17080083;PMID:21515735	1.0									Retinoblastoma
RB1:del	CNA		Responsive	RB1 deletion			ARodriguez-Vida;RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	RB1	BLCA	BLCA	Bladder carcinoma	PMID:26238431	1.0	Indirect								Bladder carcinoma
RB1:over	EXPR	Xenograft	Responsive	RB1 overexpression		09/15	ARodriguez-Vida	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Pre-clinical	Pre-clinical	RB1		PRAD	Prostate adenocarcinoma	PMID:23708653	1.0	Indirect								Prostate adenocarcinoma
RET__.	FUS		Responsive	RET fusion		01/16	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		LUAD	Lung adenocarcinoma	PMID:22327624;PMID:22327622	1.0									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion		01/16	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	Thyroid carcinoma	PMID:23056499	1.0									Thyroid carcinoma
RET__.	FUS		Responsive	RET fusion		07/17	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Early trials	RET		LUAD	Lung adenocarcinoma	PMID:28447912	1.0									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion			RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		THCA	Thyroid carcinoma	PMID:21470995	1.0									Thyroid carcinoma
RET__.	FUS		Responsive	RET fusion		06/16	RDientsmann	Nintedanib	Pan-TK inhibitor	Nintedanib (Pan-TK inhibitor)		Case report	RET		LUAD	Lung adenocarcinoma	PMID:26787234	1.0									Lung adenocarcinoma
ARID1A:.;ANXA1:over	MUT;EXPR		Resistant	ARID1A oncogenic mutation + ANXA1 overexpression	Anaxa 1 high	12/16	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	FDA approved	Early trials	ARID1A;ANXA1		BRCA	Breast adenocarcinoma	PMID:27172896	1.0									Breast adenocarcinoma
RET__.	FUS		Responsive	RET fusion		07/17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Early trials	RET		LUAD	Lung adenocarcinoma	PMID:28447912	1.0									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion			RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		THCA	Thyroid carcinoma	PMID:21470995	1.0									Thyroid carcinoma
RET__.	FUS		Responsive	RET fusion		07/17	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Early trials	RET		LUAD	Lung adenocarcinoma	PMID:28447912	1.0									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion			RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Pre-clinical	RET		THCA	Thyroid carcinoma	PMID:21470995	1.0									Thyroid carcinoma
RICTOR:amp	CNA		Responsive	RICTOR amplification		01/16	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Case report	RICTOR		L	Lung carcinoma	PMID:26370156	1.0									Lung carcinoma
ROS1__.	FUS		Responsive	ROS1 fusion		01/16	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	ROS1		LUAD	Lung adenocarcinoma	PMID:23533265	1.0									Lung adenocarcinoma
ROS1__.	FUS		Responsive	ROS1 fusion		07/17	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Case report	ROS1		LUAD	Lung adenocarcinoma	PMID:27370605	1.0									Lung adenocarcinoma
ARID1A:amp;ANXA1:over	CNA;EXPR		Resistant	ARID1A amplification + ANXA1 overexpression	Anaxa 1 high	12/16	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	FDA approved	Early trials	ARID1A;ANXA1		BRCA	Breast adenocarcinoma	PMID:27172896	1.0									Breast adenocarcinoma
ROS1__.	FUS		Responsive	ROS1 fusion		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		IM	Inflammatory myofibroblastic	PMID:24875859	1.0									Inflammatory myofibroblastic
ROS1__.	FUS		Responsive	ROS1 fusion		01/16	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	ROS1		LUAD	Lung adenocarcinoma	PMID:25264305	1.0									Lung adenocarcinoma
ROS1__.	FUS		Responsive	ROS1 fusion			CRubio-Perez;EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Clinical trials	FDA guidelines	ROS1		NSCLC	Non-small cell lung cancer	FDA	1.0									Non-small cell lung cancer
ERBB2:amp	CNA		Not Responsive	ERBB2 amplification			DTamborero;RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		ED	Endometrial carcinoma	PMID:26099744;PMID:19840887	1.0									Endometrial carcinoma
HGF:amp;ERBB2:amp	CNA;CNA		Resistant	HGF amplification + ERBB2 amplification			RDientsmann;CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	HGF;ERBB2		BRCA	Breast adenocarcinoma	PMID:22850551	1.0									Breast adenocarcinoma
SETD2:del	CNA		Responsive	SETD2 deletion			RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	SETD2		CANCER	Any cancer type	ENA 2014 (abstr 211)	1.0									Any cancer type
SH2B3:del	CNA		Responsive	SH2B3 deletion			RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	SH2B3		MDPS	Myelodisplasic proliferative syndrome	PMID:20404132	1.0									Myelodisplasic proliferative syndrome
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification		01/16	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	MET;ERBB2		BRCA	Breast adenocarcinoma	PMID:22850551	1.0									Breast adenocarcinoma
SLC44A4:over	EXPR		Responsive	SLC44A4 overexpression		02/17	CRubio-Perez	[]	[SLC44A4 inhibitor]	SLC44A4 inhibitors		Pre-clinical	SLC44A4		PRAD;PAAD	Prostate adenocarcinoma;Pancreas adenocarcinoma	PMID:27550944 	1.0									Prostate adenocarcinoma;Pancreas adenocarcinoma
SMARCA4:del	CNA		Responsive	SMARCA4 deletion		11/15	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCA4		OV	Ovarian carcinoma	ESMO 2015 (abstract 302)	1.0									Ovarian carcinoma
SMARCB1:del	CNA		Responsive	SMARCB1 deletion	INI1 gene symbol: SMARCB1	01/16	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCB1		MRT	Malignant rhabdoid tumor	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	1.0									Malignant rhabdoid tumor
SMARCB1:del	CNA		Responsive	SMARCB1 deletion		11/15	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors	Clinical Trials	Early trials	SMARCB1		MRT	Malignant rhabdoid tumor	ESMO 2015 (abstract 302)	1.0									Malignant rhabdoid tumor
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification		01/16	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	MET;ERBB2		BRCA;ST	Breast adenocarcinoma;Gastric carcinoma	PMID:22850551;PMID:26432108	1.0									Breast adenocarcinoma;Gastric carcinoma
STK11:del	CNA		Responsive	STK11 deletion			RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	STK11		LUAD	Lung adenocarcinoma	PMID:19165201	1.0									Lung adenocarcinoma
STK11:del	CNA		Responsive	STK11 deletion			RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	STK11		CANCER	Any cancer type	PMID:19541609	1.0									Any cancer type
STK11:del	CNA		Responsive	STK11 deletion		01/16	RDientsmann	[]	[SRC inhibitor;PI3K/MEK inhibitor]	SRC inhibitor + PI3K/MEK inhibitors		Pre-clinical	STK11		LUAD	Lung adenocarcinoma	PMID:20541700	1.0									Lung adenocarcinoma
STK11:del	CNA		Responsive	STK11 deletion		01/16	RDientsmann	Phenformin	Anti-diabetic	Phenformin (Anti-diabetic)		Pre-clinical	STK11		LUAD	Lung adenocarcinoma	PMID:23352126	1.0									Lung adenocarcinoma
NF1:.	BIA		Resistant	NF1 biallelic inactivation			DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Pre-clinical	NF1		CM	Cutaneous melanoma	PMID:23171796	1.0									Cutaneous melanoma
SUZ12:del	CNA		Responsive	SUZ12 deletion			RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	SUZ12		CANCER	Any cancer type	PMID:25119042	1.0									Any cancer type
SYK:amp	CNA		Responsive	SYK amplification			RDientsmann	[]	[SYK inhibitor]	SYK inhibitors		Pre-clinical	SYK		MCL;CLL	Mantle cell lymphoma;Chronic lymphocytic leukemia	PMID:16409295;PMID:19549911	1.0									Mantle cell lymphoma;Chronic lymphocytic leukemia
TMPRSS2__.	FUS		Responsive	TMPRSS2 fusion		01/16	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	TMPRSS2		PRAD	Prostate adenocarcinoma	PMID:21575865	1.0									Prostate adenocarcinoma
TMPRSS2__.	FUS		Responsive	TMPRSS2 fusion			RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	TMPRSS2		PRAD	Prostate adenocarcinoma	PMID:21575865	1.0									Prostate adenocarcinoma
TOP2A:amp	CNA		Responsive	TOP2A amplification		01/16	RDientsmann	Anthracyclines	Chemotherapy	Anthracyclines (Chemotherapy)		Late trials	TOP2A		BRCA	Breast adenocarcinoma	PMID:22864769	1.0									Breast adenocarcinoma
NF1:.;BRAF:.	MUT;MUT		Resistant	NF1 oncogenic mutation + BRAF oncogenic mutation		07/16	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	NF1;BRAF		CM	Cutaneous melanoma	PMID:23288408;PMID:231718	1.0									Cutaneous melanoma
NF1:del;BRAF:.	CNA;MUT		Resistant	NF1 deletion + BRAF oncogenic mutation		07/16	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	NF1;BRAF		CM	Cutaneous melanoma	PMID:23288408;PMID:231718	1.0									Cutaneous melanoma
TP53:del	CNA		Responsive	TP53 deletion			ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	TP53		BCL	B cell lymphoma	NCT01955668;ASH 2014	1.0	Indirect								B cell lymphoma
TP53:del	CNA		Responsive	TP53 deletion			RDientsmann	Pramlintide	Amylin analogue	Pramlintide (Amylin analogue)		Pre-clinical	TP53		THYM	Thymic carcinoma	PMID:25409149	1.0									Thymic carcinoma
TPMT:.	BIA		Increased Toxicity (Ototoxicity)	TPMT biallelic inactivation		01/16	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0									Any cancer type
TPMT:.	BIA		Increased Toxicity (Myelosupression)	TPMT biallelic inactivation		01/16	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0									Any cancer type
TPMT:.	BIA		Increased Toxicity (Myelosupression)	TPMT biallelic inactivation		01/16	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	Any cancer type	FDA	1.0									Any cancer type
MET:amp;BRAF:V600E	CNA;MUT		Resistant	MET amplification + BRAF (V600E)		12/16	RDientsmann	Vemurafenib;Panitumumab	BRAF inhibitor;EGFR mAb inhibitor	Vemurafenib + Panitumumab (BRAF inhibitor + EGFR mAb inhibitor)		Case report	MET;BRAF		COREAD	Colorectal adenocarcinoma	PMID:27325282	1.0									Colorectal adenocarcinoma
TSC1:del	CNA		Responsive	TSC1 deletion		01/16	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	TSC1		R	Renal carcinoma	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	1.0									Renal carcinoma
TSC2:del	CNA		Responsive	TSC2 deletion	Lymphangioleiomyomatosis (LAM) is a rare, progressive, systemic disease that typically results in cystic lung destruction		RDientsmann	[]	[SRC inhibitor]	SRC inhibitors		Pre-clinical	TSC2		LAM	Lymphangioleiomyomatosis	PMID:24691995	1.0									Lymphangioleiomyomatosis
UGT1A1:.	BIA		Increased Toxicity	UGT1A1 biallelic inactivation		01/16	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0									Any cancer type
UGT1A1:.	BIA		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 biallelic inactivation		01/16	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0									Any cancer type
UGT1A1:.	BIA		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 biallelic inactivation		01/16	DTamborero;CRubio-Perez	Pazopanib	VEGFR inhibitor	Pazopanib (VEGFR inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	Any cancer type	FDA	1.0									Any cancer type
VEGFA:amp	CNA		Responsive	VEGFA amplification		01/16	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	VEGFA		HC	Hepatic carcinoma	PMID:24687604	1.0									Hepatic carcinoma
